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With previous reports indicating changes in mortality, risk factors and management 
of primary liver cancer (PLC), evaluation of current trends in the incidence and 
mortality rates was indicated. Late diagnosis has been implicated to be a major 
contributor to the high fatality rates of PLC. This work aimed at:  
 studying trends of PLC by subcategories globally in general, and in England 
and Wales, in particular; 
 investigating liver-related morbidities of HIV infected patients in an African 
setting; and 
 discovering urinary biomarkers of hepatocellular carcinoma. 
The World Health Organisation (WHO) and Small Area Health Statistics Unit 
(SAHSU) databases were interrogated respectively, in order to achieve the first aim. 
The second aim was achieved through utilisation of databases of an African-based 
HIV treatment programme- AIDS Prevention Initiative in Nigeria (APIN), located in 
Jos, Nigeria. The European Union-funded Prevention of Liver Fibrosis and Cancer in 
Africa (PROLIFICA) case-control study in three West African countries was the 
platform through which urinary metabolic profiling was accomplished. Proton nuclear 
magnetic resonance spectroscopy (NMR) and parallel ultra-performance liquid 
chromatography mass spectrometry (UPLC-MS) were used for biomarker discovery 
studies. 
Mortality rates of intrahepatic bile duct carcinoma (IHBD) increased in all countries 
that were studied. Misclassification of hilar cholangiocarcinoma accounted for only a 
small increase in the rate of IHBD in England and Wales. With over 90% screening 
rate for viral hepatitides, the rates of hepatitis B (HBV), hepatitis C (HCV) and 
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HBV/HCV in HIV-infected patients in the APIN programme were 17.8%, 11.3% and 
2.5% respectively. There was attenuated immune response as well as significantly 
lower survival observed in HBV/HIV co-infection, relative to HIV mono-infected 
patients (p=0.0097). Whereas single urinary metabolites, including acetylcarnitine, N-
acetylglutamate, betaine aldehyde, 3’-sialyllactose, methionine among others 
possessed high discriminatory power to diagnose HCC, a combination of three 
metabolites: 3’-sialyllactose, methionine and 9-decenoylcarnitine significantly  
outperformed serum alpha-fetoprotein (AFP) in the diagnosis of HCC in a cirrhosis 
population (area under the receiver operating characteristic curve; [urinary panel= 
0.96] compared to [AFP = 0.64]).  
This work informs a critical assessment of current control strategies in the prevention 
of HCC, and potentially assists in the development of more affordable means of early 
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1.1 Definition  
Primary liver cancers (PLC) are malignant tumours of the liver, the major types of 
which are: hepatocellular carcinoma (HCC), arising from hepatocytes; and 
intrahepatic cholangiocarcinoma (IHCC), arising from the biliary epithelium and 
which is the most common form of intrahepatic bile duct carcinoma (IHBD). Other 
rare forms include angiosarcoma (arising from liver vessels), hepatoblastoma (from 
progenitor cells of the liver) and sarcoma (from connective tissue of the hepatic 
parenchyma). The health importance of these cancers stems from the huge burden 
of disease they incur causing hundreds of thousand deaths worldwide, and their 
dismal prognosis (Brown ML et al., 2006). Metastases of neoplasms originating from 
distant organs to the liver are common, most often from the bowel, breast, lung and 
the kidney (Keighley, 2003). 
1.2 Epidemiology 
Globally, liver cancer is the third most common cause of cancer-related death 
(Parkin et al., 2005a). At least half of over 600,000 annual worldwide deaths occur in 
China alone and a majority of the remaining half in sub-Saharan African region. Liver 
cancer carries a very poor prognosis, with an estimated 5-year survival rate of 3-5% 
(Shaib and El-Serag, 2004). It is the fifth most common cancer in the world (Parkin, 
Bray, Ferlay, & Pisani, 2005a), demonstrating a distinct variation in its geographical 
distribution, with over 80% of the cases occurring in East/Southeast Asia and sub-
Saharan Africa (Figure 1). Southern Europe and Japan are the more developed 
regions of the world with the highest incidence (Parkin, Bray, Ferlay, & Pisani 
2005a). HCC  is the most common primary liver cancer subtype, accounting for 85% 
 31 
 
to 90% of cases (El-Serag and Rudolph, 2007). Intrahepatic bile duct carcinoma, 
chiefly comprising IHCC is considered to be relatively rare, but is the second 
commonest primary liver tumour, accounting for 10-25% of PLC (Parkin, 2004).  
The major determinant of the distinct global distribution of HCC is variation in the 
prevalence of risk factors. Whereas hepatitis C virus (HCV) and alcohol is 
considered to be the most important risk factor for HCC in developed countries, 
hepatitis B infection (HBV) and aflatoxin exposure are commonly implicated in 
developing countries (Bosch et al., 2005).  
HBV and HCV infections account for more than 80% of cases of HCC globally 
(Bosch, Ribes, Cleries, & Diaz, 2005). The highest incidence of HCC is in the region 
of Southeast Asia (China, Vietnam, North and South Korea), often attributed to the 
high endemicity of HBV. In Japan however, HCV is the commonest risk factor 
(Yoshizawa, 2002). Outside of Southeast Asia, sub-Saharan countries lead, with 
Cameroon and Mozambique having relatively high HCC rates (Parkin DM et al., 
2003). Countries in southern Europe generally present with intermediate rates, 
whereas low incidence areas include countries in North America, South and Central 




Figure 1. Age-standardised incidence and mortality rates of liver cancer for both 
males and females from different regions of the world (data from IARC; produced by 
permission) 
 
The age distribution of HCC depends in most respects, upon the aetiological risk 
factor, region and gender (Nordenstedt, White, & El-Serag, 2010). While the highest 
age-specific rates occur among persons aged 75 in industrialised western societies 
and in regions more predominantly affected by HCV, developing countries such as 
Gambia and Mali tend to peak between ages 60 and 65 yrs among males (Umoh et 
al., 2011). Age at infection by viral and environmental factors account for the 
differences observed. While HCV tends to be acquired in adulthood, most carriers of 
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HBV become infected during childhood. This reflects in the earlier age of peak 
incidence of HCC in HBV endemic regions compared to regions whose major risk 
factor is HCV.  
Virtually all studies show that males predominate over females in the incidence and 
mortality of HCC with average ratios of 2:1 to 4:1 (McGlynn et al., 2001). Differences 
in exposure to risk factors might explain this observation. Men are more likely than 
women to engage in activities that enhance HBV and HCV infection, as well as in the 
consumption of alcohol and cigarette smoking. The role for sex hormones in 
hepatocarcinogenesis has been suggested by some researchers (Arakawa et al., 
1986). Evidence exists to implicate testosterone, as this hormone increases 
androgen receptor signalling in men, which could promote liver cell proliferation (Yu 
and Chen, 1993). While an increased susceptibility to liver carcinogenesis was 
demonstrated in male transgenic mice (Dunsford et al., 1990), hypophysectomised 
males showed an inhibited tendency to develop liver tumour induction by aflatoxin 
(Goodall and Butler, 1969). In contrast, oestrogen has been suggested to suppress 
interleukin (IL)-6 mediated inflammation; which could imply a reduction in liver injury 
and compensatory proliferation in women (Naugler et al., 2007).  
1.3 Aetiological Risk Factors for Hepatocellular Carcinoma  
Several factors have been implicated in the aetiology of primary liver cancer. 
Cirrhosis of the liver, chronic hepatitis B and C viral infection, dietary aflatoxin and 
alcohol are the most frequently studied. Risk factors that are still being studied 




Cirrhosis of the liver is the most important risk factor for HCC as it links most other 
factors in the pathogenesis of this cancer and is present in approximately 80% of 
HCC patients (Colombo et al., 1991;Tiribelli et al., 1989). There is however, variation 
in the predilection of each underlying cause and stage of cirrhosis in the 
pathogenesis of liver cancer. For example, the 5-year cumulative risk for HCC 
ranges between 17-30% in HCV-associated cirrhosis compared to 10-15% among 
patients with HBV-related cirrhosis. In alcoholic and biliary cirrhosis, it is 8% and 4% 
respectively (Fattovich et al., 2004). A single cohort study found that late stage 
cirrhosis of the liver; Child-Pugh stage B or C, has a threefold relative risk of HCC 
compared to stage A (Bolondi et al., 2001). This is particularly significant in centres 
where treatments exist for stage C cirrhosis as this means that the survival of the 
patients is improved, and thus contributes to the pool of incident cases of HCC. 
1.3.2 Non-cirrhotic hepatocellular carcinoma 
Most PLC occur in the background of cirrhosis. However, in some patients, HCC 
arises de novo, without preceding cirrhosis. This is more commonly associated with 
tumours in patients that have used anabolic steroids, the metabolic syndrome, as 
well as in patients with type 2 diabetes mellitus. In those patients who have 
background viral hepatitis, non-cirrhotic HCC occurs much more commonly in less 
developed regions of the world than in the West. Indeed, metabolic syndrome has 
been hypothesized to become the most important risk factor for HCC in the future 
(Siegel and Zhu, 2009;Stickel and Hellerbrand, 2010). Indeed a recent 
epidemiological study of HCC by the Newcastle group has drawn the attention of the 
world to a relatively high rate of NAFLD-associated HCC, contributing to 35% of the 
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aetiological risks identified (Dyson et al., 2014). Approximately, 22% of NAFLD-
associated HCC patients in that study had background cirrhosis. 
1.3.3 Hepatitis C Virus 
HCV is an RNA flavivirus, which prior to discovery, was described as Non-A, Non-B 
hepatitis virus. Its association with HCC has been established from case control, as 
well as prospective studies. Markers of HCV have been described in about 90% of 
HCC cases in Japan (Yoshizawa, 2002) and 44-66% of patients in Italy (Fasani et 
al., 1999;Stroffolini et al., 1999). Owing to the higher prevalence of HCV, compared 
to HBV in Western countries, HCV constitutes the most important risk factor for HCC 
in these countries, as well as Japan. Molecular clock analyses during early 2000 
have estimated that HCV began to infect large cohorts of young people in Japan, 
southern Europe and North America in 1920s, 1940s and 1960s respectively, 
following the use of contaminated needles and intravenous drug abuse (Armstrong 
et al., 2000). This infection continued to spread in blood product infusions until early 
1990s when screening was developed for HCV.  
Up to 3% of HCV-infected persons develop HCC after 30 years of infection (Hassan 
et al., 2002), often occurring in the background of advanced fibrosis and cirrhosis. 
The annual incidence of HCC in HCV-induced cirrhosis is approximately 1-4% 
(Donato et al., 2002a). Environmental and host factors interact to enhance 
progression to cirrhosis in patients chronically infected by HCV. This has been 
shown by the fact that the incidence of HCC among Japanese is higher in those 
living in Japan, compared to those living in Hawaii; who in turn, have a 2.21 higher 
incidence than native Hawaiians (Maskarinec and Noh, 2004). Old age, as well as 
older age at the time of infection, heavy alcohol intake of more than 50g per day, 
male gender, diabetes mellitus, obesity, and co-infection with HBV or HIV have all 
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been identified as host factors that enhance cirrhosis development in chronically 
HCV-infected patients (Cramp, 1999). Although, the development of cirrhosis 
increases HCC occurrence, it is not an absolute requirement; as inflammation 
continues over time, the many steps required to induce carcinogenesis can occur 
independent of the evolution of fibrosis. 
1.3.4 Hepatitis B Virus 
HBV is a DNA virus belonging to the Hepadnaviridae family. The World Health 
Organisation (WHO) has pronounced HBV as the second most important human 
carcinogen after tobacco (Department of Communicable Diseases Surveillance & 
Response, 2002). There are estimated 350-400 million people chronically infected 
with the HBV worldwide. HBV is believed to account for over 50% of cases of HCC 
globally, having a significant regional variation (Parkin, 2006). Up to 70% of HCC 
cases in South Korea, 15% in Japan and the majority of cases in sub-Saharan Africa 
are attributable to HBV (Kim et al., 2008). Chronic HBV infection induces chronic 
inflammation which leads to repeated cellular regeneration, subsequently 
progressing to HCC, following approximately 25 years of infection. Chronic infection 
with HBV confers a 10-25% lifetime risk of developing HCC (Seeger and Mason, 
2000). The carcinogenic potential of this virus is ensured by its ability to integrate its 
genetic material into the host genome in or near proto-oncogenes or tumour 
suppressor genes. However, the vast majority (70 to 90%) of people who develop 
HCC from HBV infection do so on a background of cirrhosis (El-Serag & Rudolph, 
2007). When HBV is acquired in adulthood, there is spontaneous resolution of the 
acute infection in approximately 90% of cases. Most cases that are acquired 
vertically, perinatally or by horizontal route of transmission in early childhood often 
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produce a chronic infection; with less than 10% resolving and majority progressing to 
various forms of chronic hepatitis B infection sequelae. 
Similar to HCV, several host and environmental factors enhance HCC among those 
infected with HBV, including: male gender, older age, Asian or African race, 
cirrhosis, family history of HCC, aflatoxin exposure, alcohol use or HCV and hepatitis 
D virus (HDV) co-infection. Viral factors that are associated with HCC development 
include: high levels of HBV DNA and the presence of HBeAg. HBV genotype C 
conveys a higher risk of HCC than genotype B and genotype D has a higher risk 
than genotype A (Chan et al., 2004;Yang et al., 2008). Comparisons between the 
genotypes commonly encountered in Europe (A and D) and those in Asia (B and C) 
are yet to be carried out. There remains scanty information on the E genotype, 
reported to be prevalently restricted to the West African sub-region (Dupinay et al., 
2010). 
1.3.5 Dietary aflatoxin 
Aflatoxin B1 (AFB1), a mycotoxin produced by the fungus, Aspergillus spp, was 
described as a human liver carcinogen by Wogan in 1992 (Wogan, 1992). These 
fungi grow on several food products including peanuts, cereals, cassava and 
fermented soy beans; particularly when poorly stored in high moisture conditions of 
tropical regions of sub-Saharan Africa and eastern Asia. Following ingestion, AFB1 is 
metabolised to an active substrate, AFB1-exo-8,9-epoxide.  Transgenic mice studies 
have suggested that HBV alters the expression of carcinogen metabolising proteins 
through chronic liver damage and modulates the level of binding of this aflatoxin 
substrate to DNA (Turner et al., 2002). The downstream effect leads to the 
production of the mutation, P53 249ser with the ultimate result of inhibiting the p53 
tumour suppressor gene.  
 38 
 
A synergistic effect exists between HBV and aflatoxin. Most HBV-infected individuals 
exposed to the toxin have a higher risk of HCC compared to non-exposed persons. 
A study of a prospective cohort in the mid-1990s from China demonstrated a 
significant rise in the relative risk of HCC from 7.3 in HBV-infected persons with no 
aflatoxin exposure to 60 in those who were exposed (Qian et al., 1994;Zhang et al., 
1998). The mutation in the p53 gene produced by this toxin has been found in 30-
60% of all HCC cases from affected regions (Zhang, Wang, Han, & Zhuang, 1998). 
Additionally, a study from Gambia has shown a strong relationship between cirrhosis 
of the liver among HBV patients and aflatoxin (Kuniholm et al., 2008). This study 
postulated that aflatoxin enhances hepatocarcinogenesis via promoting cirrhosis of 
the liver among chronically-infected HBV patients (Kuniholm et al., 2008). It remains 
to be demonstrated whether exposure to this toxin is a risk factor for HCC without 
the influence of hepatitis B in humans. 
1.3.6 Alcohol  
Heavy alcohol consumption, defined as the ingestion of more than 50-70g per day 
for a prolonged period, is an established risk factor for HCC, which can occur 
independently of the development of cirrhosis.  It is known that the consumption of 
over 80g per day of alcohol for over 10 years increases the risk of HCC five-fold 
(Morgan et al., 2004a). Furthermore, evidence for synergism between heavy alcohol 
consumption with HCV or HBV to increase HCC risk by promoting cirrhosis exists. A 
dose-effect relationship study in 2002 in Italy found that HCC incidence doubled in 
those with HCV infection compared to those who did not have the infection and 
drank alcohol with a daily intake of more than 60g of alcohol/day (Donato et al., 
2002a). The mechanisms by which alcohol causes HCC are hypothesised to include 
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oxidative stress, genetic susceptibility, decreased natural killer (NK) cell function and 
modulation of DNA methylation (Morgan, Mandayam, & Jamal, 2004a).  
1.3.7 Non-alcoholic liver disease and diabetes mellitus 
Many of the major risk factors for HCC (HBV, HCV, alcohol) cannot be identified in a 
proportion of HCC patients. Non-alcoholic fatty liver disease (NAFLD), a condition 
associated with insulin resistance and which contributes to the metabolic syndrome 
is reported to be increasing (Leclercq, 2010). About 20% of those who develop 
NAFLD are complicated by non-alcoholic steatohepatitis (NASH) characterised by 
hepatocellular damage, chronic inflammation and progressive fibrosis, in addition to 
steatosis. The progression of NASH ends in cirrhosis, with the development of HCC 
in some. Recent evidence from a German study suggests that HCC could develop in 
NAFLD/NASH patients in the absence of cirrhosis (Ertle et al., 2011). A significant 
proportion (41.7%) of individuals with NAFLD/NASH associated HCC in that study 
had no evidence of cirrhosis. Studies have indicated that up to 90% of all obese 
persons (BMI >30Kg/m2) and about 70% of patients with type II diabetes have some 
form of fatty liver disease (Neuschwander-Tetri and Caldwell, 2003). A 2-3 fold 
increased risk of HCC in obese men and women, compared to those with normal 
BMI have been documented in some studies (Moller et al., 1994;Wolk et al., 2001). 
HCC was found to be more common among those who had concomitant HCV 
infection, and conveying only a modest 1.4 fold risk among HBV patients. In the 
presence of diabetes and obesity, there was a 100-fold excess of HCC in the context 
of either of the chronic viral hepatitides. With the current global epidemic of obesity 
(El-Serag & Rudolph, 2007) and diabetes, and with HBV and HCV control 
programmes in place, it is reasonable to suggest that NASH would likely account for 
an increasing number of cases of HCC in the future. 
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1.3.8 Hereditary Haemochromatosis and Iron Overload Syndromes 
Hereditary haemochromatosis (HH) is a commonly encountered autosomal 
recessive disorder, mostly affecting people of North European descent and 
uncommon in Africa (Powell et al., 2000). It is principally caused by mutations in the 
HFE gene (the most important being C282Y, followed by H63D) and is associated 
with excess iron absorption. Disease manifestation is most common in C282Y 
homozygotes and C282Y/H63D compound heterozygotes. This mutation leads to 
excess storage of iron in various organs, including the liver, resulting in liver damage 
and progressive fibrosis. Some studies have established the association between 
HH and the development of HCC (Elmberg et al., 2003;Fracanzani et al., 2001). The 
risk for the development of liver cancer is particularly enhanced among male 
diabetics (Yang et al., 1998). During the last decade, research has demonstrated 
that the C282Y mutation in the HFE gene is not diagnostic of HH, but may be 
associated with higher levels of serum ferritin, transferrin saturation and deposition of 
excess iron in the liver (Fargion et al., 2001). A French study has shown that the 
incidence of HCC was significantly higher among those with this mutation and having 
alcohol-related cirrhosis compared to those who have HCV-related cirrhosis 
(Mandishona et al., 1998;Nahon et al., 2008). Studies in African populations found 
that patients who ingested iron through drinking locally brewed alcohol in iron pots, 
have a 10-fold increased risk of developing HCC, after adjusting for other aetiological 
factors (MacPhail et al., 1999;Mandishona et al., 1998;Moyo et al., 1998). 
1.3.9 Oral contraceptive pills 
Animal studies have shown that oestrogens and progestogens, contained in oral 
contraceptive pills (OCP), are inducers and promoters of liver tumours (IARC, 1999). 
Case-control studies, mostly in the USA and Europe have produced results in 
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support of the hepatocarcinogenic potential of these pills in relatively young women 
(Herman et al., 1994;Korula et al., 1991;Perret et al., 1996;Tavani et al., 1993;Yu et 
al., 1991). A meta-analysis of these studies found odds ratios of 2.5 and 5.8 in those 
who had ever used these drugs or had longer duration of use respectively, compared 
to those who never used them (Yu and Yuan, 2004).  This finding is however, not 
uniform across the world, as some series in Africa and Asia found no difference in 
the prevalence of HCC between those who took OCPs and those who did not (Kew 
et al., 1990). 
1.3.10 Dietary factors  
Studies suggesting the role of coffee drinking in modifying the aetiopathogenesis of 
HCC have been documented. Some epidemiological studies have previously 
reported that coffee drinking reduced the risk of elevated liver enzymes and cirrhosis 
(Klatsky et al., 2006;Tanaka et al., 1998). Indeed, insulin levels have been 
demonstrated to be low (in contrast to high levels in type 2 diabetes mellitus) in 
those who drink coffee (El-Serag et al., 2006). Animal studies have suggested that 
coffee reduces carcinogenesis of the liver. Tanaka and colleagues in 1990 found that 
the incidence of HCC foci in rats given concurrent aminopyrine and sodium nitrite 
with coffee solution (as drinking water) for 630 days were significantly lower than 
those rats given only aminopyrine and sodium nitrite (Tanaka et al., 1990). 
Case-control and cohort studies in Japan (Shimazu et al., 2005) and Europe (Bravi 
et al., 2007;Montella et al., 2007) evaluating the relationship between increased 
coffee consumption and HCC, found significant reductions in the risk of HCC. The 
role of diet in carcinogenesis is not new to HCC as increased dietary fibre has been 
shown to be associated with lower incidence of colorectal cancers, as well as vitamin 
C and fruits and vegetables related to lower incidence of gastric and lung cancers 
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respectively (Gonzalez and Riboli, 2010). If not causal, certain diets may be 





1.4 Risk factors and pathogenesis of intrahepatic cholangiocarcinoma 
Compared to HCC, the aetiology of intrahepatic cholangiocarcinoma (IHCC) is poorly 
understood and only one out of 10 cases of cholangiocarcinoma are associated with 
known risk factors (Ben-Menachem, 2007). The important factors are discussed 
below: 
1.4.1 Bile duct factors 
In Western industrialised countries, IHCC complicates up to 40% of patients with 
primary sclerosing cholangitis (PSC) (Shaib & El-Serag, 2004). In contrast, liver fluke 
infestation (Opisthorcis viverrini), known to be endemic in East Asia, is the most 
implicated risk factor in that region. For this reason, countries in East Asia are known 
to have the highest rates of IHBD worldwide (Shaib & El-Serag, 2004;Watanapa and 
Watanapa, 2002). An animal study has suggested that liver fluke infestation 
promotes carcinogenesis by enhancing the effect of chemical initiators. Following 
infestation with O. viverrini, Syrian hamsters that were fed nitrosamines 
demonstrated malignant change in their biliary epithelia (Thamavit et al., 1978). 
Approximately, 10% of individuals with intrahepatic bile duct stones develop 
cholangiocarcinoma (Kubo et al., 1995). Congenital fibropolycystic liver disease, bile 
duct adenomas and biliary papillomatosis are other associated biliary duct factors. 
1.4.2 Other factors 
Thorotrast, a radiological contrast agent used in the 1930s to 1950s has been 
strongly linked with IHCC (Sahani et al., 2003). Dioxins and nitrosamines, both 
industrial toxins have demonstrated epidemiological associations with IHBD (Hardell 
et al. 1984). A recent hospital-based case-control study of risk factors for IHBD in the 
USA reported that excess alcohol consumption was higher among IHCC patients 
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(22%) compared to controls (4%) (Shaib et al., 2007). A population-based case-
control study, also in the USA, involving 535 IHCC patients and 102,782 cancer-free 
controls found that biliary cirrhosis, alcoholic liver disease, non-specific cirrhosis, 
diabetes mellitus, thyrotoxicosis and chronic pancreatitis were significantly 
associated with IHCC (Welzel et al., 2007). Other factors that showed a weaker 
association were obesity, smoking and HCV infection. Additionally, a prospective 
study involving 11,000 patients with variety of causes of cirrhosis followed up for 6 
years in Denmark reported a 10 fold increase in the risk of IHCC compared to the 
general population (Sorensen et al., 1998). Case-control and prospective studies 
from Korea (Shin et al., 1996), Italy (Colombo et al.,1991;Donato et al., 2001), Japan 
(Kobayashi et al., 2000) and the USA (Shaib et al., 2005) have all corroborated the 
fact that hepatitis B (HBV) and hepatitis C (HCV), have a place in the pathogenesis 
of intrahepatic bile duct carcinoma. Other putative factors include genetic 
polymorphisms involving bile salt transporter proteins (Wadsworth et al., 2011). 
1.4.3 Pathogenesis  
Chronic inflammation of the biliary epithelium underlies the pathogenesis of this 
tumour as recurrent epithelial regeneration is engendered. The resulting increased 
cholangiocyte turnover may induce mutations of proto-oncogenes and tumour 
suppressor genes, leading to dysplastic changes and eventually, 
cholangiocarcinoma (Khan et al., 2005b). Alternatively, a putative mechanism 
involves the initial formation of mutagenic DNA adducts by toxins. Chronic 
inflammation then provides the “second hit” that exposes the bile duct epithelium to 
the adducts, resulting in cancer development (Khan et al., 2003). 
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1.5 Clinical Presentation 
HCC is asymptomatic in its early stages. A great majority of patients with malignant 
liver tumours present in advanced stages of the disease with symptoms and signs 
suggestive of liver decompensation and sometimes, of metastasis (El-Serag et al., 
2008;Gores, 2000). Nevertheless, increased awareness and the implementation of 
active surveillance have led to early diagnoses in asymptomatic cases.  
Common clinical features of advanced HCC include right upper abdominal pain, 
weight loss and malaise. In well monitored healthcare systems, the initial observation 
may be worsening liver enzymes in a patient known to have cirrhosis of the liver. 
Rare manifestations include acute abdomen from rupture of HCC nodule with 
intraperitoneal bleeding (Choi et al., 2001a). Paraneoplastic presentations have also 
been documented, but are rare, including: hypercalcaemia, hypoglycaemia, 
thyrotoxicosis and polycythaemia (extrarenal synthesis of erythropoietin) (Eastman 
et al., 1992;Sakisaka et al., 1993).  
Clinical signs, such as cachexia in advanced cases, jaundice, palmar erythema, 
gynaecomastia and signs of portal hypertension (due to associated cirrhosis of the 
liver) may be noticed. A hard, nodular liver on abdominal palpation has been 
described to be typical in many African populations, owing to the very late stage at 
which the patients present (Umoh et al., 2011). Hepatic bruits, due to hyper-




1.6 Diagnosis  
1.6.1 Hepatocellular carcinoma 
HCC is one of very few cancers where a diagnosis can be made in the absence of 
histology as it can be diagnosed on radiological criteria alone. Triple-phase helical 
computerised tomography (CT), and dynamic contrast enhanced magnetic 
resonance imaging (MRI) (Choi et al. 2001b) is usually embarked upon as soon as a 
suspicious lesion is detected during routine surveilance.  The hallmark of diagnosis 
using these techniques is based on arterial enhancement, followed by delayed 
hypointensity of the tumour in the portal venous and delayed phases (described as 
“washout”) respectively. HCC derives its blood supply from the hepatic artery, in 
contrast to the remainder of the non-cancerous liver tissue (which receives blood 
supply from both artery and portal venous system). Decreased or absence of 
contrast in the tumour tissue during the venous and delayed phases is the hallmark 
of “washout”. The performance of CT and MRI is affected by the size of the lesions. 
The accuracy of MRI to detect lesions less than 2 cm falls to 33%, but >90% for 
lesions larger than 2 cm (Ebara et al., 1986). Although, “washout” has a high 
sensitivity of 90% and specificity of 95%, about a third of HCC cases do not have this 
feature. Liver biopsy for histological diagnosis is usually unavoidable for this group. 
Indeed, in many centres in developing countries, biopsy remains the only option for 
confirming diagnosis of HCC (Ladep and Taylor-Robinson, 2007). For some less 
developed countries, the World Gastroenterology Organisation (WGO) guidelines 
recommend the use of AFP for HCC diagnosis (Ferenci et al., 2010). Serum levels of 
AFP above  200 ng/L are highly specific for HCC diagnosis in patients with cirrhosis 
(Bruix and Sherman, 2005). However, reports have indicated that the sensitivity of 
AFP falls drastically when a cut-off value of 200 ng/L is used since only a third of 
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patients with HCC have levels above that threshold (Ebara et al., 1989;Torzilli et al., 
1999).  
The diagnosis of HCC can be established if: 
a focal liver mass >2 cm is identified on one imaging technique, demonstrating 
characteristic contrast enhancement features on the arterial phase with venous 
washout on MRI, CT or CEUS;  
(i) a focal hepatic mass with atypical imaging findings, or a focal mass 
detected in a non-cirrhotic liver, should undergo a biopsy.  
(ii) Nodules smaller than 1 cm should be followed up for 2 years at 3-4 
monthly intervals, based on the updated algorithm of the American 
Association for the Study of the Liver (AASLD) (Figure 2).  
(iii) If no further growth is demonstrated, a return to routine surveillance is 
recommended.  
Percutaneous liver biopsy performed under CT guidance yields higher sensitivity and 
specificity than when US alone is utilised (Durand et al. 2001). 
1.6.2 Intrahepatic cholangiocarcinoma 
Intrahepatic cholangiocarcinoma is difficult to diagnose, as there are no definite 
imaging findings that describe the lesions accurately, no serum markers of proven 
high sensitivity and specificity, and the histological pattern is non-specific. In some 
instances, diagnosis is achieved at autopsy. Biochemical investigations offer limited 
utility in the diagnosis of cholangiocarcinoma. Liver function tests may show an 
obstructive pattern of raised alkaline phosphatase, bilirubin and gamma-glutamyl 
transpeptidase. Tumour markers for cholangiocarcinoma; carbohydrate antigen 19-9 
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(CA 19-9), carcinoembryonic antigen (CEA) and carbohydrate antigen 125 (CA-125), 
all are associated with low sensitivity and specificity and cannot be relied upon for 
diagnostic purposes (Hultcrantz et al., 1999;Khan et al., 2002a). Owing to its low 
cost, widespread availability and non-invasive nature, abdominal US is the initial 
imaging modality employed. A pulsed colour Doppler sonography may demonstrate 
a tumour-induced compression (or thrombosis of the portal vein or artery). A 
combination of MRI and magnetic resonance cholangiopancreatography (MRCP) is 
used (where available) as a second line, otherwise high resolution contrast-
enhanced spiral CT is used (Figure 3). Potential resectability is considered before 
confirming IHCC histologically, for example by endoscopic retrograde 
cholangiopancreatography (ERCP) and percutaneous transhepatic cholangiography 
(PTC). Although, these latter techniques are often required to obtain washings, 
brushings, intraductal biopsies and/or therapeutic interventions, MRCP has been 
more commonly utilised in recent years for the diagnosis of IHBD (Khan et al., 











Figure 2. Diagnostic algorithm for suspected HCC (CT, computed tomography; 
MDCT, multidetector CT; MRI, magnetic resonance imaging; US, Ultrasound) (Bruix 












1.7 Surveilance and Early Detection 
Surveilance of at-risk populations improves the treatment and outcome of HCC, 
since it leads to detection of tumours at early stages, when they are amenable for 
curative therapies such as resection, ablation and/or transplantation. High risk 
populations include virtualy al those with cirhosis and HBV-infected men (>40 
years) and women (> 50 years) (El-Serag, Marero, Rudolph, & Reddy, 2008). A 
*Where MRI/MRCP is not possible, patients should have contrast enhanced spiral/helical CT 
**FNA or biopsy is idealy avoided until resectability has been assessed by a specialist surgeon 
Table adapted from Khan et al., Gut 2002 
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breakdown of groups of high risk people for whom screening for liver cancer has 
been recommended is shown in table 1. 
 
 
Table 1. Groups in whom HCC screening and surveillance are recommended (El-
Serag, Marrero, Rudolph, & Reddy, 2008) 
Hepatitis B carriers 
 Asian males >40 yrs 
Asian females >50 yrs 
All cirrhotic hepatitis B carriers 
Family history of HCC 
Africans over age 20 yrs 
Non-hepatitis B cirrhosis 
 
 Hepatitis C 
Alcoholic cirrhosis 
Genetic haemochromatosis 
Primary biliary cirrhosis 







Liver US and AFP are the most commonly used modalities for HCC surveillance. 
The performance of US is however, operator-dependent, the technology employed, 
presence of cirrhosis and size of the tumour (Bolondi et al., 2001). Most studies have 
identified a sensitivity of above 60% and specificity, over 90% for US. The sensitivity 
is particularly low if detecting a tumour nodule in a cirrhotic liver (Kim et al., 2001). 
The upper limit of normal (ULN) serum AFP, 20ng/mL has a low sensitivity of 25% to 
65% for detection of HCC and thus fails to serve as a sole screening modality 
(Trevisani et al., 2001). Furthermore, elevated values (in the absence of malignancy) 
of AFP occur in conditions associated with high degree of liver regeneration, such as 
chronic HCV (Bayati et al., 1998). Other serum-based tests, such as des-γ-
carboxyprothrombin and lectin bound AFP, present variable sensitivities and require 
more robust data to validate their usefulness (Ishida et al., 2010;Marrero et al., 
2009). The current guidelines recommend the use of standard, non-contrast US at 6-
12 months frequency to screen for HCC in high risk individuals (Bruix & Sherman, 
2005;Trevisani et al., 2002). 
1.7.1 Advantages of screening 
If PLC is discovered at an early stage, effective treatments are available, possessing 
the advantage of improving survival. Owing to ethical issues, results of survival 
benefits from surveillance programmes have been scanty. Zhang and colleagues, 
working in China reported a survival benefit in a surveyed at-risk population 
compared to a non-surveyed population, in the only available randomised trial 
performed to date. Although, the adherence was noted to be lower than 60%, this 
study of nearly 19,000 HBV infected patients showed that testing of serum α-
fetoprotein (AFP) and  abdominal ultrasound (US) at 6 monthly intervals improved 
survival (37% reduction in HCC-related mortality) (Zhang et al. 2004). This benefit 
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could however, be annulled if curative managements, are lacking as observed by a 
similar study in another province of China (Chen et al. 2003). 
1.8 International Classification of Diseases 
Historically, the classification of diseases started in the mid-1800s, then known as 
International List of Causes of Death. The World Health Organisation (WHO) took 
over from the International Statistical Institute in 1948 about the time the 6th revision 
was published, which included causes of morbidity for the first time (World Health 
Organisation, 1949). The International Classification of Diseases, Injuries, and 
Causes of Death (ICD) has since become adopted as the International standard 
diagnostic categorisation for all general epidemiological and clinical use, among 
which are: general health situation of population groups and monitoring of incidence 
and mortality of diseases in relation to personal and resource variables. It provides 
the basis for the compilation of national mortality and morbidity statistics by WHO 
member states. The 6th version and indeed all the other revisions were necessitated 
by the need to keep abreast with advances in medical knowledge and nomenclature. 
The ICD assigns a three character alphanumeric code to every major condition, a 
fourth character is often added for more exact specification. For cancer classification, 
each tumour is assigned a topographical code, correlating with the anatomic sites of 
involvement. These topography codes are applicable to all tumours, regardless of 
their growth behaviour; whether benign, malignant, in situ or uncertain. 
Hepatocellular carcinoma (HCC) and Intrahepatic bile duct tumours (IHBD) were 
recognised as distinct entities by cancer registries for the first time in 1968 (eighth 
revision of ICD) (World Health Organisation, 1967). The ninth revision (ICD-9) (World 
Health Organisation, 1975) was adopted for the coding of incidence and mortality 
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data in England and Wales between 1979 and 1994, after which ICD-10 came into 
use for incidence data (World Health Organisation, 1992). Changes in ICD 
classification can impact upon direct comparability of disease rates over time. 
Aggregation of categories of diseases is often necessary before any valid 
comparison is possible. From 2001 however, both cancer registration and mortality 
data in England and Wales are recorded using the ICD-10 (Table 2). It is important 
to note that different countries adopt ICD changes at different time points; the impact 
on epidemiological trends of which remains to be extensively studied. 
 
Table 2. Subsets of liver tumours under by ICD codes 
SUBSET NAME ICD-10 CODE 
Malignant liver 
tumours (PLC) 
Primary liver tumour 
(mainly HCC) 
C22 (malignant neoplasm of the liver and intrahepatic bile 
ducts) 
C22.0 (hepatocellular carcinoma) 
Other  malignant 
liver tumours 
C22.2 (hepatoblastoma) 
C22.3 (angiosarcoma of the liver) 
C22.4 (other sarcomas of the liver) 
C22.7 (other specified carcinomas of the liver) 
Intrahepatic bile 
duct 
C22.1 (intrahepatic bile duct carcinoma) 
Unspecified liver 
tumours 





1.9 Study Background  
1.9.1 Current Knowledge 
Epidemiological studies of primary liver cancer (PLC) towards the end of the last 
century revealed upward trends in the incidence and mortality rates of PLC in some 
developed industrialised countries of the world, including England and Wales. 
However, despite progress made in the management of PLC, the prognosis of this 
cancer remains abysmal. The high case-fatality associated with HCC is often due to 
late presentation by most patients, absence of effective screening tools and 
personnel, besides poor health delivery systems in most developing countries. The 
current screening tools for HCC remain the use of ultrasound (US) and serum alpha 
fetoprotein (AFP). While US is operator-dependent and presents increased risk of 
missed diagnoses, in addition to being an impractical tool for use in many developing 
countries, AFP has a low sensitivity for detecting HCC (Farinati et al., 2006). Also, 
adherence to 6 monthly HCC surveillance is poor, even in resource rich countries. 
An ideal screening tool with higher sensitivity and specificity, easy accessibility, and 
which is cost-effective and culturally acceptable is a necessity in curbing the growing 
problem of HCC. 
1.9.2 Gaps in knowledge 
The impact of recent management advances and emerging risk factors on the 
epidemiology of PLC in England and Wales, as well as globally, is yet to be 
adequately studied. Although improved case ascertainment, diagnostic transfer, and 
evolution in aetiologic factors have all been postulated as explanations for earlier 
increasing international trends, widespread substantive evidence is lacking to prove 
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any of these hypotheses. The utility of the current screening tools (AFP and US) for 
primary liver cancer are limited by logistical, technical and personnel issues. Simple, 
effective and cheaper alternatives for screening are required, particularly in 
resource-limited countries where HCC is most common. The performance of pilot 
screening tools determined by metabonomic studies is promising, but limited by 
small sample sizes.  
1.9.3 Contribution of current work 
This work comprised an analysis of recent trends in mortality rates of PLC 
worldwide; including a comprehensive study of the incidence and mortality rates of 
PLC by subgroups in England and Wales. This was enabled by the fact that there is 
a robust cancer registration in the UK compared to many other countries. The impact 
of viral hepatitis co-infection of HIV patients on liver related morbidities in the African 
setting was examined as well. Importantly, urinary metabolic profiling for biomarkers 
of HCC was undertaken in a large sample study of subjects from West Africa, with 
view to establish a robust, easily accessible and applicable tool (dip-stick) for the 
screening of HCC.  
1.10 Overall aims 
The main aims of my study were to a) characterise the mortality trends of PLC 
subtypes globally, b) determine the most recent trends in the incidence and mortality 
rates of primary liver cancer in England and Wales, c) study the impact of viral 
hepatitis on HIV-infected persons, and d) metabolically profile HCC using urine, with 
an ultimate view of enabling a novel urinary diagnostic screening test for HCC.  
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1.10.1 Specific objectives 
1. To determine the age-standardised mortality rates by ICD subcategories of 
primary liver cancer in countries across different regions of the world. 
2. To determine the age-standardised incidence and mortality rates of primary 
liver cancer by ICD subcategories in England and Wales. 
3. To determine the rates and impact of liver-related morbidities on HIV in an 
African setting. 
4. To determine the impact of HBV on survival of HIV-infected patients on 
antiretroviral therapy. 
5. To analyse the metabolic profile in urine of HCC patients from Gambia, 
Senegal and Nigeria using proton magnetic resonance spectroscopy (NMR) 





2. INTERNATIONAL TRENDS IN MORTALITY RATES OF PRIMARY LIVER 
CANCERS 
2.0 ABSTRACT 
Background: As the risk factors for primary liver cancer (PLC) are likely to be 
specific for the different sub-groups, studies of mortality rates by specific PLC 
subtypes and gender of several countries may provide useful information regarding 
prevention and treatment. Global trends in the mortality rate of major subcategories 
of PLC from 1996 to 2009 were determined. 
Method: Recent primary liver cancer mortality data from the National Cancer 
Registries of 8 countries: representative of Europe, Asia-Pacific and North America 
were obtained from the World Health Organisation (WHO) database. The age-
standardised mortality rates (ASMR) of different subcategories of PLC were 
calculated, and the rates for hepatocellular carcinoma (HCC), intrahepatic bile duct 
tumours (IHBD) and unspecified liver tumours (Liver NOS) were reported in the 
present study. Trends in the ASMR of HCC and IHCC were evaluated using a 
regression method in which a least squares regression line was fitted to the natural 
logarithm of the rates. 
Results: Over the study period, high ASMR of HCC were noted in males from Japan 
(17.4/100,000), Hong Kong (15.3/100,000) and Spain (4.8/100,000). Relatively lower 
ASMR of HCC were observed in Norway (1.0/100,000), England and Wales (1.4 
/100,000), Romania (1.6/100,000), Australia (2.2 /100,000) and USA (2.3/100,000). 
The trends of ASMR of HCC has been declining in Japan, Hong Kong and Spain 
(APC; -4%, -2% and -1% respectively). ASMR of HCC increased in men in England 
& Wales (+7%), Romania (+5%), USA (+3%) and Australia (+1%). Rising trends in 
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mortality from IHCC for all evaluated countries were observed. Hong Kong registered 
the highest mean ASMR of IHBD of 2.4/100,000. Although the burden of IHBD was 
least in Romania (0.2/100,000), the greatest increase (APC: +18%) was noted in that 
Eastern European country.  
Conclusion: While a global increase in ASMR of IHBD was observed over the study 
period, mortality from HCC is increasing only in countries with relatively lower ASMR 
while decreasing in countries with high rates, suggesting differences in the control of 
risk factors for HCC such as HBV vaccination and or surveillance and management 
of incident HCC. Factors that may be contributing to the global widespread increase 





Recent data from the USA (El-Serag and Mason, 1999), France (La et al., 2000), 
Italy (La et al., 2000) and Japan (Kato et al. 1990) showed rising mortality rates of 
primary liver tumours. Epidemiological reviews indicate that mortality rates are falling 
in many developing countries (McGlynn et al., 2001). In England and Wales, excess 
mortality from PLC during 1968-1998 was attributable to IHBD (Taylor-Robinson et 
al., 2001). Also, looking at international trends in the mortality rates of hepatobiliary 
tumours, Khan and colleagues in 2002 (Khan et al., 2002b) trawled WHO mortality 
databases and observed widespread increase in the mortality rate for IHBD. 
Technological advances in the management of liver diseases, including PLC have 
been realised within the last decade and are assumed to have impacted on the 
mortality rate for PLC. Several countries have published guidelines, aimed at 
improving the management of PLC. Despite availability ultrasound for screening at-
risk populations, most recent data from England and Wales have shown that 
mortality rate for PLC has maintained its relentless upward pattern, particularly with 
regards to both IHBD and HCC in men and women.  
2.1.1 Rationale for the study 
Given their dynamic nature, further studies on trends in the mortality of PLC by sub-
types are required for the evaluation of intervention systems and proper health 
planning. The extent to which control programmes for HBV and HCV would achieve 
any significant impact can be determined by continuous monitoring of incidence and 
mortality rates of PLC. There has been increasing consumption of alcohol globally 
(Donato et al., 2002b;Hasumura and Takeuchi, 1991;Pincock, 2003), as well as an 
epidemic of obesity (James et al., 2001a;James. 2008). The global epidemic of 
obesity, as well as rise in the consumption of alcohol may act against any gains 
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reminiscent upon improved preventive methods that would have been in place in the 
last decade towards reducing the burden of PLC. Nevertheless, active mobilisation 
for surveillance of HCC to achieve early detection and meet criteria for curative 
therapies is being pursued in resource-rich countries (Khan et al., 2002a;Ryder, 
2003;Song et al., 2010).  
Trends in mortality rates may reflect progress in the management of PLC and 
mortality data are readily available (as death registration are mandatory in many 
countries) (Sharp et al., 2001). Also, as the prognosis of PLC remains poor, mortality 
data for PLC can and has been used as proxy for incidence. The study of ASMR of 
PLC of the recruited countries can provide a fair idea of the incidence of this 
emerging epidemic. Moreover, population-weighted correlation analyses had 
demonstrated that liver cancer mortality mirrors its incidence (Neuberger et al., 
1985). The data for PLC incidence held by the International Agency for Research on 
Cancer (IARC) could be used but are limited to 3 digit ICD-10 codes and hence fail 
to meet the criteria for site specific study of PLC incidence. In this current study, 4-
digit ICD-10 codes have been used in order to facilitate investigation of specific PLC 
sub-types, as the need to study tumours by subcategories was been highlighted by 
Percy and co-workers (Percy et al., 1990); whose report pointed out the enhanced 
accuracy of studying diseases by specific ICD codes. This study aimed to examine 
temporal changes of mortality from PLC by subtypes (four digit ICD codes) in select 
countries, representative of different regions of the world.  
2.1.2 Hypothesis 




The aims of the present study were to primarily calculate ASMR of PLC in countries 
from different regions of the world and to determine trends in the mortality rates of 
IHBD and HCC in particular.  
2.2 METHODS 
Liver cancer mortality statistics were obtained from the Department of Health 
Statistics and Informatics of the World Health Organisation (WHO). Population 
numbers, given by 5-year bands, were obtained from the official WHO database. 
Data were acquired from representative countries of all the health regions of the 
world. Included were countries that had optimal cancer registry data of mortality in 
the most recent past, as well as 5 year bands population counts for the period of 
mortality data. Countries where data were unavailable or incomplete were excluded. 
On one or both of these bases, countries from Africa, South America and East Asia 
were excluded. Included in the study were: Australia (Australasia), United States of 
America (North America), Japan, Romania (Eastern Europe), Spain (Southern 
Europe), Hong Kong (Asia), Norway and both England and Wales (Northern 
Europe). ASMR of PLC from 1996 and 2009 were calculated by direct 
standardisation, using 1960 world Standard population to control for age and sex 
structure differences in the population of the countries (WHO, 2011).  
Specific time periods for which data were utilised for this study are outlined below: 
 1998 – 2006 for Australia 
 1996 – 2008 for Japan 
 1999 – 2009 for Romania 
 1999 – 2008 for Spain 
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 1998 – 2008 for Norway 
 2001 – 2008 for Hong Kong 
 1999 – 2005 for USA 
 2001 – 2007 for England and Wales 
The percentage change in ASMR was calculated. The annual percent change (APC) 
for HCC, IHBD and Liver NOS in both genders, from the beginning and the end of 
the periods studied were calculated. These were determined using a regression 
method in which a least squares regression line was fitted to the natural logarithm of 
the mortality rates. 
2.3 RESULTS 
2.3.1 Hepatocellular carcinoma: General pattern  
A non-uniform pattern of trend in the mortality from HCC was found when latest 
ASMR were compared with the earlier data of the respective countries that were 
studied (Tables 3 and 4). In both sexes, increases in ASMR of HCC were observed 
in Australia, England and Wales, USA and Romania (Figure 4). In men, the highest 
increase in the mortality rate of HCC occurred in England and Wales (APC: +7%), 
followed by Romania (APC: +5%), and USA (APC: +3%), in that order. The least 
increase of 1% was observed in Australia. In women, rising trends in mortality rate of 
HCC were noted to be similar in England and Wales (APC: +4%) and Romania 
(APC: +5%). In contrast, mortality rates of HCC declined in Japan (APC: -4%), Hong 
Kong (APC: -2%) and Spain (APC: -1%).  
2.3.2 Intrahepatic bile duct tumours: General pattern  
In all studied countries there were increased ASMR of IHBD in both sexes with the 
exception of Hong Kong, where a 1% year on year decline was noted amongst 
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females (Tables 3 and 4). The highest increase was observed in men in Romania 
(APC: +18%). Consistent with the declining mortality rate of IHBD amongst females 
from Hong Kong, the smallest increase was recorded amongst men in this country 
(APC: +1%). Australia, England and Wales, Spain and USA in that order had 
intermediate rates of increase (5% to 6%) in ASMR of IHBD (Figure 5). 
2.3.3 Unspecified liver tumours: General pattern 
Falling ASMR of unspecified liver tumours were found in both men and women in 
most of the studied countries; including England and Wales, Japan, Hong Kong and 
Spain; as well as, females in the USA and Romania. During 1998 and in both sexes, 
no deaths were registered to unspecified liver tumour in Norway (Figure 6). 
However, inconsistent fluctuations were noted throughout the rest of the study period 
in Norway (Tables 3 and 4). 
2.3.4 Australia  
In Australia, there were marginal increases in the ASMR of HCC in both sexes 
between 1998 and 2006. Data were unavailable for 2005 and for which reason; the 
ASMR for that year was linearly extrapolated. A total of 244 (ASMR: 1.89) males and 
64 (ASMR: 0.41) females died due to HCC in 1998 in Australia, compared to higher 
numbers in 2006 [males: 346 (2.21) and females: 83 (0.45)]. This rise was 
inconsistent, producing an overall increase of 1% in men and no significant change 
in mortality among women during the study period.  
A smooth and more sustained increase in the ASMR of IHBD in both sexes was 
documented in Australia. One hundred and eleven (111) men (ASMR of 0.83) and 
93 females (ASMR: 0.52) died due to IHBD in 1998, rising to 214 (ASMR: 1.22) in 
men and 184 (ASMR: 0.91) in women, corresponding to a higher average annual 
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percent (APC) increased death rates in females of 7% than males (5%). While the 
ASMR of liver tumours of unspecified sub-site experienced a similar rise in females 
(5%) and males (5%).  
2.3.5 England and Wales  
In England and Wales, there was a sustained increase in the total number of deaths 
due to HCC. Six hundred and forty seven (647) people died in 2001, rising 
progressively to 1065 in 2007. The increased ASMR was more consistent amongst 
men (from 1.14 in 2001 to 1.71 in 2007) than women, resulting in APC of 7% and 4% 
respectively. 
There was a sustained rise in the mortality trend of IHBD in both sexes between 
2001 and 2007. The absolute number of deaths (ASMR) in 2001 for males and 
females were 454 (0.92) and 537 (0.79) respectively. The mortality rate rose to peak 
in 2006 for males at 1.21, while that for females rose to 1.12/100,000 in 2007. There 
was a slight decline in the ASMR of this tumour amongst men in 2007. The mortality 
rates of IHBD increased by an annual average of 5% and 6% in men and women 
respectively.   
In both males and females, deaths from unspecified liver tumours declined between 
2001 and 2007 (APC decreases of 6% in men and 9% in women). 
2.3.6 Norway 
ASMR of HCC in both males and females from Norway undulated but showed a 
general pattern of decline during 1998 to 2008. In 2008, these were 1.07 and 0.28 
compared to 1.23 and 0.40 in 1998 in males and females with APCs of -4% and -
10% respectively. The ASMR of IHBD in men and women increased more than 2 
and 4 folds respectively during 1999-2008. In 1998, no case of death due to liver 
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NOS was documented. There were inconsistent increases in the ASMR of 
unspecified liver tumour in both men and women in Norway until 2004, when it 
became smoother (APC increases of +11% and +17% in males and females 
respectively). 
2.3.7 Spain 
ASMR of HCC in Spain showed an overall decline; from 5.09 (men) and 1.37 
(women) in 1999 to 4.59 (men) and 0.95 (women) in 2008, corresponding to APC 
decreases of 1% and 4% in men and women respectively. ASMR of IHBD in both 
sexes in Spain showed a rising, but inconsistent trend (APC increased by 6% in men 
and 5% in women). A small but fluctuating decline in the ASMR of liver NOS was 
recorded in both genders between 1999 and 2008 (APC: +4% and +5% in men and 
women respectively). 
2.3.8 Romania 
There was a more than 2-fold increase in the absolute number of deaths and ASMR 
of HCC amongst men in Romania between 1999 and 2009. This was 199 (ASMR: 
1.21) in 1999 and 412 (ASMR: 2.54) in 2009 (APC: +5%). A less consistent, but 
rising ASMR of HCC was also noted amongst Romanian women (APC: +5%). 
The most dramatic increase in the mortality rate of IHBD, in both sexes, was found in 
Romania. Whereas in 1999 both males and females had 9 deaths (0.06 and 0.05 
ASMR respectively) the numbers rose to 62 (ASMR: 0.37) amongst males and 45 
(ASMR: 0.19) amongst females in 2009. APC of +18% and +15% of ASMR of IHBD 
in males and females respectively were observed during the study period. 
Liver NOS was noted to be the commonest cause of PLC subtype death in Romania. 
1019 males (6.53) and 622 (2.97) females died due to this tumour in 1999. An 
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inconsistent increase in men (APC: +1%) is seen while the rate was stable amongst 
women in Romania. 
2.3.9 Japan 
With the exception of IHBD, HCC and liver NOS realised a falling ASMR in Japan 
between 1996 and 2008. There were recorded 21,871 deaths among men in Japan 
and 8443 among women in Japan due to HCC in 1996, corresponding to ASMR of 
21.52 and 5.75 /100,000 respectively. These rates have steadily fallen from 1996 to 
recent values in 2008; 13.02 in males and 3.83 in females (APC: -4% and -3% 
respectively). A similar, but less rapid decline in the ASMR of liver NOS was also 
noted. 
There was an approximately 35% increase in the total number of deaths due to IHBD 
in both men and women in Japan between 1996 and 2008. This corresponds to a 
marginal rise in the ASMR from initial values of 0.79 (males) and 0.46 (females) in 
1996 to 1.07 (males) and 0.63 (females) in 2008 (APC of +2% in both men and 
women). 
2.3.10 Hong Kong  
In Hong Kong, data from 2001 to 2008 showed falling ASMR in all tumour subtypes 
in both sexes except for IHBD in males. Deaths due to IHBD affected 120 males 
(ASMR: 2.53) in 2001, rising to 164 (ASMR: 2.66) in 2008 (APC: +1%). Mortality 
rates of HCC and liver NOS in both sexes, as well as IHBD in females, declined 
during the study period. 
2.3.11 United States of America 
In general, there was a progressive rise in the number of deaths due to PLC 
subtypes in the US population between 1999 and 2005. The ASMR correspondingly 
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demonstrated a mild increase with the exception of a static rate in females, exclusive 
to HCC. Significant and steady increases in the ASMR of HCC and IHBD in men 
were noticed. The ASMR of HCC in men in America increased from 2.08 in 1999 to 
2.45 in 2006 (APC: +3%) and that for IHBD rose from 0.63 to 0.81 correspondingly 







Figure 4. Age-standardised mortality rates of HCC in (A) men and (B) women of 





Figure 5. Age-standardised mortality rate of intrahepatic bile duct tumours in (A) men 




Figure 6. Age-standardised mortality rate of Liver tumours, not otherwise specified 




Table 3. ASMR and number of deaths with percentage change for selected primary liver cancer subtypes in men by countries 
Tumour Australia England and Wales USA Japan 
  1998 2006 APC 2001 2007 APC 1999 2005 APC 1996 2008 APC 
HCC 1.89(244) 2.21(346) +1% 1.14(476) 1.71(820) +7% 2.08(3708) 2.45(4992) +3% 21.52(21871) 13.02 (20397) -4% 
IHBD  0.83(111) 1.22(214) +5% 0.92(454) 1.14(608) +5% 0.63(1208) 0.81(1780) +5% 0.79(830) 1.07(1684) +2% 
Liver NOS 0.52(67) 0.79(126) +5% 0.53(237) 0.37(195) -6% 1.44(2721) 1.73(3722) +3% 0.15(162) 0.12(195) -2% 
Table 3 continued 
Tumour Hong Kong Norway Spain Romania 
 2001 2008 APC 1998 2008 APC 1999 2008 APC 1999 2009 APC 
HCC 16.69(736) 14.75(774) -2% 1.23(48) 1.07(45) -4% 5.09(1703) 4.59(1889) -1% 1.21(191) 2.54(412) +5% 
IHBD 2.53(120) 2.66(164) +1% 0.34(9) 0.74(30) +11% 0.82(273) 1.30(569) +6% 0.06(9) 0.37(62) +18% 
Liver 
NOS 





Table 4. ASMR and number of deaths with percentage change for selected primary liver cancer subtypes in women by countries 
Tumour Australia England and Wales USA Japan 
  1998 2006 APC 2001 2007 APC 1999 2005 APC 1996 2008 APC 
HCC 0.41(64) 0.45(83) 0% 0.30(171) 0.40(245) +4% 0.57(1382) 0.52(1525) 0% 5.75(8443) 3.83(9783) -3% 
IHBD  0.52(93) 0.91(184) +7% 0.79(537) 1.12(763) +6% 0.51(1344) 0.60(1750) +4% 0.46(688) 0.63(1382) +2% 
Liver NOS 0.30(48) 0.27(57) +5% 0.25(167) 0.13(103) -9% 0.67(1945) 0.71(2225) +1% 0.07(115) 0.06(145) -2% 
Table 4. continued 
Tumour Hong Kong Norway Spain Romania 
 2001 2008 APC 1998 2008 APC 1999 2008 APC 1999 2009 APC 
HCC 3.42(166) 2.77(194) 0% 0.40(26) 0.28(19) -10% 1.37(696) 0.95(652) -4% 0.39(77) 0.87(205) +5% 
IHBD 1.91(110) 1.60(123) -1% 0.18(6) 0.77(45) +17% 0.55(283) 0.85(558) +5% 0.05(9) 0.19(45) +15% 
Liver 
NOS 






Figure 7. Annual percent changes of mortality rates of hepatocelular carcinoma and 





2.4.1 Hepatocellular carcinoma 
This study has found a distinct pattern of mortality from HCC for countries that were 
included in the present study, demonstrating salient changes from earlier findings by 
Khan and co-workers who had reported increases in ASMR of HCC in France, 
Japan, Australia and the USA between 1979-1997 (Khan et al., 2002). In contrast to 
their data, declining ASMR of HCC in both sexes in countries including Japan, Spain 
and Hong Kong were observed. Conventionally, Japan and Hong Kong have been 
described as high incidence countries due to the high prevalence of aetiological risk 
factors for HCC in these countries, while Spain falls within the southern European 
axis, considered to have intermediate risk. The rest of the countries: namely, England 
and Wales, Norway, Romania, USA and Australia with rising mortality rates of HCC 
are classified as low risk countries. I thus report rising trends in ASMR of HCC in low 
risk and decreasing trends in high risk countries. 
Differences in the prevalence and control of HBV and HCV, alcohol consumption, 
immigration and obesity could be playing significant roles in explaining the distinctive 
mortality trends observed. HCV has been implicated as a major contributor to the 
rising incidence of HCC in Western industrialised countries (Di Bisceglie, 1997). 
While HCV is the most incriminated risk factor in Japan, United States and several 
European countries, the period of initial spread of infection and implementation of 
control measures could be responsible for the varied mortality trend of HCC 
observed across some of the countries studied. For example, molecular clock 
analyses have estimated that HCV began to infect large cohorts of young people in 
Japan, southern Europe and North America in 1920s, 1940s and 1960s respectively 
consequent upon the use of contaminated needles and intravenous drugs 
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(Armstrong, Alter, McQuillan, & Margolis, 2000). Population-based HCV prevalence 
rates of Spain, UK and Norway were estimated at approximately 1% and for 
Romania, above 2%. HBV prevalence of the earlier aforementioned countries is 
about 2%, while the value is more than 2% for Romania. With the exception of 
Norway that has ≤ 11L per capita alcohol consumption in adults above 15 years of 
age, during 2002, all the other 3 European countries had values above 11L per 
capita (Ribes et al., 2008). The findings of this study corroborate the importance of 
these risk factors, as there were higher mortality rates of HCC in Spain, England and 
Wales and Norway, in that order. Factors such as alcohol and obesity complicate and 
accelerate pre-existing liver diseases. Notably, the HCC mortality trend for Romania 
reflects the enormous additive effects of these risk factors in that the percentage 
change of mortality rate was highest in that country.  
In my study, I could not determine the reason for the low mortality relative to 
prevalent risk factors for HCC for Romania, but it could potentially be due to a 
defective coding practice. In Romania, the mortality rate for unspecified liver tumours 
(Liver NOS) was higher than that for the major subcategories of PLC, namely, HCC 
and IHBD. Nevertheless, overall the mortality rate for PLC was highest in this 
Eastern European country compared to the other European countries selected in my 
study. It is not completely apparent what accounts for this excess mortality rate for 
Liver NOS in Romania. The impact of coding practices on epidemiological studies of 
PLC has been well recognised as alluded to by Taylor-Robinson and colleagues 
(Taylor-Robinson et al., 2001).  In order to mitigate this, follow-up enquiries by cancer 
registries could be embarked upon to ensure appropriate assignment of correct 
International Classification of Diseases (ICD) category to tumours (that is, whenever 
there were unclear diagnoses on death certificates). Abandonment of this procedure 
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in 1993 was associated with an increase in the number of deaths assigned to Liver 
NOS in England and Wales (Office for National Statistics, (ONS)). It is likely that if 
this rigorous process of checking unclear diagnoses on death certification were 
embarked upon in Romania, the rates obtained for Romania might well have been 
different. Studies of ICD coding practice and the basis of diagnosis of PLC (only 
recorded in cancer incidence data in some countries) may be helpful to determine if 
some misclassification of HCC to Liver NOS is responsible for the unexpectedly low 
ASMR of HCC in Romania.  
A recent population-based incidence study of HCC in Japan showed that by 2000, 
the incidence of HCV-related HCC started to decline in both sexes (Tanaka et al., 
2008). Additionally, HBV control efforts in Japan could be contributory to the success 
being observed in the declining mortality rate for HCC in that country.  Tajiri and 
colleagues recently reported decreasing trends in the incidence of childhood HCC 
following the nationwide introduction of passive-active HBV immunisation for high-
risk babies in Japan from 1986 (Tajiri et al., 2011). The trend in the mortality rate of 
HCC for Japan in the current study confirms falling mortality rates. Since the spread 
of HCV in Europe and North America came after Japan, and with widespread 
practice of primary prevention of HCV, it is anticipated that mortality rates may start 
to decline within the next two decades in these regions if HCV control measures are 
optimised. Already, declines in mortality rates have been documented among female 
populations in Norway, Hong Kong, Spain and the USA; and in men within the first 
three aforementioned countries. However, recent evidence suggests that emerging 
risk factors such as obesity, diabetes mellitus and factors promoting alcohol 
consumption might offset any declines in HCC death rates. Moreover, a global 
“epidemic” of obesity has been reported by some researchers (Angulo, 2002;James, 
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Leach, Kalamara, & Shayeghi, 2001a). Also, driven by cultural and marketing factors, 
alcohol consumption has increased in many industrialised nations (Donato et al., 
2002b;El-Serag and Mason, 2000a;Hasumura & Takeuchi, 1991;Jewell and Sheron, 
2010;Morgan et al., 2004b;Pincock, 2003).  
Variation in the implementation of guidelines for screening at-risk populations and of 
management of HCC could contribute to the differences in the ASMR observed 
between the countries studied. Surveillance programmes for HCC could potentially 
improve early detection and hence survival of patients with HCC as they are 
amenable to curative therapy. Improvement in survival from HCC as a result of 
surveillance has been shown in reports from China (Wong et al., 2008), Japan 
(Tanaka et al., 2006) and Spain (Zapata et al., 2010). This benefit however, is 
nullified if no facilities exist for the treatment of patients detected during such 
screening programmes. The utilisation of screening and surveillance programmes for 
HCC is unlikely to be pursued with similar rigour in all countries studied. For 
example, in the USA, although, 84% of hepatologists reported to have routinely 
screened their patients for HCC by 1998 (Chalasani et al., 1999), a recent study 
found that routine surveillance in 13,002 cirrhosis patients was adequately carried out 
in only 12% of the patients (Davila et al., 2011). Although, that study did not 
determine if missing screening was due to failures of the physician to recommend 
tests or patients to adhere to investigations, it demonstrates a low adherence to 
guidelines. This lack of adherence to surveillance guidelines may be mitigating the 
control efforts in many countries of the world. The management of HCC in Japan has 
achieved remarkable success, owing to widespread adherence to their national 
guidelines that led to the detection of early stage HCC nodules in more than 60% of 
surveyed patients, reported in one study (Izumi, 2010). Indeed, following the 
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publishing of the Japanese HCC guidelines in February 2005, it has become a widely 
adopted HCC treatment strategy in that country (Song et al., 2010). This is likely to 
have contributed to the recent declining trend in the mortality rate for HCC in Japan 
in this present study. While it is unlikely to be the sole reason for the variation in the 
death rates due to HCC in the studied countries, studies of utilisation and/or 
implementation of surveillance for HCC in these countries are warranted. 
Immigration factors could be contributory to the observed trends of mortality rate for 
HCC. Countries that have sustained increases in the ASMR of HCC in this study 
included England and Wales, USA and Australia. The New York Times reported in 
2010 that Europe was the most favoured immigration destination, followed by North 
America (Anon, 2010). People from less developed countries, with high prevalence of 
risk factors for HCC, carry with them their original propensity to contribute to the 
indigenous pool of HCC cases. This has been documented by studies in the USA, 
Australia and England and Wales. In the USA for example, the incidence of liver 
cancer was found to be higher among Japanese living in Hawaii than among native 
Hawaiians (Maskarinec & Noh, 2004). Similar findings have been documented by 
studies in England and Wales (Haworth et al., 1999a) and Australia (Khlat et al., 
1993). 
Furthermore, improved management of end-stage liver disease could paradoxically 
add to the sustained increase in the mortality rate for HCC in some of the developed 
countries. Improvement in the management of cirrhosis of the liver may lead 
paradoxically, to an increase the mortality from HCC, especially when there is sub-
optimal concurrent surveillance and management of incident cases. For example, 
reviewing the risk for HCC in decompensated alcoholic cirrhosis, Morgan and co-
workers found that significant alcohol consumers who abstained had higher 
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incidence of HCC than those who continued to drink (Morgan, Mandayam, & Jamal, 
2004a). Thus with increasing accessibility of advanced techniques for the 
management of end stage liver disease, there should exist resilient screening and 
treatment programmes for incident cases of HCC. 
2.4.2 Intrahepatic bile duct carcinoma 
Similar to the findings of earlier reported data, mortality from IHBD has been rising in 
both sexes in all the countries studied. It is notable that this tumour continues to be 
rising as a cause of death in Japanese men and women despite declining rates of 
HCC from 2000 in this population. While marked increases were observed for 
Norwegian, Romanian, Australian and Spanish populations, the trends indicated 
smaller increases in Japan, England and Wales and the USA. Only females from 
Hong Kong failed to demonstrate a rise in IHBD mortality.  
This widespread global increase in the mortality rate for IHBD was first reported by 
Khan et al. in 2002. An increase in the incidence of aetiological risk factors might be 
responsible for this global trend. Of all the risk factors, primary sclerosing cholangitis 
(PSC) is the commonest predisposing in western industrialised world. It is however, 
known that PSC-related IHBD commonly occurs in young people, peaking in the fifth 
decade (Shaib et al., 2004). One would expect a change in the trend towards 
younger age of diagnosis for this tumour if PSC were the reason for the increase. 
PSC incidence has not been shown to be rising and the increase in mortality in this 
study was higher in patients above 75 years of age. It would be expected that a 
marked rise in middle age group would be recorded if PSC were the reason for the 
increasing trend in mortality from IHBD. Environmental toxins might have some 
aetiologic role in the current trend. Spatio-temporal analysis of IHBD mortality 
between 1981 and 2004 in England and Wales has shown strong evidence for spatial 
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clustering in rural areas, suggesting a role for environmental carcinogens in these 
agricultural land use areas (Khan SA et al., 2008). Liver flukes in Southeast Asia are 
established risk factors for IHBD and for which reason, this tumour is one of the 
commonest malignancies in that region (Nakanuma Y et al., 1997). However, these 
flukes are not common in western industrialised countries. 
The progressive increase in the ASMR of IHBD may also represent an artefactual 
pattern, due to improved diagnostic yield (case ascertainment) and/or 
misclassification from ICD coding (diagnostic transfer). Improved case ascertainment 
from increased availability of better imaging modalities (CT, MRI and ERCP) could 
potentially be responsible for the increase in the ASMR of IHBD. These could have 
enhanced better characterisation of hepatobiliary tumours that would have previously 
been described as unspecified or incorrectly as extra-hepatic cholangiocarcinoma. 
This does not seem to be the case as an expected increase in the detection of early 
stage disease, consistent with improved diagnostic yield and survival is yet to be 
documented (Shaib, Davila, McGlynn, & El-Serag, 2004).  Also, the expected plateau 
in the epidemiological trend characteristic of increases due to improved case finding 
has not occurred in any of the countries. Additionally, since the definitive diagnosis of 
IHBD is based not only on imaging, but also on clinical and histological parameters, 
better designed epidemiological studies may help to determine the contribution of 
case ascertainment to the observed trends. 
Errors in death certification may impact the mortality trend of IHBD (Sharp et al., 
2001). Diagnostic transfer between hilar cholangiocarcinoma and IHBD has been 
documented to be responsible for 13% overestimation of IHBD and underestimation 
by 15% of extrahepatic cholangiocarcinoma by Welzel and colleagues (Welzel et al., 
2006) in 2006 in the USA. Allowing for this, the authors still found an overall increase 
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in IHBD in the US during the period of the study (1979-2001). In England and Wales, 
there was a 94% incorrect coding of hilar cholangiocarcinoma as IHBD, during the 
period 1990-2004 (Khan SA et al., 2010). Diagnostic transfer is common especially 
due to cross referencing to the topographic code C22.1 of Klatskin tumours (histology 
coded, M8162/3) in the second version of the ICD-oncology of 1994. It is pertinent to 
note that coding practices differ between countries and might present with the pattern 
of differences in the ASMR observed. Transfers can also occur between Liver NOS 
and IHBD. This does not appear to be significant as shown by the results obtained in 
this study, especially as the percentage increase in the mortality rate for IHBD is not 
commensurate with the percentage decrease in ASMR of Liver NOS in the 
respective countries. Moreover, there were observed simultaneous increases of 
ASMR of Liver NOS and IHBD in some of the countries studied. Thus diagnostic 
transfer alone does not explain the rising pattern observed in the mortality trend of 
IHBD in the countries studied. This widespread rise in IHBD mortality is therefore 
likely secondary to a genuine global increase in the incidence of this tumour. 
2.4.3 Summary and conclusions 
Mortality rates of IHBD have been increasing in all countries studied. In contrast, 
there was an inconsistent pattern in the mortality trend for HCC. While countries that 
were previously known to have high prevalence of risk factors for HCC are recording 
declining mortality rates, there were substantial increases in mortality rates of HCC in 
Romania, England and Wales, Australia and the USA. Liver NOS was the most 
common PLC subtype in Romania, where a marked increase in the mortality rate of 
HCC in both genders was found. Differences in risk factors and ICD coding practices, 
and immigration from regions highly endemic for risk factors to some of the 
industrialised nations could all play roles in the observed mortality trends. Moreover, 
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variations in the prevention of risk factors, such as HBV vaccination, surveillance of 
at-risk populations and management of HCC may also be contributory. 
If diagnostic transfer could be ruled out, predominantly rising trend in the mortality 
rate for IHBD could reflect a true increase in the risk factors of this tumour. It could 
also mean certain co-factors (possibly, genetic), acting on the established mutual risk 
factors for HCC and IHBD to determine the eventual outcome to either, to account for 
the differential trends. Additionally, the rising mortality rate for IHBD, despite falling 
rates for HCC in Japan confirms the poorer prognosis of IHBD and which may in part 
explain the relentless increases observed in the ASMR of IHBD in studied countries. 
Future research directions 
To fully understand the reasons for the changing trends in the mortality rate for PLC 
subcategories, further epidemiological studies will be required. A concurrent study of 
the incidence and mortality trends of HCC, IHBD and Liver NOS, would suggest 
whether there has been improvements in the survival from PLC during this period. 
Furthermore, with the continued high mortality rates of HCC in some of the countries, 
there is an urgent requirement for more sensitive screening tools and early detection 
of this lethal tumour. More accurate, reliable and readily available screening tools in 
resource-limited countries that are universally applicable would also contribute 
immensely towards curbing the menace of these tumours, particularly in developing 





3. INCIDENCE AND MORTALITY OF PRIMARY LIVER CANCER IN 
ENGLAND AND WALES 
3.0 ABSTRACT 
Background: Mortality rate of PLC in England and Wales have been rising. Studies 
of changes in the modes of diagnosis and ethnic distribution of this tumour in 
England and Wales are yet to be embarked upon. This study aimed to explore recent 
trends, modes of diagnosis, ethnic distribution and the mortality to incidence ratio of 
primary liver cancer by subtypes in England and Wales. 
Methods: Incidence (1979-2008) and mortality (1968-2008) data for primary liver 
cancer for England and Wales were obtained from the Office for National Statistics 
(ONS), being maintained by the Small Area Health Statistics Unit of Imperial College 
London. The age-standardised incidence and mortality rates of HCC, IHBD and Liver 
NOS were calculated. Trends in rates and basis of diagnosis of PLC and 
subcategories: hepatocellular carcinoma, intrahepatic bile duct and unspecified liver 
tumours, were analysed over the study period. Also, changes in the mode of 
diagnosis and distribution of these tumours by ethnic groups were explored. Partial 
least squares regression analyses were used to calculate the degree of change. I 
further extrapolated the estimated 5 and 10 year survival patterns of these tumours 
using complement of mortality to incidence ratio (1-MIR). 
Results: Age-standardised mortality rate of PLC overall increased in both sexes: 
from 2.56 and 1.29/100,000 in 1968 to 5.10 and 2.63/100,000 in 2008 for men and 
women respectively. For men, the annual percent changes in the mortality rate of 
hepatocellular carcinoma and intrahepatic bile duct carcinoma were +2% and +9% 
respectively. The use of histology for confirmation of primary liver cancer diagnosis 
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increased from 35.7% of registered cases in 1993 to plateau at about 50% during 
2005 to 2008. Afro-Caribbeans comprised 3% and 5% of hepatocellular carcinoma 
and intrahepatic bile duct carcinoma registrations, respectively. Survival from PLC is 
estimated to get poorer in 10 years (2018) relative to 2008, particularly as a result of 
IHBD. 
Conclusions: Incidence and mortality of PLC, and particularly IHBD, have continued 
to rise in England and Wales. Changes in the modes of diagnosis may be 







The incidence of primary liver cancer (PLC), otherwise coded as malignant 
neoplasms of the liver and intrahepatic bile duct (MNL) in the International 
Classification of Diseases (ICD) version 10, in many industrialised countries is 
increasing (Nordenstedt, White, & El-Serag, 2010). Major PLC subcategories include: 
hepatocellular carcinoma [HCC], intrahepatic bile duct carcinoma [IHBD] and also 
tumours where the precise histological diagnosis is not specified by the reporting 
physicians [Liver NOS]. Previous epidemiological studies of PLC in England and 
Wales have documented increases in mortality and incidence rates, but these data 
have yet to be updated covering the past decade (Haworth, Soni, V, & Balarajan, 
1999a;Taylor-Robinson et al., 2001). Taylor-Robinson and co-workers reported that 
the mortality rate of IHBD in England and Wales almost doubled between 1979 and 
1999, while rates of HCC remained stable (Taylor-Robinson et al., 2001). A study of 
the incidence of liver cell cancer by West and colleagues during 1971-2001, reported 
a rising trend of HCC among men in England and Wales (West et al., 2006). The rate 
of PLC is indeed likely to be higher in migrant populations (especially from regions 
known to be endemic to risk factors associated with PLC) than in the indigenous 
white population. 
3.1.1 Rationale for study 
A further study of the incidence and mortality of PLC will update information on rising 
trends in order to ascertain if these have continued or not. The need to update these 
trends is also borne out of the alarming increasing chronic liver disease death rates 
in the UK while deaths secondary to cardiovascular, blood, respiratory diseases have 
been falling at the same time (Figure 8). The current global epidemic of obesity 
(James et al., 2001b;James, 2008) and increased alcohol consumption (Pincock, 
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2003); both factors associated with HCC may be contributing to the burden of PLC. 
Additionally, the need to evaluate intervention endeavours, such as provision of 
guidelines (Khan et al., 2002a;Ryder, 2003) and advances in the management of 
PLC engendered this study. Moreover, a combined study of mortality and incidence 
can better provide information on the control of risk factors and survival of cases than 
would be available from either alone. Furthermore, the modes of diagnosis of the 
different tumour subtypes of PLC in the England and Wales will be studied 
concomitantly. This aspect of the study will lend support, in part, to the validity of the 
diagnosis of PLC in England and Wales.  
 
Figure 8. Standard death rates percentage changes of common diseases in the UK 





This study of the incidence and mortality of PLC will not only update previously 
documented trends, but may garner insights into the impact of diagnostic and 
management algorithms on PLC trends during the last decade. With rising rates in 
deaths from chronic liver disease during 1970 through to 2006, and also reported 
increases in alcohol consumption (Pincock, 2003), it is hypothesised that mortality 
from PLC in England and Wales is increasing. I analysed trends in the mortality and 
incidence rates of PLC overall and PLC subcategories in England and Wales, and 
examined trends in the basis of diagnosis of PLC. Whereas earlier data during a 5 
year period (1988-1992) have suggested that the incidence of cirrhosis and liver 
cancer were higher among ethnic minorities, this study was limited by the fact that it 
did not tease out the different subcategories of primary liver cancer, included a group 
of people in whom PLC is not highly prevalent (20-69 years) and was not based on 
data from the population (Balarajan and Raleigh, 1997;Haworth et al., 1999b). The 
present study analysed ethnic variations in the incidence of HCC and IHBD using 
data for the whole population of England and Wales during 1979 to 2008. This work 
is relevant because previous observed increases in the incidence of PLC in England 
and Wales is likely related to environmental factors (recent immigration). Defining 
high-risk populations by ethnicity can provide invaluable information for screening 
and surveillance programmes. Important also is the fact that population-based 
relative ethnic distribution of PLC in England and Wales has not previously been 
reported. The finding of this study could yield information that will be relevant to 
individualised surveillance and early detection of PLC; as well as lend support to 





Incidence and mortality rates of primary liver cancer are continuing to increase in 
England and Wales. 
3.1.3 Aims 
 To study the mortality (1968-2008) and incidence (1979-2008) trends with 
respect to PLC sub-site categories, particularly, HCC, IHBD and Liver NOS in 
order to determine any change(s) attributable to any specific tumour subtype. 
 To study trends in the mode of diagnosis of PLC subtypes during 1993-2008. 
 To determine the ethnic distribution of PLC subtypes. 
3.2 MATERIALS AND METHODS 
Incidence (1979-2008) and mortality (1968-2008) data for PLC [C22 as coded by the 
10th version of International Classification of Diseases] and PLC subcategories 
[C22.0 hepatocellular carcinoma (HCC), C22.1 intrahepatic bile ducts (IHBD), C22.9 
liver tumours not otherwise specified (NOS)] were extracted from the National 
Cancer Registry of England and Wales held at the Small Area Health Statistics Unit 
(SAHSU) of Imperial College London and maintained by the Office for National 
Statistics (ONS).  Mid-year population estimates by 5-year bands for England and 
Wales for the period from 1968 to 2008 were obtained from SAHSU and ONS 
databases. Data were analysed using Epi InfoTM statistical software (version 3.5.1, 
2008, Atlanta GA, USA). Age-standardised incidence rates (ASIR) and mortality 
rates (ASMR) per 100,000 were calculated. The European standard population was 
used as the reference for direct age standardisation. To define patterns of change 




squares regression line fitted to the natural logarithm of the mortality and incidence 
rates. 
Diagnoses of specific PLC sub-types are usually based on several modalities of 
investigation. The connotation, ‘Basis of Diagnosis’, as practiced by coding officers 
during registration of incident cases of cancer, describes the most advanced method 
used in making a diagnostic decision for each case. The basis of diagnosis of PLC 
has been recorded by all Cancer Registries in England and Wales since 1993 based 
on the following codes: 1 (imaging/radiology); 2 (other special tests such as clinical 
opinions and tumour markers); 3 (cytology); and 4 (histology). In clinical practice, 
histology of the liver is hierarchically ranked the gold standard of diagnosis, followed 
by imaging, cytology and serum tumour markers (“others”), in that order. The 
proportion of cases diagnosed using these modalities was determined for PLC 
overall, and specifically for HCC, IHBD and Liver NOS.  
Information on ethnicity, recorded at the time of registration (incidence data), was 
obtained for PLC and subcategories for every year. To reflect regional ethnic 
affiliation, rather than countries of origin, we categorised Indians, Pakistanis and 
Bangladeshis together as ‘South Asians’. Other ethnic categories were as follows: 
white, Afro-Caribbeans, black Africans, Chinese, and other. We then calculated the 
proportion of PLC and subcategories registered in the incidence data, among each 
ethnic group annually. These proportions were compared with the proportion of each 
ethnic group in the national population for each year. Projected mid-2008 population 
estimates by ethnic group released by the Office for National Statistics were utilised 
to calculate the proportion of each ethnic group for each year (Office for National 




Mortality to incidence ratios (MIR) has been utilized to not only interrogate the 
completeness of data in cancer registries (Parkin and Bray, 2009), but additionally as 
a proxy to estimate 5 year survival of cancer patients(Pisani et al., 1993). The MIR 
for PLC overall, as well as for HCC and IHBD by sex were calculated. These were 
derived from the crude mortality and incidence rates of the various tumours for the 
last 10 years of the study (1999-2008). The rates were then projected linearly to 
2018 and MIR were calculated. The projected 5 and 10 year survival patterns by 
gender were than calculated using the complement of MIR (1-MIR). This method of 
survival estimated has recently been validated for site specific tumours (Asadzadeh 






3.3.1 Age-standardised mortality rates (ASMR) 
Rising trends in mortality rate of PLC in England and Wales during 1968-1996 has 
been previously reported (Taylor-Robinson et al., 2001). Overall, the absolute 
mortality and ASMR of PLC continued to increase during 1996-2008 in both males 
and females. In men, this rose from 1052 cases (ASMR: 3.70 per 100,000) in 1996 
to 1731 cases (ASMR: 5.10 per 100,000) in 2008 and in women; from 770 cases 
(1.93 per 100,000) to 1178 cases (ASMR: 2.63 per 100,000) in the same period 
(Figure 9). The trend was more consistent in men than women. For HCC, men 
experienced a rise in the mortality rate (from 1.49 to 2.60 per 100,000 in 1996 to 
2008 respectively) whereas women had a relatively stable rate.  
There was a steady increase in the mortality rates of IHBD in both men and women, 
which persisted with a similar annual percent change of 9% and 10% in men and 
women respectively during 1968-2008. The numbers of those registered without a 
specific histological category (Liver NOS) fluctuated during 1968-1990, from which 
time it started to fall. This was 287 and 219 in 1996 and has fallen to 200 and 130 in 
2008 for men and women respectively. 
3.3.2 Age-standardised incidence rates (ASIR) 
Over the last decade, there was an upward trend in the incidence of PLC among 
men in England and Wales, contrasted to a relatively static rate among women. 
There was also a marginal rise in the ASIR of HCC among men contrasted to a non-
significant decline in the rate in women (774-1083 and 371-306 cases in men and 




IHBD markedly increased in both genders (annual percent change [APC]: 10% in 
both men and women) during 2001 to 2008 (437-639 and 473-672 in men and 
women respectively). The ASIR of unspecified liver tumours in both sexes has 






Figure 9. Age-standardised mortality rates of primary liver cancer (MNL), 
hepatocellular carcinoma (HCC), intrahepatic bile duct carcinoma (IHBD) in (A) 








Figure 10 Age-standardised incidence rates of primary liver cancer (MNL), 
hepatocellular carcinoma (HCC), intrahepatic bile duct carcinoma (IHBD) in (A) 





3.3.3 Basis of Diagnosis 
There were increases in the proportion of patients registered to have required 
histology to establish specific diagnosis of PLC during the last 4 years of the study 
(2005-2008). Imaging was the basis of diagnosis of HCC from 1993 up until 2005, 
when it was overtaken by histology (Figure 11). For IHBD, imaging and histology 
were relied upon with approximately equal proportion during 1993-1997. However, 
from 1998, histological confirmation was the most common modality on which the 
diagnosis of IHBD was based.  The proportion of PLC registrations having 
unsophisticated means of diagnosis remained low during 1993-2008. Cytology is 
increasingly less relied upon in the diagnosis of liver tumours. However, for IHBD, 
cytology has slightly been increasing and “others” (including: those diagnosed by 
unsophisticated means, tumour markers and clinical opinion) have dropped 





Figure 11. Proportion  of registrations (incidence) of PLC, HCC, IHBD and Liver NOS 
by the basis of diagnosis, England and Wales, 1993-2008 (PLC; Primary liver 
cancer, HCC; Hepatocellular carcinoma, IHBD; Intrahepatic bile duct carcinoma, 








Figure 12. Comparison of ethnic groups in England and Wales (2008), as recorded 
in the (A) population of England and Wales, and the registration of (B) PLC by ethnic 









Figure 13. Proportion of ethnic groups registered to have hepatocelular carcinoma 





Figure 14. Proportion of ethnic groups registered to have intrahepatic 












Figure 15 Proportion of ethnic groups registered to have unspecified liver tumours 





3.3.4 Distribution of Primary Liver Cancer by Ethnicity 
The completeness of ethnic information in the incidence data, recorded during the 
study period, ranged from 19% to 51% of cases that were registered to have had 
PLC (Table 5). For HCC and IHBD, there was an initial increase (50.3% and 57.7% 
respectively) in the proportion of those registered with ethnicity from 1993 to 1998, 
after which it remained static for two years. Following that, there was a sharp drop in 
2001 to 19% for both HCC and IHBD, rising steadily to 42% and 41% respectively in 
2007. 
Table 5. Cases of primary liver cancer (PLC) in whom ethnicity was registered in the 
incidence data in England and Wales, 1993-2008 (percentages in parentheses) 










1993 563(38.3) 554(98.4) 2(0.4) 0(0.0) 7(1.2) 0(0.0) 0(0.0) 
1994 570(36.4) 561(98.4) 1(0.2) 1(0.2) 4(0.7) 0(0.0) 3(0.5) 
1995 605(35.9) 587(97.0) 2(0.3) 2(0.3) 7(1.2) 4(0.7) 3(0.5) 
1996 888(46.5) 863(97.2) 3(0.3) 3(0.3) 7(0.8) 4(0.5) 8(0.9) 
1997 990(48.7) 964(97.4) 1(0.1) 4(0.4) 11(1.1) 7(0.7) 3(0.3) 
1998 1075(51.4) 1034(96.2) 5(0.5) 8(0.7) 15(1.4) 5(0.5) 8(0.7) 
1999 1003(47.7) 953(95.0) 11(1.1) 3(0.3) 15(1.5) 8(0.8) 13(1.3) 
2000 977(41.9) 913(93.4) 24(2.5) 8(0.8) 17(1.7) 5(0.5) 10(1.0) 
2001 443(19.1) 365(82.4) 35(7.9) 8(1.8) 11(2.5) 7(1.6) 17(3.8) 
2002 529(21.3) 461(87.1) 23(3.9) 8(1.5) 18(3.4) 9(1.7) 10(1.9) 
2003 508(20.7) 436(85.8) 20(4.3) 11(2.2) 25(4.9) 3(0.6) 13(2.6) 
2004 741(28.4) 647(87.3) 30(4.0) 18(2.4) 20(2.7) 6(0.8) 20(2.7) 
2005 908(31.8) 784(86.3) 57(6.3) 17(1.9) 26(2.9) 8(0.9) 16(1.8) 




2007 1276(41.3) 1058(82.9) 110(8.6) 14(1.1) 41(3.2) 20(1.6) 33(2.6) 








 The proportion of ethnic groups in the population of England and Wales in 2008 with 
the corresponding distribution of ethnicity amongst cancer registrations for HCC, 
IHBD and Liver NOS was compared. Year 2008 was chosen as it is the most recent 
year for which data were available for the study. White people comprised 89% of the 
population and the corresponding proportions of cases of IHBD and HCC were 85% 
and 92% respectively (Figure 12). In contrast, Afro-Caribbeans constituted about 1% 
of the population of England and Wales in 2008, yet 3%, 5% and 1% of HCC (Figure 
13), IHBD (Figure 14) and Liver NOS (Figure 15), respectively were registered to 
people whose ethnic background was Afro-Caribbean in that year. Similarly, the 
proportions of PLC registration in black Africans and Chinese were slightly higher 
than the proportion of these ethnic groups in the population as a whole (1% versus 
2% respectively) (Figure 12).  
3.3.5 Mortality to incidence ratio 
Women are projected to experience lower survival than men in general. For HCC, 
both men and women will experience rising MIR during the period of 10 years from 
2008 (i.e. 2018), although this is projected to plateau for men by 2014 (Figure 16). 








Figure 16. Estimated relative survival (A) 5 year and (10) year projections; obtained 
from complement of mortality to incidence ratios (1-MIR)*100 that was extrapolated 





This study has presented for the first time both mortality and incidence rates 
simultaneously for primary liver cancer and shown that they have continued to rise in 
England and Wales throughout the last decade. The greatest rise was in IHBD in 
both men and women (44% increase: from 910 cases in 2001 to 1311 cases in 
2008). Reassuringly, histological confirmation of PLC subcategories has become 
more widespread in diagnostic practice and less accurate modes of diagnosis have 
been declining as the sole mode of diagnostic confirmation. Generally, the 
registration of IHBD and HCC was proportionately highest among people whose 
ethnicity was registered as Afro-Caribbean.  
Using data gathered towards the end of the last century, Taylor-Robinson and 
colleagues, as well as West et al. in separate studies, reported increases in mortality 
and incidence of PLC, respectively (Taylor-Robinson et al., 2001;West et al., 2006). 
Global studies of PLC was reported by Khan and colleagues which revealed 
widespread increase in mortality from IHBD in all western countries that were studied 
(Khan et al., 2002b). Whereas a variable mortality trend from HCC was found in 
studies across countries, the present study noted that both IHBD and HCC were 
rising in incidence and mortality in England and Wales. In contrast to the other 
countries, however, the rate of increase in the mortality from PLC in England and 
Wales was greatest for IHBD, compared to HCC (Khan et al., 2002b). 
The observed increase in the incidence and mortality rates of PLC in England and 
Wales is either a result of an epidemiological artefact or real. For instance, 
misclassification of hilar cholangiocarcinoma to IHBD in increasing the incidence of 




the USA has also shown that although coding error resulted in 15% overestimation 
of IHBD, there was a significant proportion of increase that was not explained by 
misclassification (Welzel et al., 2006). A true increase may thus underlie the trend in 
the mortality and incidence being reported in the present study. Furthermore, the fact 
that both incidence and mortality increased supports a non-artefactual effect and 
suggests there has not been any significant improvement in survival from PLC, 
despite changes in the diagnosis and treatment of PLC during the last decade.   
While it has been a common cause of liver tumour-related death in England and 
Wales, IHBD is a less common PLC than HCC worldwide. Aetiological associations 
of IHBD are ill-understood, and are still being studied. Chronic infestation by liver 
fluke is associated with IHBD in South-East and East Asia (Shaib & El-Serag, 
2004;Watanapa & Watanapa, 2002). Primary sclerosing cholangitis (PSC) is the 
commonest known predisposing factor for IHBD in the Western world, often 
associated with up to a tenth of cases of cholangiocarcinoma (Cullen and Chapman, 
2003;Levy and Lindor, 2003). However, the incidence of PSC has not been shown to 
be increasing and thus cannot explain the current rise in the incidence of IHBD 
(Kingham et al., 2004). Environmental toxins and genetic dispositions (Wadsworth et 
al., 2011) have also been noted to be responsible for sporadic cases of IHBD and 
may underlie some of the observed differences in the present study. 
Changes in the basis of diagnosis may have resulted in increased case 
ascertainment and thus contributed to the rising trends in the incidence and mortality 
rates observed. These data show that the proportion of cases reported to cancer 
registries that had histology underpinning the diagnosis of PLC has been increasing. 
What this suggests is that suspicious “nodules” identified during routine screening or 




liver biopsy in many centres across England and Wales and hence diagnosed. 
Recent technological advances in the management of PLC (Bruix & Sherman, 
2005;Bruix & Sherman, 2011;Ryder, 2003), including the setting up of tertiary 
centres, modern hepatobiliary imaging, image-guided biopsies and widespread 
availability of magnetic resonance cholangiopancreatography (MRCP) may have 
contributed to the recent trends. The role of case ascertainment is further buttressed 
by the rising trend in the histological confirmation of PLC shown in this study, 
suggesting a more aggressive surveillance for PLC.  
It would be expected that an outcome of improved diagnostic yield should lead to 
detection of early stage PLC and improvement in survival. There is yet a study to be 
undertaken that describes the impact of changes in screening guidelines and 
management of PLC in England and Wales. As MIR has been recently validated to 
be a proxy indicator for cancer survival estimations (Asadzadeh et al., 2011), the 
data in the present work confirm that PLC will continue to be associated with high 
case fatality, mostly contributed to by IHBD. However, Shaib and colleagues (Shaib, 
Davila, McGlynn, & El-Serag, 2004), has recently shown that although an increase in 
the incidence of IHBD was noted during 1975 to 1999, there was neither a significant 
increase in the proportion of those found with localised disease, nor in the survival of 
those diagnosed. Lead-time bias could be responsible for the observed mutual 
increase in the incidence and mortality rates of PLC in the face of improvements in 
diagnosis.  
The exploration of ethnic information confirms that the proportion of sub-Saharan 
Africans and South Asians living in England and Wales that have PLC is higher than 
the proportion of indigenous white people (Balarajan & Raleigh, 1997;Grulich et al., 




Afro-Caribbeans, sub-Saharan black Africans and Chinese is higher than among 
indigenous white people in England and Wales. This finding is similar to a 
population-based study in the USA in 2008 that reported a higher incidence of HCC 
among immigrant populations, compared to Caucasians (Wong and Corley, 2008). 
Higher prevalence of HBsAg carriage status among immigrant populations may in 
part have predisposed ethnic minorities to HCC. The rates of HCC in people from 
Asian and African backgrounds were however, not as alarming as expected, perhaps 
reflecting the positive impact of HBV vaccination in the control of this cancer. A 
landmark study in Taiwan confirmed that HBV immunisation in children, introduced in 
1984 significantly halved the annual incidence of HCC from 0.70/100,000 in 1981-
1986 to 0.36/100,000 in 1990-1994 (Chang et al., 1997). 
The underlying reasons for the higher proportional registration of IHBD in particular 
among Afro-Caribbean populations are not clear and require further investigation. It 
suggests either a high prevalence of aetiological factors and/or more willingness to 
register ethnic information by Afro-Caribbean people (the latter being unlikely). 
Ulcerative colitis is associated with PSC, which in turn is responsible for about 10% 
of IHBD (Boberg and Lind, 2011). Reports of PSC and indeed ulcerative colitis 
among ethnic minorities are scanty. A 15-year study, published 3 decades ago 
intriguingly observed a significant rarity of ulcerative colitis among Afro-Caribbeans 
(Benfield and Asquith, 1986). Recent case control and cohort studies have 
implicated HCV, HBV, cigarette smoking, obesity, gallstones and alcohol 
consumption, among others to be contributory to IHBD, although some of these 
associations are weak (Nordenstedt et al., 2012;Palmer and Patel, 2012). A 




cigarette smoking, alcohol drinking and cirrhosis of the liver from HCV in Afro-
Caribbeans, compared to sub-Saharan black Africans (Mann et al., 2008).  
HCV-related HCC has been identified as one of many reasons for the rise in HCC 
incidence in some developed countries, including England and Wales (El-Serag and 
Mason, 2000b). The incidence of HCV in England and Wales rose significantly 
between 1960 and 1980 (Sweeting et al., 2007), owing to the practice of intravenous 
drug use (IDU) and the prevalence of HCV in the blood donor system prior to donor 
screening procedures in 1992. HCC would have only recently started to emerge in 
patients that were infected during this period as progression to end-stage liver 
disease (cirrhosis and HCC) can take 25-30 years (Higuchi et al., 2002). Alcoholic 
liver disease has also been reported to have more than doubled between 1990 and 
2003 in England and Wales (Thomson et al., 2008). With economic and social 
factors that have promoted consumption of alcohol, the influence of alcohol on the 
current rising incidence of HCC is likely to be exponential and has contributed to the 
current observation. A population-based study of the impact of alcohol consumption, 
obesity and other factors has recently lent support to the contribution of these 
lifestyle factors to rising incidence of PLC. A recently published case-control study of 
the European Prospective Investigation into Nutrition and Cancer (EPIC) cohort 
reported higher odds of HCC in people who smoked cigarettes, drank alcohol and/or 
were obese, compared to controls (Trichopoulos et al., 2011). Per capita alcohol 
consumption in the UK has increased by 150% in the past 50 years (Pincock, 2003)], 
a factor that could well have added to the rising incidence of HCC. 
Diabetes mellitus (DM), a recognised risk factor for HCC, is higher among migrant 
populations than among indigenous whites of England and Wales (Oldroyd et al., 




HCV infection was significantly higher among Afro-Caribbeans than other ethnicities 
(Gray et al., 1995). That study also reported that persistent moderate elevations in 
serum transaminases of studied patients was higher among Afro-Caribbeans than in 
other studied ethnic minorities, a factor associated with poor outcome. This may 
therefore contribute to the higher and rising rate of HCC in Afro-Caribbeans, 
compared to the rest of studied ethnic minorities. Indeed, a study of obesity among 
ethnic minorities found that the highest rate of obesity was among Afro-Caribbeans 
(30%) relative to 19% in the reference white population. 
I note that the registration of ethnicity information was lacking in more than 60% of 
PLC of the ONS database. Although data during the most recent year with 40% 
registration of ethnic information were utilised in the analysis, it is possible that a 
disproportionate registration of ethnic information would have skewed the findings. 
With progressive increases in ethnic registration during liver cancer registration, 
follow-up analyses should provide a better distribution of PLC by ethnic groups in 
England and Wales.  
The major strength of the present study is the fact that the population cancer registry 
data of England and Wales were used. I have been able, for the first time, to 
demonstrate trends in both mortality and incidence together of PLC, the basis of 
diagnosis and ethnic distribution for the whole population of England and Wales. The 
information on the basis of diagnosis was objective evidence of the modality of 
investigation for PLC during the period when data on mode of diagnosis were 
collected routinely across the country. The ethnic trends in PLC registrations 
presented here provide important insight on high risk groups and possible focus for 
prevention strategies. However, due to the limited number of individual registrations 




based on the ethnic proportions in the population as a whole. I advocate further 
studies to corroborate and expand these findings. To determine the impact of 
guidelines and of improved management of PLC, information on adherence to 
surveillance schedules, tumour stage at diagnosis, ethnicity, and survival of patients 
will need to be gathered. With such a low fatality rate, the search for better 
performing screening and diagnostic tools should be a priority as current tools have 
low sensitivities and specificities. Newer techniques, including the use of urinary 
metabonomics hold some promise but wait on validation experiments. The Imperial 
group has recently reported the impressive diagnostic performance of panels of 
urinary metabolites in discriminating HCC in some African populations (Shariff et al., 
2010;Shariff et al., 2011). Until the latter is achievable, follow-up studies of these 
changing trends in the mortality and incidence of PLC in England and Wales need to 
be closely monitored.  
3.4.1 Conclusion 
Mortality from PLC has continued to increase in both sexes in England and Wales. 
The incidence of IHBD increased in both genders, while that of HCC increased only 
among males. Increasing use of histological confirmation of PLC and subcategories 
lends support to better characterisation of liver tumours. While the proportional 
registration of all major categories of PLC was greatest in Afro-Caribbeans, there 
were modestly higher proportions of sub-Saharan black Africans and Chinese with 
HCC, compared to indigenous white populations. Better characterisation of PLC is 
being achieved in England and Wales, providing opportunities for targeted 




3.4.2 Future research directions 
The pattern of change in mortality trends for PLC warrants a close examination of 
data to study the epidemiological factors underlying the current rapid increase in 
incidence and mortality of PLC in general and IHBD in particular. Further studies of 
the pathogenesis of HCC and IHBD are engendered. 
Additional data on the impact of changing patterns of risk factors, role of increased 
alcohol consumption and contribution of obesity will be helpful to facilitate successful 
preventative measures. There is also need to evaluate adherence to screening and 
surveillance guidelines by physicians and patients for the detection of potentially 






4. ROLE OF TUMOUR MISCLASSIFICATION IN THE RISING TRENDS IN 
INTRAHEPATIC BILE DUCT CARCINOMA IN ENGLAND AND WALES  
4.0 ABSTRACT  
Background: Cholangiocarcinomas (CC) can be sub-divided into intrahepatic 
(IHBD) or extrahepatic (EHCC). Hilar, or ‘Klatskin’, tumours are anatomically 
extrahepatic. Most international studies, including England and Wales, report 
increasing IHBD and decreasing EHCC incidence. The second edition of the 
International Classification of Diseases for Oncology (ICD-O-2) assigned ‘Klatskin’ 
tumours a unique histology code (8162/3), but this was cross-referenced to the 
topography code for intrahepatic (IHBD), rather than extrahepatic bile duct 
carcinomas (EHCC). Under the third ICD-O edition, Klatskin tumours are cross-
referenced to either IHBD or EHCC. The impact of changing ICD-O classifications 
and the potential misclassification of hilar/Klatskin tumours on IHBD incidence rates 
in England and Wales was studied.  
Methods: Age-standardised incidence rates (ASIR) of IHCC and EHCC in England 
and Wales between 1990 and 2008 were calculated. I then transferred all ‘Klatskin’ 
tumours from IHBD to EHCC and reanalyzed rates from 1995, when ICD-O-2 was 
introduced in England and Wales.  
Results: In England and Wales, during 1990-2008, ASIR of IHBD rose from 0.43 to 
1.84/100,000 population in males and from 0.27 to 1.51/100,000 in females; but fell 
for EHCC (0.78-0.51; 0.62-0.39). After transferring all ‘Klatskin’ tumours from IHBD 
to EHCC, there remained a marked increase in ASIR of IHBD and a decrease in 




Conclusions: Changes in ICD-classification may be influencing observed changes 
in IHBD and EHCC incidence rates. Coding misclassification is likely to have been 
skewing CC registration to an intrahepatic site, thereby contributing to the rise in 








Cholangiocarcinoma (CC) is a lethal tumour, arising in the epithelium of bile ducts. 
CC is divided into intrahepatic cholangiocarcinoma (IHBD) and extrahepatic (EHCC). 
IHBD is the second most common PLC worldwide, after HCC (Khan et al., 2008). CC 
arising at the liver hilum (hilar CC) is anatomically defined as a subset of EHCC, 
since the bifurcation of the hepatic ducts lies outside the liver parenchyma. IHCC are 
conventionally documented to account for 5-10% of all CC cases; hilar CC for 60–
70%; and EHCC for 15–20% (Khan et al., 2002a;Klatskin, 1965a;Nakeeb et al. 
1996). The eponym ‘Klatskin’ tumour has been adopted for hilar CC, particularly in 
the USA, after the American hepatologist who first described the unique features of 
these tumours in 1965 (Klatskin, 1965b). The terms ‘hilar’ and ‘Klatskin’ are used 
interchangeably.  
IHBD and EHCC have distinct clinical and morphological features (Khan et al., 
2002a;Klatskin, 1965b;Nakeeb et al., 1996). Previous epidemiological studies from 
England and Wales showed that ASMR of IHBD increased markedly over a 30-year 
period after 1968, from 0.10 to 1.49 in men and 0.05 to 1.24 in women (Taylor-
Robinson et al., 2001). There was a 15-fold increase in age-specific mortality rates in 
those aged 45 years and above; and since 1993, IHBD are the commonest recorded 
cause of liver tumour-related death in England and Wales (Taylor-Robinson et al., 
2001). Age-standardized incidence rates (ASIR) for IHBD increased concomitantly, 
approximately 12-fold (West et al., 2006). These studies showed an accompanying 
fall in mortality and incidence rates for EHCC (Taylor-Robinson et al., 2001;West et 
al., 2006). Recently, a number of international studies have reported increasing 




few decades (Khan et al., 2002;McGlynn et al., 2006;Patel, 2001;Patel, 2002;Shaib 
& El-Serag, 2004;Shaib et al., 2004).  
The reasons for these dynamic trends in different sub-groups of CC are unclear. The 
trends may reflect genuine changes in the incidence of these tumours. However, 
given the complexity over how CC are classified and several revisions of the 
International Classification of Diseases (ICD) coding system for liver and biliary tract 
tumours over the past three decades, trends in CC rates could theoretically be 
influenced by coding misclassification. This is particularly likely if hilar/Klatskin 
tumours, which account for the majority of CC and are in fact extrahepatic, are 
misclassified as intrahepatic tumours. To date, only one published study has 
examined this issue (Welzel et al., 2006). This investigation, performed in the USA 
examined the impact of classification of Klatskin CC on IHBD and EHCC incidence 
rates using data from the Surveillance, Epidemiology and End Results (SEER) 
cancer registry program of the United States National Cancer Institute (NCI) (Welzel 
et al., 2006). Studying data from 1992 to 2000, before ICD-O-3 was introduced, the 
investigators found that 91% of the Klatskin CC reported between 1992 and 2000 
were incorrectly coded as IHCC, rather than EHCC, resulting in an overestimation of 
IHBD incidence by 13% and a similar underestimation of EHCC incidence. No similar 
studies have been done elsewhere. 
The aim of this study was to: 
 analyse incidence trends in IHBD and EHCC in relation to changes in 
ICD-O classification, and to investigate the impact of potential 
misclassification of hilar/Klatskin tumours on site-specific incidence 




4.2 METHODS  
The bi-axial International Classification of Diseases for Oncology (ICD-O) of the 
WHO classified CC as intra- or extrahepatic. The ICD-O was introduced in 1979 and 
assigns two codes dependent upon the anatomical topography and morphology 
(based on histology) of the tumour (Fritz A et al., 2000). Topography codes are 
defined in the neoplasm section of the ICD, and are applicable to all tumours, 
regardless of whether their growth behaviour is malignant, benign, in situ or 
uncertain. A number of different revisions of the ICD and ICD-O have been 
introduced over the past 40 years. In the 10th revision of the ICD, currently in use for 
cancer registration statistics in England and Wales, HCC is coded as C22.0, IHBD 
as C22.1 and of the EHCC as C24.0 (World Health Organisation, 1992). These 
codes include several morphological/histological sub-codes for more specific 
delineation of tumours, as outlined in ICD-O, including: 8180/3 for combined 
hepatocellular carcinoma and CC, 8160/3 for CC, 8010/3 for carcinoma ‘not 
otherwise specified (NOS)’, 8140/3 for adenocarcinoma NOS, 8000/3 for ‘malignant 
neoplasm’ and 8162/3 for Klatskin tumours. IHBD (coded to C22.1) are considered a 
PLC (C22), whereas EHCC (C24.0) are recognised as a subset of biliary tract 
cancers (C24).  
In the first edition of the ICD-O, hilar/Klatskin tumours were not assigned a specific 
morphology/histology code and could therefore be classified as either intrahepatic 
(C22.1) or extrahepatic (C24.0). In the second edition (ICD-O-2), ‘Klatskin’ tumours 
were given a unique histology code, 8162/3, but this was cross referenced to the 
topography code for intra- rather than extrahepatic bile duct tumours (Percy C et al., 
1990;Welzel, McGlynn et al., 2006). ICD-O-2 came into use in the US in 1992 and in 




later in the UK in 2008, the histology code 8162/3 was cross-referenced to either 
intra or extrahepatic bile duct tumours. Thus, hilar/Klatskin tumours may have been 
misclassified in all versions of the ICD-O.  
4.2.1 England and Wales cancer registration data  
Registration data, including full details of histological classification, for all cancers 
coded as IHBD (C22.1) and EHCC (C24.0) in the whole of England and Wales, 1990 
to 2008, were extracted from the National Cancer Registry held at the Small Area 
Health Statistics Unit (SAHSU) at Imperial College London. Annual population 
estimates were obtained from the ONS.  
4.2.2 Data analysis 
The total number of cases and the ASIR of IHBD, EHBD and Klatskin tumours were 
analysed by year and sex. ASIR in England and Wales were standardised using the 
2001 European standard population as the reference population. Age-specific 
incidence rates (ASpIR) were calculated using the following age groups: 20-44, 45-
64, 65-74 and over-75 years. Age-standardised incidence rate for IHBD and EHCC 
specifically between 1990 and 2008 was calculated. IHBD was defined by 
topography code C22.1 (intrahepatic bile duct) and histology codes 8140, 8160, 
8161, 8020, and 8010. EHCC was defined by topography code C24.0 and histology 
codes 8010, 8020, 8041, 8070, 8140, 8144, 8160, 8161, 8260, 8310, 8480, 8490, 
and 8560. All ‘Klatskin’ tumours (8162/3) were removed from the IHBD dataset and 





4.3 RESULTS  
4.3.1 Total numbers of cases, 1990 to 2008 
Between 1990 and 2008, the total number of cases reported to have IHBD (C22.1) 
rose from 226 to 1311. Male cases increased from 116 to 639, and females from 110 
to 672. In the same period, the number of cases reported to have EHCC (C24.0) 
declined from 465 to 329. The decline in males was from 211 to 170 and in females 
from 254 to 159 (Table 7).  
4.3.2 Incidence rates 
In England and Wales, ASIR of IHBD (C22.1) increased from 0.34 to 1.67 per 
100,000 population/year between 1990 and 2008 (Figure 17). An increase from 0.43 
to 1.84 was seen in males and from 0.27 to 1.51 in females. In the same time period, 
ASIR of EHCC (C24.0) declined from 0.70 to 0.45 (Figure 18): a reduction from 0.78 
to 0.51 in males and from 0.62 to 0.39 in females. All 82 cases with histology code 
8162/3 (i.e. ‘Klatskin’ tumours specifically) were then removed from the IHCC 
(C22.1) dataset and included with the EHCC (C24.0) dataset, prior to reanalysis of 
the incidence rates. There was still a marked increase in the ASIR of IHBD (C22.1), 
even when 8162/3-coded tumours were excluded, from 0.87 to 1.39 per 100 000 
population, between 1995 (when ICD-O-2 was introduced) and 2008 (Figure 18). 
The rise was from 1.04 to 1.51 in males and from 0.73 to 1.29 in females. 
Concurrently, even after all the Klatskin tumours were included in the EHCC (C24.0) 





Table 6. Number of cases per year of IHBD (C22.1) and EHCC (C24.0), between 
1990 and 2008 in England and Wales. 
 No. of cases with IHBD  No. of cases with EHCC 
Year  F M Total  F M Total 
1990 110 116 226  254 211 465 
1991 127 99 226  226 215 441 
1992 167 142 309  256 233 489 
1993 176 151 327  235 200 435 
1994 194 168 362  216 178 394 
1995 297 291 588  210 168 378 
1996 362 305 667  189 172 361 
1997 413 361 774  157 139 296 
1998 417 359 776  194 151 345 
1999 385 367 752  189 144 333 
2000 504 420 924  138 127 265 
2001 473 437 910  138 110 248 
2002 506 441 947  127 109 236 
2003 474 464 938  126 110 236 
2004 573 489 1062  100 110 210 
2005 592 559 1151  135 139 274 
2006 676 608 1284  155 162 317 
2007 691 557 1248  138 186 324 
2008 672 639 1311  159 170 329 





Table 7.  Total number and relative percentages of Klatskin tumours (histology code 
8162/3) classified as C22.1 (IHBD) and C24.0 (EHCC) per year in England and 
Wales, between 1995 and 2008. ICD-O-2 was in use throughout this period. 





1995 3 (100%) 0 (0%) 3 
1996 6 (100%) 0 (0%) 6 
1997 6 (100%) 0 (0%) 6 
1998 11 (92%) 1 (8%) 12 
1999 9 (100%) 0 (0%) 9 
2000 6 (86%) 1 (14%) 7 
2001 9 (100%) 0 (0%) 9 
2002 10 (91%) 1 (9%)  11 
2003 10 (100%) 0 (0%) 10 
2004 12 (86%) 2 (14%) 14 
2005 10 (100%) 0 (0%) 10 
2006 18 (95%) 1 (5%) 19 
2007 17 (100%) 0 (0%) 17 
2008 15 (94%) 2 (6%) 17 






Figure 17. Comparison of age-standardised incidence rates per 100,000 population 
for tumours coded to C22.1 (excluding M8162/3) and C24.0 (including M8162/3), 
between 1990 and 2008 in England and Wales. Males and females combined. 
 
4.3.3 Age-specific incidence rates (ASpIR) 
In England and Wales, ASpIR analysis showed that the greatest increase in 
incidence for IHBD (C22.1), excluding 8162/3 (Klatskin tumours), occurred in the age 
group of 75+ years (Figure 15A). This was the case for both sexes. The decline in 
incidence rates of EHCC (C24.0), including 8162/3 (Klatskin tumours), was most 






Figure 18. Comparison of age-standardised incidence rates (ASIR) per 100,000 
population for tumours coded to C22.1 (IHCC, intrahepatic bile duct carcinoma) and 
C24.1 (EHCC, extra-hepatic bile duct) between 1990 and 2008 in England and 





Figure 19. Age-specific incidence rates by gender per 100,000 population for bile 
duct cancers in England and Wales, 1990-2008. (A) C22.1/IHBD (excluding M8162/3 







This study includes the first European investigation to analyse the impact of 
misclassification of hilar/Klatskin tumours on IHBD incidence rates; the first ever 
study to examine a whole national dataset. ‘Klatskin’ and ‘hilar’ CC are the same 
entity and should be coded as extrahepatic tumours, yet the main finding of this 
investigation is that of confusion and inconsistency regarding the ICD topographical 
classification of CC. Discrepancies between coding guidelines in the first and second 
versions of the ICD-O may have resulted in the classification of anatomically-
unspecified CC/Klatskin tumours as IHBD. These findings suggest that, in England 
and Wales, reported increasing rates for IHBD could be due to the incorrect 
classification of hilar/Klatskin CC as intrahepatic tumours rather than extrahepatic. 
The rising incidence of CC coded as intrahepatic in England and Wales has been 
sustained into the 21st century, as has the falling incidence of CC coded as 
extrahepatic.   
After excluding 8162/3 (Klatskin tumours) from the IHBD (C22.1) group, there was 
still a marked increase in the ASIR from these cancers. This is because the 
misclassification of Klatskin tumours resulted in overestimation of IHBD incidence 
rates by only 1%. Yet, according to published studies, Klatskin/Hilar tumours account 
for the majority of all CC. Welzel and colleagues also acknowledged that the number 
of Klatskin tumours in the United States SEER database was low, at 8% (Welzel et 
al., 2006). I found that the proportion of Klatskin tumours registered in England and 
Wales was even lower; 0.9% during the period 1995-2004, when ICD-O-2 was in 
use. Even if the estimations that Klatskin tumours make up 60-70% of all CCs (Khan 
et al., 2002a;Klatskin, 1965b;Nakeeb et al., 1996) are overstated, the proportion of 




representation of the true number. Cancer registries in England and Wales do not 
code a tumour described as a ‘hilar’ CC with the designated Klatskin code, 8162/3. 
Thus, ‘hilar’ and ‘Klatskin’ CC are coded differently, even though they are the same 
entity, and it is therefore not currently possible to determine the true prevalence of all 
hilar/Klatskin tumours. As a result of this, it is also not possible to determine the true 
prevalence of IHBD and EHCC in England and Wales.  
In experience, ‘hilar’ is preferred over ‘Klatskin’ as a clinical term in the UK. This 
could explain the low number of CC coded as ‘Klatskin’ in our data. Most hilar/CC 
pathology reports in the UK are not likely to specify “Klatskin”, but rather state “Hilar” 
or simply “Cholangiocarcinoma”, with no site specified.  
Coding is not the only issue here. There are several potential weak points in the 
registration process which need to be addressed. Pathologists should be 
encouraged to seek clarification on the site of a reported CC to prevent unspecified 
extrahepatic CC being classified as IHBD, in concordance with current ICD rules. 
Clinicians need to be clearer too, when documenting medical notes and death 
certificates. Given that documentation and writing of death certificates in the England 
and Wales tends to be carried out by relatively junior members of the specialist 
team, clearer guidance on accurate documentation needs to come from senior 
specialists. 
Conclusions and further work 
Close surveillance of incidence trends for hepatobiliary tumours is recommended, 
particularly in light of recently reported dynamic changes. Trends should be adjusted 
for the potential misclassification of Klatskin tumours until the WHO establishes an 




hilar/Klatskin CC would permit more accurate monitoring of incidence trends of 
intrahepatic and extrahepatic CC. I recommend raising awareness amongst cancer 
registries that the terms ‘hilar’ CC and ‘Klatskin tumour’ are the same entity; 
otherwise the code 8162/3 for Klatskin tumours is not particularly useful. Consensus 
in coding practice should be reached on this important matter by the UK Association 
of Cancer Registries as well as all relevant international bodies. A proposal for the 
revision of the ICD-O need to be considered, ensuring that all ‘hilar/Klatskin’ tumours 
are coded topographically to extrahepatic tumours only, rather than as currently to 
intra- or extrahepatic. Moreover, the description of code 8162/3 should be changed 
from ‘Klatskin’ to ‘Hilar/Klatskin’. Alternatively, bile duct cancers could be sub-
classified as intrahepatic, perihilar or distal with the term Klatskin being omitted 
altogether. Intrahepatic mass lesions impinging on common hepatic duct, the right 
and/or the left hepatic ducts should be termed perihilar; the terms intrahepatic versus 
extrahepatic are unhelpful in this situation. I suggest similar studies on cancer 
registry practices are carried out in other countries which have reported changes in 
CC rates. A consistent global classification of CC is required to accurately compare 
trends around the world. Finally, it is important to note that however CC are 
classified, the incidence of IHBD appear to be increasing overall and the reasons for 





5. IMPACT OF VIRAL HEPATITIS ON HIV INFECTION IN AN AFRICAN 
COHORT 
5.0 ABSTRACT 
Background:  Owing to shared routes of infection, hepatitis B and or C co-infecting 
HIV patients is/are common in many regions of sub Saharan Africa. However, large 
data from Africa characterising the rates and impact of hepatitis B (HBV) and 
hepatitis C (HCV) infections on response to long-term antiretroviral therapy (ART) of 
HIV infection are lacking. These parameters were determined in the present study. 
Methods: This was a retrospective cohort study of 19,408 adults who were recruited 
between June 2004 and December 2010 in the AIDS Prevention Initiative in Nigeria 
(APIN) programme at Jos University Teaching Hospital. Serological assays; 
including HBsAg and HCV Ab were used to categorise hepatitis status of the 
patients. HBsAg was determined using Enzyme immunoassay (EIA) (Monolisa 
HBsAg Ultra3; Bio-Rad). HCV antibody was tested using third generation enzyme 
immunoassay (DIA.PRO Diagnostic, Bioprobes srl, Milan, Italy). HIV RNA levels 
were measured using Roche COBAS Amplicor HIV-1 monitor test version 1.5 
(Roche Diagnostics, GmbH, Mannheim, Germany) with a detection limit of 400 
copies/mL. Flow cytometry was used to determine CD4+ cell count (Partec, GmbH 
Munster, Germany). Comparison of categorical and continuous variables were 
achieved using Pearson’s chi-squared and Kruskal Wallis tests respectively, using 
MedCalc Statistical Software version 12.7.5 (MedCalc Software bvba, Ostend, 
Belgium; http://www.medcalc.org; 2013)  
Results:  With an overall screening rate for hepatitis of over 90% for each virus; 




453(2.5%) HIV infected adults respectively. The rate of liver disease was low, but 
highest among HIV mono-infected patients (29, 0.11%), followed by HBV co-infected 
patients (15, 0.08%). Patients with HBV co-infection and triple infection had higher 
log10 HIV RNA loads (HBV: 4.6 copies/mL vs HIV only: 4.5 copies/mL; P <0.0001) 
and more severe immune suppression (HBV: 645, 55.4%; HBV/HCV: 97, 56.7%) 
prior to initiation of antiretroviral therapy (ART) compared to HIV mono-infected 
patients (1852, 48.6%) (P<0.0001). Of 3,025 patients who were 4.4 years on HAART 
and whose CD4 cell counts results at baseline and end of follow up were available 
for analyses, CD4 increase was significantly lower in those with HBV co-infection 
(HBV: 144 cells/mm3; HBV/HCV: 105 cells/mm3) than in those with HCV co-infection 
(165 cells/mm3) and also in those with human immunodeficiency virus (HIV) mono-
infection (150 cells/mm3) (P =0.0008).  
Conclusion: High rates of HBV and HCV infections were found in this HIV cohort. 
CD4 recovery was significantly diminished in patients with HBV co-infection. Further 
studies would be required to document the impact of these co-infections on the 








Studies of the prevalence of hepatitis in HIV infected individuals confirm that the 
rates of hepatitis B (HBV) in HIV-infected patients vary widely with tendency towards 
higher values compared to HBV prevalence in the general population (Adekunle et 
al., 2011;Adesina et al., 2010). In the north central region of the Federal Republic of 
Nigeria, the prevalence of hepatitis B and hepatitis C in HIV-infected people were 
27.8% and 18.3% respectively, and triple infection (HBV/HCV/HIV) was found in 
7.2% of 180 HIV-infected patients (Forbi et al., 2007). HBV prevalence in population 
studies in Nigeria is between 10 and 20% (Ladep and Taylor-Robinson 2007).  
Although it is widely recommended that HIV-infected patients are screened for 
hepatitis before antiretroviral therapy, no data from Nigeria are accessible to 
ascertain adherence to this guideline. Reports from Thailand confirm that compliance 
to hepatitis screening in HIV patients prior to initiating ARVs was poor (between 55-
69%) (Kiertiburanakul et al., 2011;Sungkanuparph et al., 2008). Inadequate 
information on hepatitis in HIV patients may underpin one reason for national health 
schemes in many developing countries not offering integrated hepatitis services in 
HIV-infected persons. As a consequence, patients co-infected with HBV and HCV 
are being ignored in regards to timing of antiretroviral therapy, screening for cirrhosis 
of the liver and hepatocellular carcinoma, as well as in the choice of ARV regimens 
that have the potential to optimise their care. 
Rising trends in the prevalence of HBV and HCV among HIV-infected individuals 
during the last decade have been reported in a study in the USA. That study, 
involving about 30,000 HIV-infected patients recorded a low, but significantly 




60% in 2004 (Buskin et al., 2011). The researchers found that the rate of HBV and 
HCV increased from 7 to 8.5% and 9 to 24% respectively. To date, no report of 
trends in the rate of hepatitis in patients infected with HIV from sub-Saharan African 
countries has been published.  
The choice of ART regimen can be critical in achieving good treatment outcomes; 
and knowledge of hepatitis co-infection is vital in this regard. Lamivudine resistance 
in HIV/HBV co-infected patients on ART has been described in some studies within 
the West African sub-region (Kouanfack et al., 2012;Stewart et al., 2011). A 
Francophone study has recently demonstrated the advantage of treating HBV-HIV 
co-infected patients with Tenofovir-containing ARV regimen, particularly for wild type 
precore mutant and lamivudine-resistant HBV (Benhamou et al., 2006). Guidelines 
for the choice of ART regimens generally recommend screening for hepatitis, but not 
routinely undertaken and/or largely depends on availability of resources. Even where 
screening for hepatitis takes place, a large number of HIV physicians base the 
choice of ART on available drugs rather than on informed co-morbid conditions.  
The importance of well-designed research to answer these questions cannot be 
overemphasised in order to advice adequate provision of resources for the 
optimisation of care for HIV/hepatitis co-infected individuals in Africa. Thus, I aimed 
to determine the rate of hepatitis screening in HIV infected patients, magnitude of 
hepatitis infection in this large cohort, impact of hepatitis co-infection on baseline HIV 





5.2 PATIENTS AND METHODS 
5.2.1 Study Population 
The AIDS Prevention Initiative in Nigeria (APIN) and Harvard School of Public Health 
HIV program, supported by a grant from the United States President’s Emergency 
Plan for AIDS Relief (PEPFAR) started to provide antiretroviral therapy, at no cost to 
patients in Nigeria from 2004 until the time of writing this report. This programme is 
run on a community-based model (although the major sites in Nigeria are located 
within tertiary health centres), in which integrated community prevention outreaches, 
on-site HIV screening, counselling, provision of medications, follow up, monitoring 
and evaluation of all activities are embarked upon. Jos University Teaching Hospital 
(JUTH) site is one of several centres in Nigeria, with latest HIV prevalence of 4.4% 
(Agaba et al., 2011). JUTH has a specialised centre of care for HIV infection where 
patients are seen at the outpatient facility at planned intervals of 4 to 12 weeks.  
 
The initial first line ARVs in this population included Stavudine/Zidovudine, 
Lamivudine and Efavirenz/Nevirapine. However, from 2006, Truvada® (Tenofovir 
plus Emtricitabine) started to be administered to HIV patients going on ART in the 
programme. From June 2004 to December 2010, approximately 19,408 HIV-infected 
individuals had been recruited in the JUTH/APIN/Harvard programme and were 
initiated on ARVs and anti-tuberculosis drugs, if indicated.  
 
For the initial part of the study, all subjects whose HIV status were confirmed by 
Western blot assay and enrolled in the programme between 2004 and 2010 were 
included. Information on age, gender, educational attainment, status of hepatitis B 




recent assays were also included as were information on the last day of follow-up, 
death or discontinuation of therapy. 
 
Subjects were defined as having HBV and HCV infection if they tested positive for 
hepatitis B surface antigen (HBsAg) and hepatitis C antibody (HCV Ab), respectively 
on baseline blood samples. HIV RNA levels and CD4+ cell count were determined at 
baseline for patients and at 3 monthly intervals until the end-point of the study. 
Hepatotoxicity was defined based on the recommendation of the AIDS Clinical Trials 
Group(AIDS Clinical Trial Group 1996); as elevated alanine aminotransferase (ALT) 
values ≥5 folds of upper limit of normal (ULN) (41IU/mL for JUTH) if baseline ALT 
was within normal range or of ≥3.5 folds of baseline, if ALT at baseline was higher 
than 41IU/mL prior to commencement of ART or anti-tuberculosis medications. 
 
Diagnosis of tuberculosis was established based on sputum smear positivity on at 
least two of three sputa collected according to an established local protocol. Patients 
who are coughing are given three universal containers. They are required to cough 
up sputum into the container, the first thing in the morning. On arrival to hospital, 
they produced the second sputum. The third sputum was brought on the second day. 
This protocol was practical for those patients that lived close to the research centre 
at JUTH. In view of the limitations of resources and the fact that most patients 
infected with HIV are likely to have smear-negative TB, chest X-ray findings, typical 
clinical presentation (cough for more than two weeks, fever, night sweating, weight 
loss and history of prolonged contact with a person known or suspected to have TB), 
according to WHO guidelines for resource-limited settings was used to define a TB 





Recruited patients gave written informed consents approved by the ethical 
committee at JUTH and the institutional review board (IRB) at the Harvard School of 
Public Health. For the present work, I obtained a further approval for secondary use 
of data. 
 
5.2.2 Study Design  
This was a retrospective cohort study. The pro-forma utilised in the analyses is 
summarised in Figure 20. The number of HIV-infected individuals who were 
screened for hepatitis B and hepatitis C were divided by the total number of patients 
recruited to ascertain the proportion of hepatitis screening. The rates of HBV and 
HCV were calculated from the population that underwent serological testing. All 
patients who had hepatotoxicity, liver cirrhosis and hepatocellular carcinoma were 
categorised into a single group (liver disease). As there was overlap of the 
morbidities, further categorisation of the cumulative rates of liver related morbidities 
was undertaken.  
Case-controlled analyses of the impact of hepatitis co-infections on baseline HIV 
viral load and CD4+ cell counts were also embarked upon.  
5.2.3 Laboratory testing 
Before recruitment into the APIN programme, subjects were screened for HIV, using 
enzyme linked immunoassay (ELISA) and subsequently confirmed by Western Blot 
assay. HBsAg was determined using Enzyme immunoassay (EIA) (Monolisa HBsAg 
Ultra3; Bio-Rad). HCV antibody was tested using third generation enzyme 




were measured using Roche COBAS Amplicor HIV-1 monitor test version 1.5 
(Roche Diagnostics, GmbH, Mannheim, Germany) with a detection limit of 400 

























5.2.4 Statistical Analyses 
As the diagnoses of HBV, HCV and liver diseases were likely to overlap, the 
cumulative prevalence of liver morbidities by overlapping diagnoses were calculated; 
categorised into HBV only, HCV only, HBV/HCV, and liver disease. The relationships 
in the demographics of the patients and liver morbidities, as wel as baseline HIV 
parameters were determined. The obtained characteristics of HBV, HCV, HBV/HCV 
and HIV only subjects were compared against each other at baseline using Chi-
squared and Kruskal Walis tests for categorical and continuous variables 
respectively. Analyses were accomplished using MedCalc Statistical Software 
225 excluded (enrolment after 31st 
Dec 2010) 
1,526 excluded (no information on 
age, gender and hepatitis screening) 17,882 –Analysis of baseline characteristics, rate of hepatitis 
co-infection 
10,946 -Analysis of HIV RNA 
load, CD4+ cel counts and 
prevalence of liver disease at 
end of folow up 
6,952 excluded (yet to commence or 
on ART for <12 months) 
7,921 excluded (Baseline data on 
CD4+ cel count not available) 
3,025 -CD4+ cel gain 
determination 
19,633 subjects enroled at 
APIN (June 2004-March 2012) 
 
Figure 20. Flow-chart representation of analyses on HIV-infected individuals at APIN, 




version 12.7.7 (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 
2013). P values of <0.05 were considered statistically significant.  
5.3 RESULTS 
Between June 2004 and Dec 2010, 19,408 HIV subjects had been enrolled. Median 
follow up period was 53 months (interquartile range: 31-72 months). Table 8 
presents a summary of the main characteristics of the cohort at baseline. Subjects 
diagnosed with hepatitis B were more likely to be young (median age: 32; p<0.001), 
male and to have had high HIV RNA loads and CD4+ cell count below 200/mm3. 
Hepatitis C co-infected individuals were more likely to be males, older (median age: 
36 yrs), have had low level of education and high HIV RNA in their plasma.  
5.3.1 Hepatitis screening and prevalence of co-infections 
At the beginning of the study period (year 2004), 99.3% and 99.5% of recruited HIV 
infected individuals underwent HBV and HCV screening, respectively. There has 
been a significant decline in the rates of screening for HBV and HCV during 
approximately 7 year study period to 73.0% and 87.6% respectively in 2010 
(P<0001) (Figure 21). Overall, the prevalence of HBsAg was 20.7%. A significant 
increase in the rate of HBV from 14.4% in 2004 to 21.0% in 2010 was observed 
(P<0.001) and although, fluctuating rates of HCV Ab was recorded among those that 
were screened, an increasing pattern was noted. The prevalence of HCV Ab was 
10.6% in 2004, increasing to 11.7% in 2010. Higher rates of HBV infection was found 





Table 8 Baseline characteristics by hepatitis status of patients at APIN, 2004-2010 
Characteristic  Total, n (%) HBV HCV Triple 
infection 
HIV only 
      
Gender 
  Male 





















  15-29 
  30-39 
  40-49 






























  Present 


















  None 
  Primary 
  Secondary 



























CD4; cells/mm3  
  <200 
  200-499 
































































Figure 21. Rates of hepatitis co-infection of HIV infected individuals in both genders 
































































































5.3.2 Overlapping Diagnosis 
Cumulatively, 3,185(17.8%) patients were positive for HBsAg and 2,014 (11.3%) 
patients had HCVAb. 453 (2.5%) patients had evidence of combined HBV and HCV 
infections (Figure 22). Liver disease was diagnosed in 50 (0.3%) patients. Of these, 
15 had HBV, 6 had HCV and 29 had no evidence of hepatitis co-infection. None of 
those with triple infection had a diagnosis of liver disease. Diagnoses of liver disease 
were achieved via conventional means, including: assessment of sequential serum 



























 Figure 22. Prevalence of hepatitis B, hepatitis C, hepatitis B &C and liver disease 
diagnoses among HIV infected individuals (AIDS Prevention Initiative in Nigeria cohort) 




5.3.3 Impact of Hepatitis co-infection on outcome of ART 
Higher proportion of HBV (645, 55.4%) and HBV/HCV (97, 56.7%) infected patients 
had CD4+ cell counts below 200 cells/mm3 at baseline compared with HCV (343, 
52.5%) and HIV-only (1852, 48.6%) patients (P<0.0001). The median HIV RNA at 
baseline were Log10 4.6 copies/mL each for HBV and HCV patients; and 4.5 
copies/mL for HIV mono-infected patients (P<0.0001). At the end of follow up on 
ART (median duration: 4.4yrs [interquartile range: 2.6-6yrs]), no significant difference 
in HIV RNA load suppression was observed in all study groups. However, there was 
a significantly lower CD4+ cell increase among those individuals co-infected by 
HBV/HCV (105 cells/mm3) and HBV (144 cells/mm3) than in HCV (165 cells/mm3) 
and HIV-only (150 cells/mm3) patient groups (P=0.008) (Figure 23). 
 
 
Figure 23. Median CD4 increase by hepatitis status following ART (AIDS Prevention 































In this large cohort of HIV-infected sub-Saharan African patients, I found that 
whereas chronic HBV and HCV were frequent diagnoses, liver disease was not 
commonly reported; although it was investigated only when there were overt clinical 
symptoms. Overall, one out of every five patients had HBV and more than a tenth 
had HCV. Almost every patient that who was recruited at the beginning of the study 
was screened for HBV and HCV. This is rather remarkable for a resource limited 
setting and much higher than obtainable in some cohorts elsewhere (Kiertiburanakul 
et al., 2011;Sungkanuparph et al., 2008). The fact that this study site benefitted from 
grants for research and involved the services of specialists may explain the high 
hepatitis screening rate. However, this initial enthusiasm was not sustained, as there 
has been a significant decline in the rates of screening for hepatitis during the study 
period. Interestingly, diagnoses of HBV and HCV showed significant rising trends. I 
surmise that there may be a selection bias in this regard as people tend to go to 
tertiary care centres to seek treatment. 
My findings corroborate the reports of other researchers who had observed higher 
prevalence of HBV and HCV infection among HIV-infected patients than in the 
general population (Chun et al., 2010). Studies of prevalence of HBV in the general 
population of people living within the study area during the period between 2002 and 
2007 had found rates of between 10.3% and 15.1% (Egah et al., 2007;Jombo et al., 
2005;Sirisena et al., 2002;Uneke et al., 2005). These confirm that the rates of 
hepatitides are higher in the HIV patients than in the general population of Nigeria. 
The fact that HIV and hepatitis viruses share the same routes of transmission 
supports this explanation. However, it remains unknown whether hepatitis infection 




The precise modes of transmission of HBV and HCV in this cohort are not known 
although most of the subjects incriminated heterosexual route for the acquisition of 
HIV. However, it has been reported that transmission of HBV most commonly occurs 
in early childhood among African populations (Lesi et al., 2007), compared to high 
transmission rates among adults in industrialised countries (Puoti et al., 2008). 
Whereas intravenous drug use is the major route of transmission of HIV and indeed 
hepatitis viruses in western industrialised countries, heterosexual and horizontal 
routes, as well as indiscriminate injections (unsterile needles) are thought to be the 
prevalent modes of transmission of these viral infections in African communities 
(Simonsen et al., 1999). Many patients may have iatrogenic transmission from poor 
sterilisation during routine medical, obstetric, dental and surgical procedures. Most 
HIV/hepatitis co-infected patients in Nigeria are postulated to have become infected 
by hepatitis viruses before HIV (Lesi et al., 2007). Longitudinal studies will be 
required to appropriately determine patients that may have acquired hepatitis before, 
at the same time or after HIV infection. Such a study has the advantage of providing 
additional information for reinforcing prevention methods, for example HBV 
vaccination, not only for the present cohort, but for HIV-infected patients in HBV 
endemic regions. 
The incidence of liver disease in my study was not assiduously documented, 
although observed to be common. Only 11 patients were documented to have had 
PLC. Eight of these patients were screened for hepatitis. While four were HBsAg 
positive, 4 were negative to both HBV and HCV. As population-based cancer 
registries are not routinely available and/or reliable in Nigeria owing to poor 
registration of diseases and deaths, it was not possible to compare the incidence of 




in United States have confirmed that PLC occurs about 6 times more commonly in 
HIV-infected individuals than in the general population (Engels et al., 2008;Shiels et 
al., 2009). With such a high rate of HBV and HCV infection in this African cohort, 
there is a chance that a large number of PLC cases were missed or will yet manifest.  
It should be noted that prior to free provision of ART to HIV patients in Nigeria from 
2004, the cost of these medications was prohibitive and the incidence of HIV 
mirrored its mortality (Idoko, 2012). It is thus likely that most patients would have 
died earlier than they could present with hepatocellular carcinoma (HCC). 
Furthermore, with prolonged ART, many of these patients will survive longer and 
HCC could become more frequently diagnosed.  
Unfortunately, the study design did not allow for prospective evaluation of hepatitis 
status. In addition, the patients were treated with ARVs (Truvada) that in some cases 
may have been both active on hepatitis and HIV infection. The baseline evaluation 
and hepatitis status seems to indicate that other non-infectious causes of hepatic 
disease may need to be considered. It will be anticipated that HIV hepatitis co-
infected patients would have higher incidence of liver disease. This would have been 
the case if the definition of liver disease were restricted to end-stage liver disease 
(fibrosis, cirrhosis and liver cancer). However, I included hepatotoxicity of ARVs in 
the definition. This would explain, in part the higher incidence of liver disease in HIV 
mono-infected patients. Chronic liver disease was small in the cohort, perhaps due 
to under reporting, or perhaps a high threshold for recording cases in the 
database. Reasons for the apparent rarity of liver disease in HIV/hepatitis co-infected 
patients and higher cases of liver disease in HIV mono-infected than hepatitis co-




At baseline, patients with hepatitis co-infection had higher HIV RNA than patients 
with HIV mono-infection. Correspondingly, a higher proportion of patients co-infected 
with HBV had CD4+ cell counts below 200 /mL compared to HIV mono-infected 
individuals. The finding of higher HIV RNA at baseline corroborates earlier findings in 
a study of a small number of patients (1,564) from the same study site (Idoko et al., 
2009), as well as another study from China (Sheng et al., 2004). Following ART, the 
gain in CD4+ cell count was significantly diminished in those patients who had 
hepatitis B co-infection compared to those with HIV mono-infection. In contrast to 
these findings, two studies that assessed the impact of hepatitis B on response to 
ART found no difference in CD4+ cell gain (Konopnicki et al., 2005;Law et al., 2004). 
The underlying reasons for the differential outcomes are not obvious. Differences in 
environment are unlikely, as my findings are in contrast to the observation of a study 
of South African patients (Hoffmann et al., 2008). I note however, that whereas the 
Republic of South Africa study had a shorter duration of follow up (1.5 years), my 
cohort was followed for a longer duration on ART (4.4 years). Nevertheless, results 
of hepatitis B and long-term HIV outcomes (7 years) in the USA found no difference 
in the HIV load suppression and CD4+ cell gain. Be that as it may, as the natural 
history of HBV is likely to differ between American and African populations, owing to 
differential age at acquisition of hepatitis infections, studies comparing African 
patients on long-term ART would provide a better assessment.  
The present findings suggest that CD4+ cell loss by HIV is accentuated by HBV, 
despite on-going HIV treatment. A few studies have highlighted that active HBV 
infection is associated with T-lymphocyte exhaustion (Dunn et al., 2009;Iser et al., 
2011). This has been further strengthened by the fact that inhibition of HBV DNA 




2008;Zoutendijk et al., 2012). One would expect such an effect to be universal. 
However, variable outcomes of ART in regards to HIV load suppression and/or 
increases in CD4+ cell count in HBV co-infected versus HIV mono-infected patients 
have been reported. While some studies found no differences between HBV and HIV 
mono-infected groups (Hoffmann et al., 2008;Hoffmann et al., 2009a), others found 
non-sustained differences in CD4+ cell increases (Law et al., 2004;Sagoe et al. 
2012). Studies of HIV treatment outcomes of HBV co-infected and HIV mono-
infected African patients comparing HBV suppressive agents versus regimens that 
are non-HBV suppressing will be required to adequately characterise the importance 
of HBV in the era of ART. 
This study was not without limitations. First, the use of HBsAg positivity as the sole 
indicator of chronic HBV infection may be misleading. The definition of chronic HBV 
would require a positive HBsAg assay carried out consecutively, at least 6 months 
apart. As single HBsAg was utilised to define cases of HBV in this current study, 
cases of misclassification might have occurred. Also, delineating HBV cases by their 
HBV DNA loads and HBeAg status would have provided more meaningful analyses. 
However, as it is generally known that HBV infection in Africans occur more 
commonly in childhood, the chance of falsely misclassifying HBV is low. Restricted 
by the terms of IRB approval to utilise data only, additional HBeAg and HBV DNA 
analyses could not be performed.  
Another issue that could have led to misclassification to hepatitis status is reliance 
on anti-HCV Ab results to define active HCV infection. Earlier data (unpublished) 
from a sub-group of the current cohort had found HCV viraemia of 33% in those that 




“HCV”; only a third may actually be HCV viraemic. More studies with better 
characterisation of HCV status in this cohort would be required. 
Missing data were another issue I encountered. In some of the patients, HBsAg and 
HCV Ab and baseline CD4+ data results were unavailable. Also, reliance on 
diagnosis of liver diseases (hepatotoxicity, cirrhosis and PLC) from clinical notes of 
the patients, where available, could have hampered the interpretation of these data. 
As a result of these, analysis of the rates of hepatitis was accomplished among 
those that had available hepatitis results. Also, CD4+ cell gain was analysed for 
3,012 patients for whom there were baseline and follow up results and who were on 
ART. 
In conclusion, high and increasing rates of HBV, HCV and HBV/HCV co-infections 
were found in this large HIV infected cohort of Africans. The prevalence of liver 
disease, particularly liver cancer was low; mostly reported among HBV/HIV and HIV-
only individuals. HBV co-infection was associated with high HIV RNA load and 
decreased CD4+ cell counts at baseline and attenuated immunological recovery 
after a median follow up duration on ART of 4.4 years. These findings underscore 
the urgent need to maintain a strict hepatitis screening policy among HIV-infected 
patients undergoing ART, as well as inclusion of ART regimens with potent anti-HBV 
activities in HBV-endemic regions of the world. Longitudinal studies in African 
patients to ascertain super-infection of HIV by hepatitis, assessments of impact of 
HBV-suppressive versus HBV non-suppressive ART regimens and predictive value 
of hepatitis on the mortality of the present cohort will form a significant contribution to 





6. IMPACT OF CHRONIC HEPATITIS B INFECTION ON SURVIVAL OF HIV-
INFECTED PATIENTS  
6.0 ABSTRACT 
Background: Hepatitis B has been reported to be high in HIV-infected African 
populations. However, the impact of HBV infection on the survival of HIV-infected 
Africans on long-term highly active antiretroviral therapy (HAART) remains poorly 
characterised. I investigated the impact of HBV/HIV co-infection on survival of HIV 
infected patients undergoing antiretroviral therapy in a West African population. 
Methods: This was a clinic-based cohort study of HIV-infected adults enrolled in 
Nigeria, West Africa. Study subjects (9,758) were screened for hepatitis B and 
hepatitis C at ART initiation. Kaplan-Meier survival and Cox proportional hazards 
models were used to estimate probability of survival and to identify predictors of 
mortality respectively, based on hepatitis B surface antigen status. All patients had 
signed an informed, written consent before enrolment into the study; and 
additionally, permission for secondary use of data from the Harvard institutional 
review board was obtained. 
Results: Patients were followed up for a median of 41 months (interquartile range: 
30-62 months) during which, 181 (1.9%) patients died. Most of the deaths; 143 
(79.0%) occurred prior to availability of Tenofovir. Among those that were on ART, 
hepatitis B co-infected patients experienced a significantly lower survival than HIV 
mono-infected patients at 74 months of follow up (94% vs. 97%; p=0.0097). 
Generally, hepatitis B co-infection: HBsAg-positive/HIV-positive (Hazards Rate [HR]; 
1.5: 95% CI 1.09-2.11), co-morbid tuberculosis (HR; 2.2: 95% CI 1.57-2.96) and 




Categorising the patients based on use of Tenofovir, HBV infection failed to become 
a predictor of mortality among those on Tenofovir-containing HAART.  
Conclusions: HBsAg-positive status was associated with reduced survival and was 
an independent predictor of mortality in this African HIV cohort on ART. However, 






Viral hepatitis infection is the leading cause of cirrhosis and primary liver cancer in 
Africa (de et al., 2012), where HBsAg prevalence is up to 20% in the general 
population (Ott et al., 2012). Owing to shared routes of transmission, hepatitis 
infection rates among HIV-infected patients are significantly higher than in the 
general population (Forbi et al., 2007;Mayaphi et al., 2012).  
Since the global scale-up of ART, numerous studies have shown that the efficacy of 
ART in suppression of HIV in Africa is comparable to that obtained in resource-rich 
countries (Etard et al., 2006;Lawn et al., 2005;Zachariah et al., 2006), though there 
are conflicting data on whether HBV co-infection affects HIV suppression (Hoffmann 
et al., 2008;Hoffmann et al., 2009a;Matthews et al., 2011). In the developed world 
setting, liver disease has emerged as a leading cause of death in the era of ART 
(Konopnicki et al., 2005;Shafran, 2007;Tuma et al., 2010a) and hepatitis plays an 
important role in the progression to cirrhosis in hepatitis B and hepatitis C patients, 
who are co-infected with HIV (Tuma et al., 2010b). This pattern has continued 
despite increasing availability and administration of HBV-active ART. 
The role of viral hepatitis and consequent chronic liver disease on mortality has not 
been widely studied in HIV-infected African populations (Hoffmann and Thio, 
2007;Rockstroh et al., 2011), but some studies have noted high death rates during 
the initial period of ART (Johannessen et al., 2008;Mzileni et al., 2008). However, 
most of the published studies have been small (Etard et al., 2006;Lawn et al., 
2005;Zachariah et al., 2006). Knowledge of the prognostic effect of liver-related 




would help inform guidelines on screening and treatment with a potential to reduce 
excess mortality in HIV-infected patients.  
The Federal Republic of Nigeria is categorised as a low income country, with a 
population of over 150 million and an estimated HIV prevalence of 4.4% (Agaba et 
al., 2011) and HBsAg prevalence rates of up to 20% (Ladep & Taylor-Robinson, 
2007a).  The aims of the present study were: 
I. to assess the impact of hepatitis B infection on the survival of HIV-infected 
individuals; and  
II. to identify predictors of mortality in a large cohort of HIV patients on ART in 
Nigeria. 
6.2 METHODS 
6.2.1 Study setting and patients 
The study was conducted as part of the “AIDS Prevention Initiative in Nigeria” (APIN) 
programme, affiliated to the Jos University Teaching Hospital (JUTH), Jos, Plateau 
State in the north-central region of Nigeria. Most patients enrolled into the 
JUTH/APIN programme were detected through Voluntary Counselling and Testing 
(VCT) services in adjacent communities. Hospitalised patients were investigated on 
clinical suspicion or referred from nearby health centres. Subjects found to be 
reactive to HIV by ELISA were confirmed by Western blot assay prior to enrolment. 
Serum liver function tests (LFTs), full blood count, HIV RNA and CD4 cell counts 
were measured in all recruited patients at baseline who were also screened for 
tuberculosis (TB), prior to commencement of HAART, following the Nigeria national 
HIV treatment guidelines (www.naca.gov.ng). From June 2004 to December 2010, 




and were being monitored, on ART and/or on anti-tuberculosis drugs. This number 
estimates at least 13% of all HIV-infected patients within the catchment area (Agaba 
et al., 2011). Onsite and offsite training was provided to personnel working at 
JUTH/APIN by HIV specialists from the Harvard School of Public Health (Boston, 
Massachusetts), Northwestern University (Chicago, Illinois) and Johns Hopkins 
University (Baltimore, Maryland), USA.  
All patients were subjected to pre-treatment counselling. A patient tracking team; 
responsible for providing support to all enrolled patients (in terms of adherence 
fostering and to follow-up missing patients) was put in place in 2006. Treatment 
support groups (Hope Support), comprising mostly of HIV-infected patients, were set 
up within the clinic and surrounding communities as well.  
Ethical approval for the present study was obtained from the Ethics Committee of 
JUTH and an additional Institutional Review Board (IRB) of Harvard School of Public 
Health, USA. 
6.2.2 Laboratory Testing 
Before recruitment into the APIN programme, subjects were screened for HIV using 
Rapid HIV test kits and subsequently confirmed by Western Blot assay. HBsAg was 
determined using Enzyme immunoassay (EIA) (Monolisa HBsAg Ultra3; BioRad, 
Hercules, CA, USA). HCV antibody was tested using third generation enzyme 
immunoassay (DIA.PRO Diagnostic, Bioprobes srl, Milan, Italy). HIV RNA levels 
were measured using Roche COBAS Amplicor HIV-1 monitor test version 1.5 
(Roche Diagnostics, GmbH, Mannheim, Germany) with a detection limit of 400 
copies/mL. Flow cytometry was used to determine CD4+ T-cell count (Partec, GmbH, 




6.2.3 Recruitment, treatment, monitoring and endpoints 
Initial first-line antiretrovirals (ARV) in 2004 included Stavudine/Zidovudine, 
Lamivudine and Efavirenz/Nevirapine. Abacavir and Truvada® (Tenofovir plus 
Emtricitabine) have been administered since 2007 at APIN. Additionally, second-line 
treatment with protease inhibitors, in cases of treatment failure also became 
available since early 2007. However, during 2004 to 2006, Tenofovir and second-line 
agents were not available and HAART was not individualised. During 2007-2010, 
those patients commencing HAART that were co-infected with HBV, as well as those 
requiring second line agents, for virological failure were given ARVs containing 
Tenofovir.  
Patients with CD4 cell counts below 200 cells/mm3 were prescribed co-trimoxazole 
960mg once a day, as prophylaxis for Pneumocystis jiroveci pneumonia (PCP). After 
an initial 4 weeks of fortnightly dispensing, ARVs were provided on a monthly basis 
to those patients on ART. Paper-based format of data entry was ensured by nurses, 
physicians and trained clinical officers and same-day computerised data entry was 
carried out by Data Officers who were supervised by a Data Manager. Personal 
information, medical history, physical examination, laboratory investigation and chest 
X ray reports comprised the initial records. Follow-up blood tests performed every 3 
months, including LFTs, FBC, HIVRNA and CD4 cell count. Drug-related 
hepatotoxicity was defined as alanine aminotransferase (ALT) values ≥5 fold over 
the upper limit of the normal range (ULN) (41iu/mL for JUTH), or if ≥3.5 fold over 
ULN, if the baseline ALT was above ULN. 
 
As HBV DNA and HCV RNA assays were not available routinely for this cohort, 




hepatitis B surface antigen (HBsAg) and hepatitis C antibody (HCV antibody), 
respectively, on baseline blood samples. 
The main end-point of my study was all-cause mortality. Most deaths were reported 
through the activities of the Tracking team and Hope Support groups. Other 
outcomes that were censored included those that stopped treatment (detected by 
pharmacy records), transfer to another health centre or lost to follow-up. 
6.2.4 Statistical analyses 
The profile of how the patients were selected for analyses is presented in Figure 24. 
Patients were included only if they had hepatitis B and hepatitis C screening 
performed on their sera at baseline. Apart from over 7000 patients who did not have 
one or both HBV and HCV screening, we additionally excluded those that were 
recruited after December 2010, and those with incomplete information (gender, age 





Figure 24. Profile of study cohort, AIDS Prevention Initiative in Nigeria, Jos 
University Teaching Hospital, in the Federal Republic of Nigeria, 2004-2010 
 
 
Kaplan-Meier models were used to estimate survival of the patient groups, while a 
Cox proportional hazard modeling was applied to identify independent predictors of 




significant association was detected, the variable was fitted into the multivariate 
model and hazard ratios calculated. Subsequently, we analysed the hazards of 
death for those patients on TDF-containing HAART, as well as for those not on TDF-
containing HAART. Analyses were accomplished using MedCalc Statistical Software 
version 12.7.7 (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 
2013). P values less than 0.05 were considered statistically significant.  
 
6.3 RESULTS  
6.3.1 Baseline characteristics 
Of the 9,748 adults that were commenced on HAART, 6,523 (66.9%) were women. 
The median age of the study population was 33 years (range 15-80 yrs.) and 5,915 
(60.7%) of the patients had commenced HAART during the initial period, 2004-2006. 
The median follow-up duration was 41 months (Interquartile range 30-62 months). 
Summary of the baseline characteristics of patients recruited in the study is 
presented in Table 9. TB treatment was administered to 1,641 (16.8%) patients. For 
those that had CD4 results at baseline, there was a significantly higher median CD4 
cell count in women than in men (M: 146 (95% CI=136-156) cells/mm3; F: 188 
(95%CI=179-195) cells/mm3; p<0.0001). The median baseline HIV RNA load was 
log10 4.52 (95% CI=4.50-4.55)(M:4.6(95%CI=4.6-4.7) copies/mL; F:4.5(95%CI=4.4-
4.5) copies/mL; p<0.0001). HBsAg-positive rate was common in this study cohort; 






Table 9. Baseline characteristics and associated deaths among HIV-infected patients 














Age-group (years)  0.008*     
15-29 3,147 45(1.4)  393 4(4.0) 2,754 41(1.5) 
30-39 3,967 73(1.8)  1,378 31(2.2) 2,589 42(1.6) 
40-49 2,001 47(2.3)  1,069 35(3.3) 932 12(1.3) 
50+ 644 16(2.5)  389 9(2.3) 255 7(2.7) 
HBsAg status  0.034     
HBsAg +ve 1,950 48(2.5)  721 25(3.5) 1,230 23(1.9) 
HBsAg –ve 7,808 133(1.7)  2,508 54(2.2) 5,300 79(1.5) 
Liver disease   0.9     
Present 23 0(0.0)  5 0(0.0) 18 0(0.0) 
Absent 9,728 181(1.9)  3,220 79(2.5) 6,508 102(1.9) 
TB diagnosis  <0.0001     
Present 1,640 55(3.4)  743 30(4.0) 898 25(2.8) 
Absent 8,118 126(1.6)  2,486 49(2.0) 5,632 77(1.4) 
HIV RNA at baseline (viral 
copies/mL) 0.06*     
<400 1,267 25(2.0)  408 11(2.7) 859 14(1.6) 
400-9,999 1,950 23(1.2)  565 9(1.6) 1,385 14(1.0) 
10,000-29,999 1,523 22(1.4)  427 10(2.3) 1,096 12(1.1) 
≥30,000 5,019 111(2.2)  1,829 49(2.7) 3,190 62(1.9) 
CD4 cell count at baseline 
(cells/mL) 0.003*     
<200 1,599 24(1.5)  605 7(1.2) 994 17(1.7) 
200-499 1,050 4(0.4)  295 1(0.3) 755 3(0.4) 




Period of enrolment <0.0001     
2004-2006 5,920 143(2.4)  1,963 67(3.4) 3,958 76(1.9) 
2007-2010 3,838 38(1.0)  1,266 12(0.9) 2,572 26(1.0) 
*p values indicate comparison for trend 
 
6.3.2 Survival analyses 
Of those patients that were on HAART, 181 patients (1.9%) died during the follow-up 
period. One hundred and forty-three (79.0%) of those that died, started ART during 
the initial period (2004-2006). Patients who were co-infected with HBV had a lower 
survival rate, compared to patients negative for HBsAg (Figure 25). The survival 
probability of HBsAg-positive versus HBsAg-negative patients at 78 months of 
follow-up was 94% and 97%, respectively (p=0.009). This was the case particularly 
for men; as HBV infection did not result in survival differences in women. HBsAg-
positive men had lower survival, compared to HIV mono-infected men (HIV-
positive/HBsAg-positive: 88.5%; HIV-positive/HBsAg-negative: 96.5%; p=0.04).  
Fitting the non AIDS-related factors into the Cox regression multivariate model, 
independent predictors of death for duration of follow up were found to be male sex, 
co-morbid tuberculosis and HBV infection. Male gender, age ≥40 years at 
recruitment, co-morbid tuberculosis, HBsAg positivity, and recruitment during the 
initial phase of the study were all significantly associated with death (Table 10). The 
hazard of mortality was significantly reduced in patients who started ART during 
2007-2010 (HR: 0.64 [95% CI: 0.42-0.88]), compared to those enrolled during the 
earlier phase of the programme (p=0.0081). Of note, HBsAg-positivity, male gender 





As the majority of the deaths occurred during the initial follow-up period, I performed 
an additional Cox proportional hazard analysis of death during 12 months from 
recruitment into the study. Age ≥ 40 yrs at recruitment, HBV infection (HBsAg-
positive) and enrolment during 2004-2006 were significant predictors of mortality 




Figure 25 Kaplan-Meier survival curves according to hepatitis co-infection status for: 







Table 10. Multivariate analyses of predictors of mortality in HIV-infected individuals, 
AIDS Prevention Initiative in Nigeria JUTH, 2004-2010 
 HAART Covariate HR (95% CI) SE Coefficient p value 
All time Male 1.5(1.08-2.00) 0.15 0.4 0.0134 
 HBsAg +ve 1.5(1.09-2.11) 0.17 0.4 0.0129 
 
Latter recruitment 
(2007-2010) 0.6(0.42-0.88) 0.19 -0.5 0.0081 
 TB diagnosis 2.2(1.57-2.96) 0.16 0.8 <0.0001 
Initial 12 months     
 HBsAg +ve 2.1(1.32-3.21) 0.23 0.7 0.0015 
 40-49 years 1.9(1.16-3.07) 0.25 0.6 0.011 
 ≥50 years 2.5(1.31-4.80) 0.33 0.9 0.0057 
 
Earlier recruitment 
(2004-2006) 6.3(3.86-10.31) 0.25 1.8 <0.0001 
None-TDF-
based HAART Male 1.8(1.16-2.68) 0.21 0.6 0.0084 
 HBsAg +ve 4.3(2.60-6.95) 0.25 1.4 <0.0001 
 
Latter recruitment 
(2007-2010) 0.3(0.14-0.57) 0.36 -1.2 0.0004 
TDF-based 




6.3.3 Virological suppression 
Owing to lower survival associated with HBV infection, the impact of HBsAg-positive 
status on HIV RNA suppression, following long-term HAART was explored. Thus, I 
analysed HIV viral load on 8,515 patients, of which 1,643 were HBsAg-positive and 
6,872 were HBsAg-negative. HBV co-infection was associated with higher HIV RNA 
log10 copies (HBsAg-positive: 4.59(95%CI=4.53-4.65) vs HBsAg-negative: 
4.49(95%CI=4.47-4.52); p<0.0001) at baseline. However, the median HIV RNA load 
at ≥12 months on HAART was not different between the study groups (HBsAg-
positive: 2.3(95%CI=2.3-2.3) vs HBsAg-negative: 2.3(95%CI=2.3-2.3) (Figure 26). 
 
 
Figure 26 Median HIV RNA load at baseline and at ≥12 months on HAART of HBV 
and HIV mono-infected groups; JUTH/APIN 2004-2010; HBV: hepatitis B co-






































In this African HIV-infected cohort of 9,758 patients on HAART, followed up for a 
median period of 41 months, the impact of HBV infection on survival and 
independent predictors of mortality of HIV-infected patients undergoing antiretroviral 
therapy were determined. HIV/HBV co-infection was found to be significantly 
associated with a lower probability of survival, compared to HIV mono-infection. On 
the other hand, relatively recent recruitment into the APIN programme was 
significantly associated with reduced rate of death in both groups. Apart from HBV 
co-infection, tuberculosis and male sex were also significantly associated with 
mortality.  
Two studies from South Africa found conflicting outcomes regarding the impact of 
HBV co-infection on HIV mortality. Hoffman and colleagues in 2008 reported similar 
probability of deaths in HBV/HIV and HIV mono-infected patients over a 72-week 
period. In contrast, Matthews and colleagues (2011) observed a significantly higher 
mortality in HBV co-infected patients, compared to HIV mono-infected 1,771 patients 
in South Africa over 48 weeks follow-up duration (Matthews et al., 2011). 
The findings in the present study corroborated those of a large study of HIV-infected 
men in the US in which non AIDS-related mortality was highest among HIV/HBV-
infected patients, despite being on HBV-active HAART (Hoffmann et al., 2009b) and 
in which no association between HBV infection and higher rates of HIV virologic 
failure was found. Similarly, in South African patients, HIV/HBV co-infection was not 
associated with lower HIV RNA suppression during ART (Hoffmann et al., 




The reasons for the negative impact of HBV infection on mortality are not fully 
understood, but it is unlikely to be related to accentuation of HIV replication, as 
similar found similar levels of virologic suppression in co-infected versus HIV mono-
infected patients was observed. HBV infection in this population frequently occurs 
early in life and is postulated to precede HIV infection (Lesi, Kehinde, Oguh, & 
Amira, 2007) by which time liver damage may be irreversible and non-responsive to 
ART. Inflammatory response commonly occurs during the early phase of ART(Hirsch 
et al., 2004) and could be contributing to the flaring of HBV infection(Crane et al., 
2009).  
 I noted higher mortality during the early phase of ART in this study population. It is 
possible that this effect is a result of patients with more advanced disease entering 
the programme and this is supported by the change in overall mortality over time. 
However, analysis restricted to only those who are taking Tenofovir suggests a 
beneficial impact in those with HBV.  
Tuberculosis is a common co-morbidity of HIV-infected patients and was an 
independent predictor of mortality in the present study, in agreement with the results 
of other studies across Africa (Lawn et al., 2008;Lim et al., 2012;Richter et al., 1995). 
It is known that the relative risk of anti-tuberculous therapy-induced hepatotoxicity is 
higher in HBV/HIV co-infected patients than in HIV mono-infected individuals (de et 
al., 2010). However, I did not identify any significant association between death and 
decompensated liver disease. Notably, none of the patients who had hepatotoxicity 
from ARVs died in this study. Nevertheless, symptomatic hepatotoxicity (particularly, 
jaundice) frequently prompts patients to seek alternative drugs, a common feature in 
African HIV populations (Chitturi and Farrell, 2000;Mudzviti et al., 2012), and/or 




patients might have died at home or away from JUTH and therefore these data 
would not have been captured in this data set. 
Male gender was a significant predictor of mortality in the study cohort. Men had 
lower CD4 cell count at HAART commencement than women. Indeed, the CD4 cell 
count at commencement of HAART has been found to correlate with response and 
ultimately, survival (Biadgilign et al., 2012). These data confirm this, as a significant 
trend of decreased death rate with increasing CD4 cell count prior to commencing 
ART was found. It is not clear the reason why men had higher HIV RNA load and 
lower CD4 cell count at baseline, but it is possible that antenatal HIV screening 
services as part of mother to child transmission of HIV (PMTCT) services might have 
enabled more women to be diagnosed at stages earlier than men.  
Limitations encountered in the present study include the following: First, the causes 
of death were not well ascertained and autopsy rates in this population are low. 
Precise dates of death of several patients were not recorded and I depended on 
information from carers, Hope Support and Tracking teams. I was thus limited in 
describing disease-specific deaths. Whenever any of the patients had any serious 
illness, such as liver disease, they were referred to specialist consultation in the 
affiliated hospital (JUTH). As no linkage of records, exists currently between JUTH 
and APIN, considerable amounts of information that would have been relevant to our 
analyses may have been missed. It would have been quite informative to determine 
the contribution of factors associated with mortality in those who were yet to be on 
treatment for their HIV infection. This factor could not be examined as follow up 
documentation of deaths and routine investigations were undertaken only in those 




Second, the diagnosis of chronic HBV infection based on a single test for the 
detection of HBsAg could be misleading as the standard definition of chronic 
hepatitis B is based on two tests performed at least 6 months apart. A small chance 
of misclassification may have occurred due to this; however, because HBV 
transmission commonly occurs in childhood in Nigeria, it is unlikely that the cases 
identified as HBsAg positive had acute HBV. Unpublished confirmation of HCV and 
HBV viraemic status by molecular methods revealed that HCV viraemia in 314 anti-
HCV positive patients was 31.2% while of 264 HBsAg positive individuals, HBV 
viraemia was documented in 86%. Characterising the patient groups by their 
viraemic status would have enhanced the power of this study.  
In conclusion, HBV infection, tuberculosis and male gender were significantly 
associated with mortality during a 41-month median period, following 
commencement of ART therapy. Patients recruited during the latter period of 
enrolment, coinciding with increased access to Tenofovir-based treatment 
experienced less deaths. Indeed, HBV was not a significant predictor of mortality in 
those patients that were being administered Tenofovir-containing HAART. HBsAg-
positive status was not associated with reduced HIV viral load suppression following 
HAART. Long-term follow-up and enhanced monitoring are needed to assess 
incidence of end-stage liver disease, hepatocellular carcinoma and disease-specific 
deaths in this cohort. These data support an active approach to identifying all 
HIV/HBV co-infected individuals in resource poor settings, if Tenofovir is not routinely 





7. METABOLIC PROFILING OF HEPATOCELLULAR CARCINOMA 
7.0 Definitions 
Metabonomics is a study of the overall metabolic response to functional, drug and 
disease stimuli, while metabolomics is the analytical description of complex 
biological samples (Fiehn, 2001;Nicholson and Lindon, 2008). The former seeks to 
characterize and quantify all such small molecules in the sample. Metabonomics is 
able to provide robust information on cellular and organ function, complementing 
genetic, epigenetic and proteomic knowledge. Magnetic resonance spectroscopy 
(MRS) and mass spectrometry (MS) are the most commonly used methods for 
metabolite characterisation.  
7.1 Tumour metabolism 
Generally, tumour cells require increased amounts of energy (ATP) and substrates 
for synthesis of nucleotides, lipids and proteins for rapid proliferation. There is 
increasing evidence that this altered metabolism in tumour cells is both a cause and 
effect of carcinogenesis (Ward and Thompson, 2012). Cancer is thus visualised as a 
metabolic disease and the solution of two metabolic equations: first and foremost, to 
produce enough energy to survive when supplies and waste disposal are limited and 
second, to divert enough metabolic intermediate from energy products to 
biosynthetic pathways that provide the critical biomass needful to support cell 
proliferation. 
7.1.1 Glycolysis in the tumour cell 
To simulate an anaerobic condition, Warburg in 1924 placed a section of rat cancer 
tissue in Ringer’s lactate that was saturated with nitrogen and observed that the 




not if it was left plain (Warburg, 1958). Warburg later on discovered that even in the 
presence of suficient oxygen, cancer cels preferentialy metabolise glucose by 
glycolysis rather than oxidative phosphorylation, a more eficient pathway for energy 
production. He hypothesized that this increase in glycolysis in the presence of 
oxygen by cancer cels is a reflection of defective mitochondrial oxidative 
phosphorylation (Warburg, 1958). Indeed tumour cels take up high amount of 
glucose to fuel heightened glycolysis, the basis for which glucose-labeled positron 
emission tomography (PET) is used for tumour identification (Arif et al., 2009). Apart 
from a faster rate of production of ATP, glycolysis also provides intermediates for the 
pentose phosphate pathway and subsequent biosynthesis of nucleic acids, both of 
which are of benefit to rapidly dividing tumour cels (Figure 27). 
 
 
Figure 27. Altered glycolytic and mitochondrial metabolism in tumour cels 
Key: G6P, glucose-6-phosphate; TCA, tricarboxylic acid cylcle; ATP, adenosine-tri-




7.1.2 Mitochondrial metabolism and cancer 
It is yet to be clearly defined the role that mitochondria play in tumour cell function. 
Primary defects in the mitochondrial membrane (small and absent cristae, as well as 
deficiency of β-F1 subunit of ATPase); the site of oxidative phosphorylation has been 
suggested by some researchers (Kroemer and Pouyssegur, 2008;Lopez-Rios et al., 
2007). However, some groups have shown that despite a high glycolysis rate, 
oxygen consumption by cancer cells is not reduced (Weinberg and Chandel, 2009). 
Undoubtedly, HCC is a highly vascular tumour in the early stages and is certainly 
likely to be adequately supplied with oxygenated blood. 
7.1.3 Molecular effectors of tumour metabolism 
Hypoxia-inducible factor 1(HIF 1) and p53 are the commonest effectors that undergo 
mutations in HCC and may be responsible for some of the metabolic changes in 
HCC. A short introduction of these effectors follows. 
7.1.3.1 HIF1 
HIF1, a transcription factor which stimulates glycolysis in tumour cells is activated by 
diverse stress situations, including hypoxia, inflammation, metabolic and oxidative 
stressors (Harris, 2002;Kroemer & Pouyssegur, 2008;Weinberg & Chandel, 2009). 
This heterodimeric complex (consisting HIF 1α and HIF 1β) is stabilised at low 
oxygen levels, but is degraded by the proteosome in normoxic conditions. HIF1 
stimulates glycolysis by increasing the expression of the rate limiting pro-glycolytic 
enzyme, hexokinase; as well as the expression of glucose transporter isoform 1 
(GLUT 1) (Weinberg & Chandel, 2009). By inhibiting pyruvate dehydrogenase 
(PDH), HIF1 decreases the conversion of pyruvate to acetyl-coA (often required for 
production of electron donors, NADH and FADH2; both cofactors in oxidative 




overemphasised as HIF1β deficient hepatoma cells in mice were found to have 
reduced growth rates and glycolytic intermediates compared to wild-type hepatoma 
cells (Griffiths et al., 2002). 
The role of HIF1 in HCC is being further investigated and recent data involving 
animal models have demonstrated high HIF1 activity and GLUT1 (downstream 
counterpart) in liver cancer cells (Amann et al., 2009;Wang et al., 2009b;Yao et al., 
2009). Vascular endothelial growth factor (VEGF) plays a vital role in the 
development of HCC (Armengol et al., 2004). HIF1 induces the expression of VEGF 
in hypoxic conditions thereby enhancing neovascularisation. This pro-angiogenic 
property leads to increased tumour growth but persistent central tumour hypoxia, 
thus allowing HIF 1 to remain active. 
7.1.3.2 p53 
The p53 gene is essential for a high quality of life and fidelity of replication of the 
organism. This tumour suppressor gene has been implicated in alterations in 
metabolism. p53 enhances the expression of cytochrome c oxidase 2 (SCO2), 
required for the assembly  of the oxidative phosphorylation enzyme, cytochrome c 
oxidase (COX) (Matoba et al., 2006) but negatively regulates phosphoglycerate 
mutase (PGM) (Kondoh et al., 2005). Additionally, p53 transcriptionally activates the 
TP53-induced glycolysis and apoptosis regulator (TIGAR), which is also an inhibitor 
of phosphofructokinase activity. This inhibition of phosphofructokinase in turn lowers 
the level of the allosteric activitor of glycolysis, fructose 1,6-biphosphate (FBP) 
(Bensaad et al., 2006). Since wild-type p53 downregulates PGM, mutation of p53 




7.1.4 Metabolite effects on carcinogenesis 
Lactate, thought to be a “waste” product of glycolysis, can stimulate HIF1 
independently of hypoxia, thereby conditioning the tumour environment (Hsu and 
Sabatini 2008). Also, lactate has been suggested to suppress anticancer immune 
effectors (Koukourakis et al., 2006;Kroemer & Pouyssegur, 2008;Swietach et al., 
2007). 
TCA cycle intermediates; including fumarate and succinate can stimulate HIF1 
production. Germ line mutations of TCA cycle genes lead to defective enzymes 
(fumarate hydratase and succinate dehydrogenase) (Gottlieb and Tomlinson, 2005) 
which result in the inability to metabolise their substrates. The sum effect of these 
changes is the accumulation of HIF1 as fumarate and succinate competitively inhibit 
α-ketoglutarate-dependent HIF-1 α-prolyl hydrolase, the enzyme that destroys HIF1. 
7.2 Magnetic resonance spectroscopy and metabolic profiling of HCC 
The behaviour of atoms when subjected to a magnetic field is referred to as nuclear 
magnetic resonance (NMR). Atoms with odd mass numbers such as hydrogen (1H), 
phosphorus (31P) and carbon (13C) possess this property, often described as “spin” 
and behave as dipoles aligning along the axis of an applied magnetic field (Figure 
28). As protons relax following excitation, they generate radiofrequency signals 
which are detectable by receiver coils as “free induction decay”. The frequency 
spectrum is expressed by the mathematical process of Fourier transformation.  
Being the most abundant atom in living organisms, studies of 1H NMR spectra are 
mostly carried out and it not only provides information on metabolic differences 







Figure 28. Spin atributes of protons 
Protons possess “spin” and align along an applied magnetic field (BO) 
 
Metabolic profiles have been generated from biological substances including: intact 
tissue, bile (Khan et al., 2005a), serum (Wiliams et al., 2009) and urine (Sharif et 
al., 2010;Sharif et al., 2011). Yang and coleagues used in vitro magic angle 
spinning NMR and found that HCC tissues had high levels of lactate, glutamate, 
glycine, leucine, alanine, choline metabolites and reduced levels of triglycerides, 
glucose and glycogen compared to normal adjacent liver tissue (Yang et al. 2007). 
7.3  Mass spectrometry and metabolic profiling of HCC 
Mass spectrometry started to be used for metabolic profiling about 40 years ago 




and complements the latter technique. Constituent fragments of, or primary 
metabolites are detected and distinguished by their molecular weights and ionic 
charges. Prior to analyses, biological fluids require separation using certain methods, 
among which are gas chromatography (GC) or liquid chromatography (LC). LC 
requires less extensive pre-treatment and derivation steps than GC and thus 
amenable to biofluid analyses. The samples are ionized after separation using 
electrospray ionization (ESI); often combined with LC-MS. ESI is highly sensitive and 
offers a soft ionization as well as an excellent quantitative analysis (Want et al., 
2007). The particles are then detected by a time-of-flight (TOF) analyser, which 
allows the detection of analytes in the m/z 50-1000 range (Figure 29). LC-MS has 
been used for metabolic profiling of HCC. Yin and colleagues identified 
dihydrosphingosine and phytosphingosine in serum of patients with HCC using 
reversed phase (RP) LC and hydrophilic interaction chromatography (HILIC) MS (Yin 






Figure 29. Principles of liquid chromatography mass spectrometry 
 
Hypothesis 
 HCC cels secrete metabolites into the systemic circulation that are detectable 
in urine. 
Aims 
 To determine urinary biomarkers of HCC; 
 To compare the relative concentration of identified biomarkers with those of 
controls (cirhosis, non-cirhotic liver disease and healthy subjects); and 






8. BIOMARKER DISCOVERY OF HCC IN WEST AFRICAN PATIENTS USING 
PROTON NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY   
8.0 ABSTRACT 
Background: The main clinically-used biomarker of hepatocellular carcinoma (HCC) 
in routine screening, surveillance and diagnosis, serum alpha fetoprotein (AFP), has 
a low sensitivity. Ultrasound imaging is impractical in severely resource-deprived 
communities. This study aimed to determine the diagnostic performance of urinary 
metabolites using proton NMR spectroscopy of patients from West Africa and to 
explore the correlation of identified metabolites with clinical stage of HCC. 
Methods: Urine samples were collected at two sites in West Africa on the case-
control platform of the "Prevention of Liver Fibrosis and Carcinoma in Africa" 
(PROLIFICA) study. 600MHz NMR was used to acquire one-dimensional spectral 
data from the urine samples, using a standard 1D NMR pulse sequence with 
presaturation of the water peak. Areas under the operating characteristic curves 
(AUC) of the relative concentration of metabolites identified, measured in 290 
patients: 63 with HCC, 32 with cirrhosis (Cir), 107 with non-cirrhotic liver disease 
(DC) and 88 healthy volunteers (NC), were compared to serum AFP. Correlation of 
identified metabolites with Barcelona Clinic Liver Cancer (BCLC) stage of HCC was 
made. 
Results: Multivariate modelling of the spectral data showed distinct urinary 
metabolic profiles of patients with HCC, compared to Cir, DC and NC with sensitivity 
(95%CI)/ specificity (95%CI) of 81%(77-95)/84%(64-96), 85%(73-94)/93%(86-97) 
and 97%(89-100)/99%(94-100), respectively. The metabolites that were significantly 




controls (DC and Cir), were N-acetylglutamate, dimethylglycine, 1-
methylnicotinamide, aspartate, methionine, acetylcarnitine, carnitine, 2-oxoglutarate, 
indole-3-acetate, and creatine. Urinary metabolite profiles performed better than AFP 
in discriminating HCC from other non-malignant liver conditions (AUC: HCC vs. DC; 
metabolite profile [0.9] vs. AFP [0.8], p=0.0001; HCC vs. Cir; metabolites [0.9] vs. 
AFP [0.7], p=0.0068). There was a significant positive correlation of N-
acetylglutamate, acetylcarnitine, methionine, aspartate, dimethylglycine and creatine 
with BCLC stage of HCC. 
Conclusions: NMR spectroscopy of urine of this West African population has 
identified metabolites that implicate altered energy-related pathways in the 
pathogenesis and progression of HCC. Additionally, the urinary metabolic profiles 
performed better diagnostically than serum AFP. These findings confirm that a panel 






Hepatocellular carcinoma (HCC), the commonest primary liver cancer, carries a poor 
prognosis being the third most common cause of cancer-related death (Parkin et al., 
2005b;Parkin, 2006). The incidence to mortality ratio of HCC approaches unity in 
most developing countries, owing to very late diagnosis. It is responsible for 
approximately 700,000 deaths per year globally. There is a high incidence of HCC in 
sub-Saharan Africa and a steadily rising incidence in several developed countries 
(El-Serag et al., 2004;El-Serag, 2007;El-Serag & Rudolph, 2007;Khan et al., 2002b). 
Alpha-fetoprotein (AFP), a commonly used serum biomarker for diagnosis of HCC, 
lacks sufficient sensitivity for detection of HCC at stages amenable to curative 
therapies, besides being expensive (Daniele et al., 2004). Biomarkers for early 
detection and which may form targets for therapy of HCC are thus urgently needed.  
Metabolic profiles, often affected by many pathological processes may assist in the 
development of novel diagnostic tests, and/or complement current tools in clinical 
use. Liver tissue (Yang et al., 2007), faecal material (Cao et al., 2011) and serum 
(Chen et al., 2011a;Chen et al., 2011b;Yin et al., 2009;Zhou et al., 2012) have been 
studied for molecular fingerprints of HCC using metabolomics. Most studies using 
urine have been undertaken in Chinese populations (Chen et al., 2011b;Wang et al., 
2013b;Wu et al., 2009;Ye et al., 2012a), comparing HCC versus healthy controls. 
Metabolic biomarkers discriminating HCC from healthy controls are limited as they 
may represent fingerprints of decompensating liver disease (as most HCC occur in 
the background of cirrhosis) rather than those of malignancy, and hence may not be 
useful for screening of HCC in patients with cirrhosis (Bruix & Sherman, 2011). It has 
previously been shown that urinary biomarkers of HCC in a small pilot study of HBV-




patients (Shariff et al., 2010). Shariff and colleagues have also been found similar 
metabolic changes in an HCV-associated HCC cohort from Egypt (Shariff et al., 
2011), suggesting that the metabolic changes are as a result of the process of 
carcinogenesis, rather than aetiopathogenetically specific to HCC. 
In this study, I aimed to determine urinary metabolites of HCC from a West African 
population (Gambia and Nigeria). A comparison of the diagnostic performance of the 
metabolite profiles with AFP was also ensured. Additionally, I examined the 
relationship between the intensities (relative concentrations) of identified metabolites 
with BCLC stage of HCC. 
8.2 METHODS 
8.2.1 Study design/subject selection 
Samples for the present study were from subjects recruited in Nigeria and Gambia, 
who are formally consented to participate in the Prevention of Liver Fibrosis and 
Carcinoma in Africa (PROLIFICA) project. PROLIFICA is a European Union 
Framework 7-funded project (PROLIFICA: www.prolifica.eu). The case-control 
platform involved identifying cases (HCC, chiefly arising on the background of 
chronic hepatitis B viral infection) and three classes of control, namely: 
i. mainly hepatitis B-related cirrhosis,  
ii. mainly non-cirrhotic chronic hepatitis B-related liver disease, and  
iii. healthy volunteers from the same African populations. 
Urine samples were collected for metabonomic studies using urinary proton (1H) 
nuclear magnetic resonance spectroscopy (NMR) at Imperial College London. 




Association for the Study of the Liver (EASL) guidelines were stored at -80oC until 
air-transported on dry ice to Imperial College London. Ethics committees of JUTH, 
Nigeria and MRC, Gambia; as well as Imperial College London granted approval for 
the study. 
In particular, the EASL guidelines utilised in the recruitment of HCC cases (n=63) 
was based on two imaging techniques showing early arterial enhancement and rapid 
venous washout; or one characteristic imaging with serum AFP >400 ng/mL (Anon 
2012). Two groups of disease control (cirrhosis; n=32 and non-cirrhotic liver disease; 
n=107) and a group of healthy subjects (n=88) provided urine samples for 
comparisons. All controls were subjected to liver ultrasound scan and underwent 
serological testing for HBsAg, anti-HCV and HIV screening. Staging of HCC was 
performed according to the Barcelona Clinic Liver Cancer (BCLC) criteria (Llovet et 
al. 1999). 
8.2.2 Urine collection methodology and handling  
Approximately 5mL of non-fasted urine samples were collected into universal 
containers after obtaining informed written consent and administration of dietary 
questionnaires. The questionnaires captured information on the 72-hour as well as 
24-hour dietary recall as well as drugs the subjects would have taken. The collected 
samples were immediately placed in cold-boxes prior to transportation to storage 
facilities. It was ensured all urine samples were aliquoted into storage (-80 degrees 
freezer) eppendorfs within one hour of collection. In situation where this was not 
immediately achievable, the samples were stored in -20 degrees freezers before 
transportation to the laboratory. These were transported, accompanied by laboratory 




Shipments of samples from the participating sites to Imperial College London were 
on dry ice. However, after one failed shipment from Nigeria, I developed a visual 
protocol (see Appendix F) for sample handling and transportation that has ensured 
successful shipment of studied samples. The urine samples had to be accompanied 
in order to ensure smooth transition through customs and immigration checkpoints. 
8.2.3 Sample preparation  
Prior to spectral acquisition, samples were thawed at room temperature. Sample 
preparation and acquisition methods were performed according to previously 
published methods (Beckonert et al., 2007). 400 µL urine sample was mixed with 
200 µL of phosphate buffer solution (0.2 M Na2HPO4/0.04 M NaH2PO4, pH = 7.4 plus 
0.1% sodium azide, 1 mM 3-trimethylsilyl-1-[2,2,3,3,-2H4] propionate (TSP)) to 
stabilize the urinary pH. The samples were allowed to stand for 10 min prior to 
centrifugation at 13000 rpm for 10 min in order to remove insoluble material. 400 µL 
of the supernatants from each urine sample was aliquoted into 5 mm NMR tubes 
(Wilmad LabGlassTM, New Jersey, USA) for proton nuclear magnetic resonance (1H 
NMR) studies. 
8.2.4 1H NMR spectral acquisition and processing 
1H NMR spectra were acquired with a 600 MHz spectrometer (Bruker Avance) 
operating at 600.13 MHz for 1H at 300 K. It was equipped with a 5 mm broad-band 
inverse configuration probe. Samples were randomly analysed in automation with a 
B-ACS 60 sample changer system. Urine samples were analysed using water 
suppressed 1D NMR spectrum using the NOESYPRESAT pulse sequence (256 
transients). Irradiation of the solvent (water) resonance was applied during 
presaturation delay (2.0 s) for all spectra and for the water suppressed 1D NMR 




including the 90° pulse (~ 10 µs), pulse frequency (~ 4.8 ppm), receiver gain (~ 200), 
and pulse powers were optimised for each sample set run.  The spectral width was 
20 ppm for all spectra. The NMR data were processed with an exponential line 
broadening of 1.0 Hz prior to Fourier transformation, which were collected with 
approximately 32 k real data points. Data [-1.0 to 10.0 ppm] were imported into 
MATLAB 7.0 software (MathWorks, Natick, MA), where they were automatically 
phased, baseline corrected and referenced to the TSP peak (0.00 ppm), using 
scripts written in-house. To reduce analytical variation between samples the residual 
water signal (4.70 – 5.00 ppm) was truncated from the data set.   Normalisation to 
total area was performed by calculating, for each spectrum individually, the ratio 
between each variable and the sum of each spectrum after removal of regions 
specified above. Assignment of endogenous urinary metabolites was made by 
reference to published literature data (Bollard et al., 2005;Nicholson et al., 1995). 
8.2.5 Multivariate statistical analyses 
The acquired spectra were divided into small regions of 0.02±0.01ppm, representing 
specific metabolites. These regions were aligned (controls mild shifts in the spectra) 
and normalised (controls differential dilution of samples). A matrix of samples against 
variables (ppm bins) was thus generated and transferred to SIMCA 13.0 (statistical 
software) for unsupervised principal components analysis (PCA) and supervised 
partial least squares discriminant analysis (PLS-DA). Using these techniques, 
outliers were identified; with some being removed from the model (especially those 
due to experimental artefacts). The models were subjected to “leave-one-out” 
validation, a technique in which each sample in turn was automatically excluded from 




membership of the excluded sample predicted. This technique was applied to every 
7th sample until each sample was excluded once.  
8.2.6 Univariate statistical analysis 
The metabolites that contributed most to the OPLS-DA separation were identified 
through analysis of the loading and S-line plots using MATLAB 7.0 and SIMCA 13.0, 
respectively. Identified metabolites were confirmed using an in-house statistical total 
correlation spectroscopy (STOCSY) tool. Intensities of the metabolites were 
expressed as concentration relative to creatinine (controls for differential kidney 
function of the subjects). Using MedCalc Statistical Software version 12.7.7 
(MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2013), Mann-
Whitney U test of significance was applied to study the differences in the median 
values of identified metabolites between HCC (cases) and the three classes of 
controls. 
The ability of single metabolites and each model to discriminate HCC from cirrhosis, 
non-cirrhotic liver disease and healthy control subjects were examined for sensitivity 
and specificity based on measurement of Area under the Receiver Operating 
Characteristic (AUROC) curves. The AUROC curves were modelled to compare the 
diagnostic performance of these metabolite panels with serum alpha fetoprotein; 
each for HCC versus cirrhosis, HCC versus non-cirrhotic liver disease and HCC 
versus healthy. 
Finally, the regression coefficients of each of the significant metabolites were 





8.3.1 Study population 
290 West African subjects were recruited at study sites in Nigeria (Jos University 
Teaching Hospital) and Gambia (Medical Research Council, Fajara, Gambia). These 
consisted of 63 patients with HCC; 32 with cirrhosis (Cir); 107 non-cirrhotic liver 
disease (DC) and 88 healthy (NC) subjects (Table 11). Patients with HCC were 
significantly older than the other classes and comprised mostly of males (79%). Most 
of the HCC patients had advance disease at recruitment. HBV constitutes the most 
common aetiological factor for HCC in this study population. 25(39.7%) had HBV, 
12(19%) with HCV, whereas a substantial proportion of HCC subjects [16(25.4%)] 





Table 11. Clinical and baseline laboratory characteristics of patients and control subjects recruited at Jos University Teaching 
Hospital, Nigeria and Medical Research Council, Gambia 
 HCC subjects (n=63) 
Nig(n=63); Gam(n=0) 
Cirrhosis subjects (n=32) 
Nig(n=32); Gam(n=0) 
Non-cirrhotic liver disease 
subjects (n=107) Nig(n=53); 
Gam(n=54) 
Healthy controls (n=88) 
Nig(n=16); Gam(n=72) 
Age ; yrs(Median, range) 46(26-80) 39(21-58) 37(22-82) 41(26-98) 
Male/Female, n (%) 50/13(79.4/20.6) 25/7(78.1/21.9) 58/49(54.2/45.8) 36/52(40.9/59.1) 
BCLC stage†   
Stage A, n (%) 2(4.3) / / / 
Stage B-C, n (%) 26(55.3) / / / 
Stage D, n (%) 19(40.4) / / / 
Body Mass Index; Kg/m2 NA NA 21.5(14.9-34.1) 22.0(16.2-44.9) 
Serum AFP values 
(median, range); ng/mL 
201(0-1,085) 150(0.2-853) 7(0.2-902) 15(1.6-387) 
Serum albumin, g/L 26.0(4.0-49.0) 23.0(10.0-47.0) 41.5(4.4-57.0) 42.0(22.0-51.0) 
Serum ALT, IU/L 72.0(4.0-1,336) 41.0(8.0-122.0) 28.0(2.0-498.0) 28.0(13.0-65.0) 
Serum creatinine, µmol/L  83.5(1.0-273.0) 85.0(5.4-899.0) 79.0(9.2-1000.0) 70.0(46.0-116.0) 
Serum bilirubin, µmol/L 19.2(0.7-241.5) 54.5(2.4-884.3) 11.0(0.6-83.4) 12.0(7.0-28.0) 
Aetiology of liver disease  
HBV, n (%) 25(39.7) 23(71.9) 103(96.3) / 
HCV, n (%) 12(19.0) 2(6.2) 1(0.9) / 
HBV/HCV, n (%) 2(3.2) 1(3.1) 1(0.9) / 
Neg hepatitis, n (%) 16(25.4) 3(9.4) 0(0.0) 88(100) 
Unknown, n (%) 8(12.7) 3(9.4) 2(1.9) / 
† Unable to classify 15subjects owing to insufficient information; Nig: Nigeria; Gam: Gambia
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8.3.2 Multivariate analysis 
Principal components analysis of samples demonstrated class clustering (Figure 30). 
PCA scores plots of patients by country of recruitment failed to demonstrate any 
clustering or significant outliers (Figure 31). OPLS-DA of various class combinations, 
including: HCC vs. Cirrhosis, HCC vs. DC and HCC vs. NC enabled identification of 
discriminatory metabolites of HCC (Figure 32).  
8.2.2.1 Diagnostic performance of models 
The sensitivities (95% CI) of urinary model to discriminate HCC from NC, DC and Cir 
were 95.0% (86.1-99.0), 88.3% (77.4-95.2) and 83.3% (71.5-91.7) respectively, 
whereas that for AFP were 48.3% (35.2-61.6), 50.8% (37.3-63.9) and 49.2% (36.1 -
 62.3) respectively (Table 12). Similarly, the specificities of urinary model were 
92.13% (84.5-96.8), 88.5% (80.7-93.9) and 83.8% (66.3-94.5) for HCC vs. NC, HCC 
vs. DC and HCC vs. Cir respectively. There were comparatively lower specificities of 
AFP to discriminate HCC from these classes [71.4% (41.9-91.6), 86.0% (77.3-92.3) 





Figure 30. Representative spectra (top) and principal components analysis (PCA) 
plot (bottom) coloured by class of subjects (Green: hepatocellular carcinoma; Blue: 






Figure 31. PCA scores plot of subjects by recruitment site; Nigeria (green circles) 








Figure 32. Loadings plot (MATLAB) displaying region of interest which was used to 
identify discriminating metabolites (HCC vs. DC). Peaks above the horizontal line 
indicate metabolites with higher concentration in HCC than DC whereas those below 
the line; higher in DC than HCC.  
 
Table 12. Diagnostic accuracy of urinary model based on NMR spectroscopy versus 
serum AFP for HCC versus controls  
Comparison 
class 
 AUC (95% CI) SE AUC 
difference(95% 
CI) 
SE P value 
HCC vs. NC Model 0.89(0.80-0.98) 0.03 
0.16(0.05-0.32) 0.08 0.034 
AFP 0.73(0.58-0.88) 0.08 
HCC vs. DC Model 0.93(0.89-0.97) 0.02 
0.16(0.08-0.24) 0.04 0.0001 AFP 0.78(0.70-0.85) 0.04 
HCC vs. Cir Model 0.86(0.78-0.94) 0.04 






8.3.3 Metabolite Assignments 
Using statistical total correlation spectroscopy (STOCSY) tool in MATLAB, a 
combination of loadings plot (Figure 32) and VIP plots, as well as online database 
(www.hmdb.ca), it was possible to identify metabolites that were most influential in 
discriminating HCC from controls. Of the resonances identified by a combination of 
S-line and VIP plots, it was not possible to identify 13.3% of these using the online 
databases. 
The intensities (relative concentrations) of several metabolites including: 
acetylcarnitine, dimethylglycine, carnitine, creatine, indole-3-acetate, creatine, 
methionine, N-acetylglutamate and 2-Oxoglutarate were significantly increased in the 




Table 13. Pattern of alterations of urinary metabolites in HCC patients compared to controls 
Metabolite Chemical shift (ppm) 
HCC vs Healthy HCC vs Liver disease HCC vs Cirrhosis 
VIP FC p values VIP FC p values VIP FC p values 
Beta-hydroxybutyrate 1.20    1.02 1.31 0.0002 1.48 1.07 0.14 
Caprate 1.27     1.25 0.0015    
Lactate 1.33     1.63 <0.000001    
Alpha-hydroxyisobutyrate 1.36  -1.05 0.46  1.14 0.002 1.23 1.17 0.56 
Acetate 1.92    1.07 1.40 0.000004 1.00 1.34 0.02 
N-acetylglutamate 2.04 0.69 1.72 <0.000001 0.84 1.79 <0.000001 1.21 1.47 0.0005 
Methionine 2.14    1.66 2.58 <0.000001 1.45 2.38 0.018 
Formiminoglutamate 2.17 1.31 1.25 0.019       
Succinate 2.41       1.00 -1.00 0.94 
9-methyluric acid 3.16    0.34 1.23 0.00005    
Pyruvate 2.35 3.26 -1.66 0.0009 2.84 1.25 0.41 1.00 1.44 0.023 
2-oxoglutarate 2.45 1.81 2.20 <0.000001 1.98 2.08 <0.000001 2.53 1.56 0.009 
Citrate 2.52 2.15 2.50 <0.000001 2.44 1.07 0.12 8.51 1.05 0.67 
Dimethylamine 2.72 1.40 1.29 0.0004 0.98 1.40 0.000001 1.73 1.16 0.17 
Trimethylamine 2.89       1.78 -1.04 0.91 
Creatine 3.04 1.31 1.21 0.00001 2.80 1.17 0.000013 5.40 1.14 0.012 
N,N,N-Trimethyllysine 3.12 1.11 1.66 0.00008 0.89 1.51 0.00004 0.81 1.42 0.05 
Citrulline 3.16       2.11 -1.02 0.25 
Acetylcarnitine 3.19 4.29 3.54 <0.000001 4.90 3.78 <0.000001 1.79 3.00 0.023 
Carnitine 3.23 9.42 5.20 <0.000001 11.80 4.68 <0.000001 8.97 2.95 0.015 
Betaine aldehyde 3.24 
3.27 
3.30 
1.14 2.21 <0.000001 0.90 2.28 <0.000001 1.34 1.76 0.032 
TMAO 32.93 -1.54 0.00002 16.37 -1.10 0.17 7.22 1.31 0.2 
1,3-Dimethylurate    1.45 1.62 0.022    
Methylguanidine 3.36 2.04 2.05 <0.000001 1.05 1.68 <0.000001 2.64 1.01 0.82 
1,3-Dimethylurate 3.43    1.00 1.87 0.000013 2.32 1.92 0.034 




Choline 3.52 1.96 2.67 <0.000001 1.71 2.44 <0.000001 1.59 1.59 0.014 
Phenylacetate 3.55     1.73 <0.000001 1.45 1.26 0.014 
Glycine 3.57 4.82 -1.05 0.55 6.33 1.02 0.89 5.17 -1.08 0.57 
Myoinositol 3.63 0.76 1.55 <0.000001       
Phenylacetylglutamine 3.67       1.87 1.53 0.0035 
3-methylhistidine 3.70       8.45 1.46 0.012 
Delta-hydroxylysine 3.78       1.98 1.47 0.00079 
Guanidinoacetate 3.80       1.40 1.18 0.14 
Indole-3-acetate 3.65 1.58 2.00 <0.000001 1.57 2.00 <0.000001 2.23 1.52 0.001 
Dimethylglycine 3.72 2.95 2.49 <0.000001 2.74 2.28 <0.000001 5.32 1.36 0.009 
trans-aconitate 3.74    1.58 2.29 <0.000001    
N-Phenylacetylglycine 3.75     2.07 <0.000001 2.20 1.46 0.0022 
Aspartate 3.91    1.38 2.40 <0.000001    
Betaine 3.90 1.26 2.28 <0.000001       
Creatine 3.95 5.01 1.84 <0.000001 5.52 1.83 <0.000001 8.59 1.74 0.0042 
Hippurate 3.97 4.45 -1.23 0.07 4.25 -1.14 0.82 25.66 -1.29 0.008 
Creatinine 4.06 15.04 -1.49 <0.000001       
1-methylnicotinamide 4.48 0.82 3.83 <0.000001 0.69 3.24 <0.000001    
NADPH 4.61    0.69 2.53 <0.000001    
Glucose 4.64 1.36 2.66 <0.000001 1.21 2.69 <0.000001 2.34 1.47 0.09 
L-Fucose 5.21        1.43 0.023 
Allantoin 5.40        1.26 0.62 
Ribose 5.24 1.04 2.22 <0.000001 0.96 2.00 <0.000001 2.25 1.44 0.014 
5-Hydroxyindole-3-acetate 7.21 1.26 -1.57 0.0003 1.03 -1.20 0.2    
Phenylacetate 7.29 0.90 -1.63 0.000001 0.60 -1.29 0.015    
Phenylacetylglutamine 7.37 2.79 -1.66 0.0003 1.72 -1.13 0.29    
5-Hydroxytryptamine 7.42 1.27 -1.77 0.001 0.85 -1.22 0.43    
Hippurate 7.55 3.52 -3.18 <0.000001 3.74 -2.44 <0.000001    




Alpha-hydroxyhippurate 7.84 3.36 -3.32 <0.000001 3.16 -2.55 <0.000001    
N-Formyl-L-aspartate 8.07       0.68 1.36 0.44 
Inosine 8.19       0.75 -1.98 0.000041 
Guanosine triphosphate 8.13 0.48 1.82 <0.000001 0.57 1.73 0.000001 0.94 1.61 0.02 
Formate 8.46    0.34 1.32 0.005 0.44 1.19 0.98 
Positive fold change (FC) indicates higher relative concentration in HCC than controls while negative value indicates down-regulation
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8.3.4 Additional statistical analysis 
Metabolites corresponding to the resonances that contributed most strongly in 
discriminating between groups were subjected to further analyses. Particularly, liver 
disease controls were given an ordinal score of one (1), cirrhosis; a score of two (2), 
intermediate HCC (BCLC A-C); three (3) and advanced HCC (BCLC D); four (4).  
 
Figure 33. Trends in metabolite concentrations of some identified metabolites by 
study classes (p<0.000001 in most cases). Holm-Sidak’s comparison tests found 
significant association between categories; 1: non-cirrhotic liver disease; 2: cirrhosis; 




Changes in median concentrations of urinary metabolites among the 4 categorised 
phenotypic states; chronic liver disease control, cirrhosis, BCLC stage A-C, and 
BCLC stage D showed significant positive trends, relative to disease states (Figure 
33). 
 
8.3.4 Correlation of metabolites with stage of HCC 
There was poor correlation with stage of HCC by serum AFP (p=0.7). However, the 
relative concentration of N-acetylglutamate, methionine, acetylcarnitine, indole-3-
acetate, aspartate, dimethylglycine, and creatine were significantly positively 
correlated to category and clinical stage of HCC (Figure 34).  
 
Figure 34. Correlation of relative concentration of metabolites by BCLC stage of 





In this multi-centre cohort, including subjects from two West African countries, it was 
possible to use urinary NMR spectroscopy to distinguish patients with HCC from a) 
healthy volunteers, b) non-cirrhotic (predominantly hepatitis B-related) liver disease, 
and importantly, c) those with cirrhosis. Using pattern recognition, as well as 
complex multivariate and univariate statistics, urinary metabolic profiles performed 
significantly better than serum AFP in discriminating HCC from both the disease and 
healthy control groups. Several metabolites with significant high fold changes were 
identified that discriminated between HCC and controls. Furthermore, the relative 
concentration of creatine, acetylcarnitine, N-acetylglutamate, methionine and 
dimethylglycine significantly correlated with the clinical stage of HCC. 
For all three binary classes examined (HCC vs. NC, HCC vs. DC and HCC vs. Cir), 
models obtained by 1H NMR spectroscopy prediction found a higher AUC (0.8-0.9), 
whereas AFP performed less well (AUC=0.7-0.8) in discrimination of HCC. Since 
most HCC occur in a background of liver disease, it was important that metabolites 
discriminating HCC from liver disease be well characterised. In general 33, 37 and 
25 metabolites that had relative concentrations significantly different between HCC 
and the three groups of control (NC, DC and Cir, respectively) were found. However, 
examining the trends in metabolite concentrations, relative to disease category, 
acetylcarnitine, methionine, creatine, creatinine and N-acetylglutamate showed a 
significant trend in stage of HCC, compared to liver disease.  
The carnitines (carnitine and acetylcarnitine), metabolites involved in the initial stage 
of β-oxidation of free fatty acids, were significantly elevated in the urine of subjects 
with HCC compared to all the non-HCC controls. The finding of relatively higher 
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carnitine corroborates data in the literature (Chen et al., 2011b;Shariff et al., 2010). 
The high excretion of these metabolites in urine may be a result of suboptimal renal 
function, leading to poor reabsorption, excess ingestion of carnitine-containing foods 
or increased biosynthesis. As the renal function, estimated by serum creatinine in the 
present study were comparably similar and ingestion of foods high in carnitine 
content, such as meat, is rather rare in West African populations (proteins are 
traditionally restricted from diet of patients with liver disease (Shariff et al., 2010), 
increased synthesis of carnitines in order to meet the high metabolic demands of the 
rapidly growing tumour in the liver may be responsible for this phenomenon. This is 
further supported by the fact that acetylcarnitine was proportional to the stage of 
HCC. Moreover, acyl co-A synthase, the initial enzyme prior to β-oxidation of fatty 
acid has been reported to be up-regulated in HCC tissues, relative to adjacent non-
HCC tissues (Sung et al., 2003a;Sung et al., 2003b). Downstream, carnitine 
palmitoyltransferase-1 (CPT1) has similarly been shown to be more highly 
expressed in HCC tissues, compared to non-involved tissues (Kurokawa et al., 
2011). These data therefore support the up-regulation of alternative energy 
pathways; in this case, β-oxidation of fatty acids in HCC. 
Creatine is an amino acid that occurs in tissues and in urine, and was significantly 
raised in urine of HCC compared to controls in the present study. Creatine functions 
as part of the energy shuttle of the cell in a reaction reversibly catalysed by creatine 
kinase. Creatine has been reported to be elevated in the urine of patients with HCC 
relative to cirrhosis by our study group (Shariff et al., 2010), as well as after partial 
hepatectomy in experimental rats (Bollard et al., 2005). Recently, mitochondrial 
isoenzyme of creatine kinase activity was found to be higher in serum of cirrhosis 
patients with HCC than in those without HCC (Soroida et al., 2012). Relatively higher 
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urinary creatine in HCC may thus represent excess energy transfer process, a 
requirement of rapidly growing HCC cells.  
In the human body, creatine is synthesized mainly in the liver by the use of 
component parts from three amino acids - arginine, glycine, and methionine. There 
was a tendency for glycine to be lower in the urine of patients with HCC, compared 
to controls although this was not significant, suggesting its high utilisation by rapidly 
growing HCC tissues. 
Methionine is an amino acid required for normal growth and development. It is useful 
for protein synthesis, as well as an intermediate in transmethylation reactions, such 
as methyl group donation for DNA and RNA intermediates. This reaction is catalysed 
by methionine adenosyltransferase (MAT), the responsible for the synthesis of s-
adenosylmethionine (SAMe), the principal methyl donor in the reaction. Research 
has demonstrated that MAT1A, the subunit of MAT expressed mostly in adult normal 
liver, is often silenced in human HCC (Avila et al., 2000;Cai et al., 1996;Frau et al., 
2012;Wang et al., 2009a) . It is thus postulated that excess methionine as a result of 
reduced utilisation by tumour cells is excreted in higher concentration in HCC 
patients than in controls, resulting in hypomethylation. 
Urinary N-acetylglutamate was significantly higher in HCC than in controls and 
correlates with tumour stage. This finding corroborates previous data which revealed 
higher glutamate signals in HCC tissues and serum of HCC patients than in adjacent 
healthy liver tissues and serum of cirrhosis patients respectively (Nahon et al., 
2012;Yang et al., 2007). Up-regulation of glutaminolysis has been reported to 
provide an alternative energy source for tumorigenesis (Meng et al., 2010). 
Glutamine is “trapped” in malignant cells for this process (Dang, 2010). Through 
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glutaminolysis, more energy is made available to rapidly dividing HCC cells, as well 
as the generation of 2-oxoglutarate, an intermediate substrate in the tricarboxylic 
acid cycle. 
There was a higher relative intensity of creatinine in the urine of patients with 
cirrhosis and healthy volunteers than in those with HCC. This finding corroborates 
those of Shariff and colleagues in a previous study (Shariff et al., 2010). More 
recently, Chen and colleagues have reported, using mass spectroscopy, that serum 
creatinine had a significantly high fold change in healthy volunteers compared to 
patients with HCC (Chen et al., 2011b). Creatinine is a breakdown product of 
phosphocreatine in muscle produced at a fairly constant rate and excreted in the 
kidneys. Reduced muscle mass, commonly observed in end-stage liver disease 
patients in Africa (Ladep & Taylor-Robinson, 2007;Shariff et al., 2010) may underlie 
the basis of inverse correlation of this metabolite with HCC relative to other controls. 
Another source of creatinine would be meat which is often traditionally excluded in 
the meals of patients with overt liver disease, such as cirrhosis and HCC. The 
malnourished status of patients with end-stage liver disease in the study cohort is 
suggested further by the significantly lower serum albumin in those with HCC and 
cirrhosis compared to normal serum albumin concentrations in those with non-
cirrhotic liver disease and healthy volunteers. Therefore, the observed inverse 
relationship of urinary creatinine concentration in HCC relative to controls may thus 
represent sarcopenia of cancer cachexia, a feature most prevalent in West African 
patients. 
Identified metabolites, highly expressed in HCC confirm the fact that cancer cells use 
alternative energy for their metabolic processes, as well as complement genetic and 
epigenetic information during HCC pathogenesis. Earlier data had reported 
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increased acyl Co-A synthase activity, global DNA hypomethylation, enhanced 
glycolysis and glutaminolysis by HCC. These data corroborate work found in non-
African populations and additionally demonstrates the feasibility of collaborative 
networking in solving research needs of resource-limited countries. 
To the best of knowledge, only a few human studies of urine proton NMR 
spectroscopy have so far been conducted to characterise HCC metabolites. These 
pilot studies involved small numbers of patients and were restricted to single 
populations (Shariff et al., 2010;Shariff et al., 2011). In contrast to these, HCC 
patients recruited in the current study were about 4 times more in number than in 
previous studies. HCC diagnosis was based on established international guidelines 
(EASL) and included 3 control groups. Additionally, the concentrations of identified 
metabolites were normalised relative to creatinine peaks whereas earlier data 
utilised data normalised to the total spectral integral. This is pertinent as renal 
function as well as sarcopenia would affect the excretion of metabolites. As 
creatinine excretion is not the most sensitive measure of renal function, it remains to 
be proven whether normalization to the creatinine peak is better than normalization 
to total spectral integral.  
It is uncertain how the discriminatory metabolites found on urinary NMR will perform 
in patients with early HCC in the African population, although a serum-based mass 
spectroscopic experiment successfully discriminated between TNM stage 1 HCC 
and healthy volunteers in a Chinese population (Chen et al., 2011b). There were 
only two patients at early stage HCC in the present study which made it statistically 
impractical to assess these as a separate group. These were combined with 
intermediate stage HCC patients. A significant difference in the relative concentration 
between this intermediate stage and liver disease controls was demonstrated.  
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 As well as answering some research questions, the present study raises more 
questions. It is yet to be determined whether the metabolic changes found in HCC 
are specific to primary liver tumours, or representative of tumorigenesis in general. 
Studies that would compare the metabolic profiles of secondary liver tumours to 
those of HCC would be relevant in this regard.  Further, larger studies including 
profiling of other adenocarcinomas, such as colorectal metastases, ovarian and 
prostate cancer are required. However, the present findings provide discrimination of 
HCC from both cirrhotic and non-cirrhotic liver disease, using urinary metabolic 
profiling. The development of a urinary dipstick for use at village level in Africa for 
screening of at-risk populations is the ultimate goal and this study provides some 
evidence that a battery of discriminate metabolites may be a future possibility that 
would be simple to perform and may outperform blood tests, such as AFP. Further 






Figure 35. Schema of altered intermediary metabolism of the liver in HCC identified 
in the present study  
 
 
The development of a diagnostic urinary dipstick would be practical for screening at-
risk populations for HCC. First and foremost, there is need to widely validate the 
performance of the panel with or without current recommendations. It may prove 
valuable to combine the use of urinary metabolites with USS (where the technology 
allows) to improve the diagnostic yield in the evaluation of small size HCC. In 
resource-limited settings, liver imaging could be reserved for those who are 
screened “positive” by urinary metabolite profiles of HCC. Those patients in whom 
dynamic imaging reveals atypical findings may be identifiable by this technology 
and/or liver histology. Furthermore, the altered metabolic pathways identified in this 




Figure 36. Possible clinical translation of urinary metabolite panel to improve curent 
diagnostic schema of HCC 
 
 
In conclusion, proton NMR spectroscopy of urine of this West African population has 
identified metabolites that provide clues for the implication of altered energy-related 
pathways in the pathogenesis and progression of HCC. Additionaly, it has shown 
that the metabolic profiles yielded a beter diagnostic performance than serum AFP. 
These findings confirm that a panel of urinary metabolites may prove useful for 





9. BIOMARKER DISCOVERY IN UK HCC PATIENTS USING PROTON 
NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY 
9.0 ABSTRACT 
Background: There has been a proliferation of biomarker discovery studies for 
HCC using metabonomics. Most of these studies are hampered for generalizability 
as they were carried out on samples from subjects with predominantly single 
aetiological factors for and relatively advanced HCC. The current study aimed to 
determine the urinary metabolites of small, treatable HCCs and assess the 
diagnostic performance of discovered metabolites.  
Methods: Urine samples were collected from patients seen at the Liver Unit of St 
Mary’s Hospital, London. 600MHz NMR was used to acquire one-dimensional 
spectral data from the urine samples, using a standard 1D NMR pulse sequence with 
presaturation of the water peak. Identification of metabolites was ensured using 
multivariate statistical techniques and from library of metabolites. Relative 
concentrations of discriminating metabolites were compared between HCC and 
controls. Areas under the operating characteristic curves (AUC) of the metabolites 
measured in 99 patients: 17 with HCC, 48 with cirrhosis (Cir) and 34 with non-
cirrhotic liver disease (DC) were computed individually and in combination (based on 
logistic regression), to determine their diagnostic capacity.  
Results: All 17 patients with HCC were at BCLC stage A at recruitment. The 
laboratory parameters, including serum albumin, creatinine and ALT were 
comparable between cases and controls. The most common recorded aetiological 
factor for HCC was HCV (4 patients), followed by HBV (2), HCV/alcohol (2), and 
alcohol (2). Seven patients either had non-alcoholic steatohepatitis (NASH) or did 
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not have a definite aetiologic agent identified. Orthogonal partial least squares 
discriminant analysis (OPLS-DA) found a good separation between HCC and 
controls. Uracil and glycine were up-regulated in the urine of HCC patients compared 
to controls whereas creatinine and phenylacetylglutamine were down-regulated. The 
sensitivity and specificity of a combination of these markers were 90% and 81% 
respectively (p<0.0001) (AUC>0.8 for both HCC vs. Cir and HCC vs. DC). 
Conclusions: Urinary metabolic profiling using NMR in this aetiologically 
diverse sample of small HCC patients has identified discriminatory biomarkers, 
possessing high diagnostic predictability. Further validation experiments in larger 






In the previous chapter, it was described how 1H NMR was used on a total of 290 
urine samples from patients that were recruited under the case-control platform of 
PROLIFICA to identify candidate biomarkers of HCC. The technique discriminated 
patients with HCC, compared to healthy and disease controls. Most importantly, the 
diagnostic performance of the urinary metabolites was significantly better than the 
current clinically-utilised serum marker, AFP. Additionally, there was a significant 
correlation between the relative concentration of some urinary metabolites and 
clinical stage of HCC. 
The findings of the previous study corroborate earlier preliminary study of patients 
from Nigeria (Shariff et al., 2010) as well as in an Egyptian population (Shariff et al., 
2011) in whom urinary 1H NMR studies identified discriminatory urinary metabolites 
for HCC. Additionally, it complements several Chinese studies that utilised mass 
spectrometry for the same purpose. The metabolites identified are mostly those 
involved in cellular energy processes of HCC, confirming differential tumour 
metabolism. 
As most of the HCC patients recruited in the West African study were at 
intermediate/advanced clinical stage at presentation, it is debatable whether NMR is 
able to discriminate early HCC; a group for which curative therapy would prove 
valuable. A recent study by Tan and colleagues using serum liquid chromatography-
mass spectrometry, has shown that patients with solitary HCC lesions <2cm could 
be discriminated from those with chronic liver disease with a sensitivity and 
specificity of 87.5% and 72.3% respectively (Tan et al., 2012). The pursuit for more 
studies of differential urinary metabolites of HCC would prove valuable as urine can 
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easily be accessed and such a test can simply be performed in the community, clinic 
and/or bedside. Moreover, most of the aforementioned studies have been performed 
in HCC patients with single aetiologic agents (i.e. HBV in Sub Sahara Africa and 
China, and HCV in Egypt). A study of biomarker of HCC in England, where liver 
transplant services for small HCCs exist, and the possibility of encountering more 
widespread aetiological factors of HCC would be important.  
9.1.1 Hypothesis 
Urinary metabolites can discriminate small HCCs from controls (healthy, non-
cirrhotic liver disease and cirrhosis).  
9.1.2 Aims 
 To determine the urinary metabolic profile of small HCCs using NMR 
spectroscopy  
 To assess the diagnostic performance of discriminatory urinary metabolites of 
small HCCs 
9.2 METHODS 
9.2.1 Study design and subject recruitment 
This was a laboratory-based case control study of HCC (cases) and two groups of 
liver disease controls, including:  
i) Cirrhosis, confirmed by histology; and 
ii) non-cirrhotic liver disease. 
Random urine samples were collected from subjects at St Mary’s Hospital Imperial 
NHS Trust, London between October 2008 and July 2012. All subjects gave written 
and informed consent in accordance with the local Research Ethics Committee 
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approval. HCC cases were identified during the monthly Liver multidisciplinary team 
meeting at St Mary’s Hospital. HCC was diagnosed using EASL guidelines (two 
imaging techniques showing early arterial enhancement and rapid venous washout; 
or one characteristic imaging with serum AFP >400 ng/mL) ( 2012). 
9.2.2 Multivariate statistical analyses 
Obtained NMR spectra were normalised and aligned using an in-house MATLAB 
script and  then subsequently transferred to SIMCA 13.0 (Umetrics, Umea, Sweden) 
for unsupervised, principal components analysis (PCA) followed by supervised, 
orthogonal partial least squares discriminant analysis (OPLS-DA) (Stenlund et al., 
2008). Using these techniques, outliers (mostly as a result of analytical variation) 
were identified; and excluded. The supervised models were subjected to “leave-one-
out” validation, as previously described (Kohavi and Ron, 1995).  
9.2.3 Univariate statistical analysis 
The metabolites that correlated strongest with disease (case/control) groups were 
identified through analysis of the orthogonal partial least squares discriminant 
analysis (OPLS-DA) loadings plot. Identified metabolites were confirmed using 
STOCSY. Intensities of the metabolites were charted on heat maps of relative 
intensity of each sample by metabolite. Using MedCalc Statistical Software version 
12.7.7 (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2013), 
Mann-Whitney U tests were applied to study statistical differences in the median 
values of identified metabolites between HCC, and controls (cirrhosis and non-
cirrhotic liver disease). 
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9.2.4 Diagnostic performance of panels of metabolites 
The ability of each model and some highly expressed metabolites to discriminate 
HCC from cirrhosis and non-cirrhotic liver disease controls were examined for 
sensitivity and specificity using area under the receiver operating characteristic 
curves (AUC).  
9.3 RESULTS 
 
9.3.1 Study population 
Seventeen (17) patients with HCC (all cases were at BCLC stage A); 48 with 
cirrhosis (Cir); and 34 non-cirrhotic liver disease (DC) subjects were recruited in the 
study (Table 14). There was no significant difference between the age of cases 
versus controls. There were also no significant differences between serum albumin, 





Table 14. Clinical and baseline laboratory characteristics of patients and control 
subjects recruited at Imperial NHS Trust, St Mary’s Hospital, London 
Parameter HCC (n=17) Cir (n=48) DC (n=34) 
Age, yrs 
(Median, range) 
65(52-78) 63(27-86) 51(23-79) 
Sex (M/F) 13/4, (76.5/23.5) 32/16, (66.7/33.3) 21/13, (61.8/38.2) 
BMI 26.3 27.5 25.7 
Serum albumin, 
g/L 
33.0 36.0 40.5 
Serum ALT 51.0 40.5 43.0 
Serum Cr 88.0 74.5 78.0 
Serum bilirubin 15.0 15.5 15.0 
Aetiology of 
Liver Disease 
   
HCV 4 16 11 
HBV 2 2 1 
HCV/ALC 2 9 0 
ALC 2 15 3 
Unknown/NASH 7 2 11 
 
 
9.3.2 Multivariate analysis 
OPLS-DA of binary combinations, including: HCC vs. Cirrhosis and HCC vs. DC 
showed some distinguishable clustering of HCC versus controls (Figure 37). The 
relative intensities of some of these metabolites varied between HCC and controls 







Figure 37. Orthogonal partial least squares discriminant analysis results of HCC 
versus controls (HCC=green circles; non-cirhotic liver disease=red circles; 




9.3.3 Univariate analysis 
There was significantly altered concentration of several urinary metabolites in HCC 
compared to controls. Some of these include ketone bodies (acetate), betaine 
aldehyde, glycine, ribose, indole-3-acetate, phenylacetylglutamine, among others 
(Tables 15 & 16, Figure 38). 
 
Table 15. Summary of urinary metabolites discriminating small HCCs from Liver 
disease in UK patient population 
Metabolite Chemical 
shift 
VIP FC p 
value 
Acetate 1.92 3.75 1.28 0.01 
Adenine 8.20 0.70 -1.04 0.89 
Beta-hydroxybutyrate 1.20 15.41 1.31 0.12 
Betaine aldehyde 3.43 1.57 1.38 0.02 
Citrate 2.52 3.67 1.19 0.61 
Dimethylglycine 3.73 2.62 1.53 0.01 
Glycine 3.57  1.38 0.03 
GTP 8.13 0.52 1.68 0.02 
Hydroxyindole_3_acetate 7.21 1.56 -1.33 0.11 
Hydroxyphenylacetate 7.16  1.50 0.49 
Indole-3-acetate 3.65 5.93 1.43 0.03 
Methionine 2.16 3.44 1.30 0.33 
3-methylhistidine 3.70 6.16 1.25 0.016 
N,N,N-Trimethyllysine 3.12 1.44 1.08 0.49 
N-Alpha-acetylornithine 4.18 1.65 1.21 0.14 
Phenylacetylglutamine 7.36 2.36 1.17 0.84 
Phosphorylcholine 3.22 1.36 1.37 0.09 
Pyruvate 2.35 3.33 -1.53 0.2 
Ribose 5.24  1.50 0.01 
Syringic acid 3.84 1.60 1.53 0.02 
Thiamine 5.45 2.55 1.58 0.008 





Table 16. Summary of urinary metabolites discriminating small HCCs from cirrhosis 
in UK patient population 
Metabolite Chemical 
shift 
VIP FC p 
value 
1,3-dimethylurate 3.30 3.84 -1.13 0.61 
1-methylnicotinamide 4.48 1.01 -1.47 0.29 
5-hydroxytryptamine 7.10  2.60 0.01 
Acetylcarnitine 3.19 1.00 -1.05 0.96 
Arginine 1.73 2.55 -1.14 0.15 
Beta hydrobutyrate 1.20 3.20 -1.10 0.06 
Betaine aldehyde 3.24 1.48 1.12 0.38 
Caproate 0.89 2.77 -1.07 0.22 
Carnitine 3.22 1.19 1.19 0.77 
Choline 3.52 3.31 -1.19 0.14 
Citrate 2.55 2.12 1.19 0.81 
Creatinine 4.06 6.00 1.04 0.65 
Dihydrothymine 1.07 1.42 -1.08 0.37 
Glycine 3.57 3.20 1.21 0.11 
Indole-3-acetate 3.66 7.76 -1.20 0.001 
Lactate 1.33 2.34 1.19 0.07 
Methionine 2.14 2.23 1.01 0.91 
Methylguanidine 3.36 1.57 1.04 0.69 
Myoinositol 3.63 3.30 -1.07 0.71 
N,N,N-Trimethyllysine 3.12 3.19 1.03 0.98 
Phenylacetylglutamine 3.67 7.60 -1.28 0.0009 
Sarcosine 3.61 1.61 -1.05 0.24 
TMAO 3.27 19.19 1.16 0.22 





Figure 38. Some of the urinary metabolites that significantly discriminated between 
HCC and controls shown by relative intensities 
9.3.4 Diagnostic performance of panels of metabolites 
The relative intensities of those metabolites that were significantly different in 
concentration in urine of patients with HCC versus controls were logistically 
regressed in order to assess diagnostic potential of panels of urinary metabolites. 
The sensitivities (95% CI) of these panels to discriminate HCC from DC and Cir were 
68.7% (41.3-89.0) and 84.6% (54.6 - 91.8) respectively. Similarly, the specificities of 
these panels were 100% (90.3-100) and 89.4% (76.9 – 96.5) for HCC vs. DC and 
HCC vs. Cir respectively. The corresponding AUC of these models were 0.87 and 





Figure 39. Area under the receiver operating characteristic curves (AUC) to assess 
the diagnostic performance of panels of metabolites discriminating HCC from non-




9.4 DISCUSSION  
Translation of putative tumour markers has been hampered by the fact that most 
biomarker discoveries are undertaken in subjects with advanced tumours. To 
investigate whether patients with small HCCs could be discriminated metabolically 
from those with cirrhosis or non-cirrhotic liver disease, urinary NMR of patients from 
the UK whose HCC qualify for curative therapy were analysed. The supervised 
multivariate model (OPLS-DA) found a good separation of the cases (pre transplant 
HCCs) from controls; and metabolites responsible for the separation were identified. 
5-hydroxytryptamine, betaine aldehyde, dimethylglycine, GTP, thiamine, ribose and 
glycine were significantly up-regulated in HCC patients while indole-3-acetate, 
trimethylamine and phenylacetylglutamine were significantly down-regulated. 
Intriguingly, the sensitivity and specificity of a panel of these urinary metabolites 
were about 85% and 100% respectively. Metabonomic technology, using NMR can 
thus discriminate HCC from liver disease controls irrespective of the clinical stage of 
the tumour. This thus possesses the potential for biomarker discovery that could be 
useful for diagnostic and pathophysiological postulations, thus has the potential to 
augmenting genetic and epigenetic mechanisms. 
The metabolites found in this experiment are similar to some that discriminated 
controls from intermediate/large HCC from African patients (in the last chapter). In 
contrast, whereas indole-3-acetate was down-regulated and glycine up-regulated in 
HCC patients in the present study, these metabolites were altered in the opposite 
directions in the West African sample of HCC patients, as well as in a similar study 
involving an Egyptian population (Shariff et al., 2011). 
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Reasons for the differences are unclear, although it is to be noted that whereas the 
HCC patients from Egypt had advanced disease, HCC patients in the present study 
population included only early stage HCC patients. This divergent finding may thus 
represent differential metabolic activity related to tumour size of HCC patients. 
Two studies have reported up-regulation of urinary glycine excretion in HCC. A study 
of 33 TNM stage 1 HCC patients (Chen et al., 2011b) and one designed to identify 
metabolic signatures of early HCC recurrence after surgery (Ye et al., 2012b), both 
found increased urinary glycine excretion in HCC. Involvement of glycine in 
methylation process of nucleic acid synthesis of malignancy may thus underlie the 
differential urinary glycine concentration found in the present study. This is further 
buttressed by the fact that GTP was significantly higher in the urine of patients with 
HCC than in those of controls in the present study. Urinary nucleosides have been 
observed to be significantly higher in HCC patients than in healthy volunteers in a 
study in Taiwan by Jeng and coleagues (Jeng et al., 2009). 
Phenylacetylglutamine, a normal urinary metabolite in humans was down-regulated 
in HCC patients in the present study. Its lower excretion in HCC is of uncertain 
significance, but does not seem to be as a result of suboptimal synthetic function of 
the liver, as serum prothrombin time and albumin; both markers of hepatic synthetic 
function were not significantly different between HCC patients and controls. The fact 
that Glutamine N-acetyl transferase, the enzyme that catalyses the formation of 
phenylacetylglutamine from phenylacetyl-CoA and glutamine, has been purified from 
human liver mitochondrion suggests that modulation of this pathway may be 
important in the early stage of hepatocellular carcinogenesis. Thus the up-regulation 
and down-regulation of glycine and phenylacetylglutamine respectively in this 
present study population, relative to the West African patient population suggests 
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some dynamism in the tumour microenvironment during HCC carcinogenesis. There 
is an obvious need to verify this in future experiments, as this may prove vital as 
therapeutic targets in individualised therapeutic approach. 
The alterations of urinary metabolites in this present study suggest pathways that 
could be disturbed in early stage HCC pathogenesis. Tryptophan, choline, nucleic 
acid and glucose metabolism were significantly prominent. 5-hydroxytryptamine is 
known to regulate biochemical processes and is synthesised from tryptophan. Its 
role in tumorigenesis has recently been suggested by researchers (Liang et al., 
2013;Soll et al., 2010). To further implicate the role of tryptophan metabolism, indole-
3-acetate, a breakdown product of this amino acid was significantly altered in the 
urine of HCC patients in this study. 
The finding of a high diagnostic performance of urinary metabolites in this study 
population puts to rest the contention regarding the ability of proton NMR to identify 
biomarkers for discrimination of early stage HCC and suggest that the clinical 
translation of a urinary diagnostic would be globally applicable. Important also is the 
fact that the HCC population was diverse, including several aetiological agents of 
HCC. The biomarkers thus represent hepatocarcinogenesis rather than specific to 
aetiological agents of HCC. It may however, prove useful to consider that the panel 
of markers that would suffice for diagnosing early stage HCC would incorporate 
some, and/or be different from the ones that would be required to diagnose 
medium/large HCCs. 
The strength of the present study is enhanced by the fact that all HCC cases were 
confirmed to be early and qualified for curative therapy. Also, cirrhosis was routinely 
diagnosed based on histological evidence. However, these findings are limited by 
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the small sample size of HCC patients, not helped by the fact that several of the 
patients had to be excluded on account of containing drug or sugar metabolites. The 
fact that the internal validation outcome (using 1000 times permutations) did not yield 
a favourable measure, particularly for HCC versus cirrhosis suggests over-fitting of 
the models used in this experiment. In as much as these metabolites can be applied 
to separate HCC from controls by about 85% sensitivity, it may not be applicable to a 
new set of patients. There is thus the need to carry out this study in a larger sample 
size, in order to improve its power. 
Another issue is the fact that the metabolites we have identified could be indicative of 
carcinogenesis and not specific to hepatocellular carcinoma. A further study that 
compares the urinary metabolic profiles of HCC against those of patients with other 
solid tumours such as the prostate, breast, ovary and colon, as well as metastatic 
tumour to the liver will best test whether or not these metabolites are specific to 
HCC.  
In conclusion, NMR of urine of patients with early, transplantable HCC identified 
discriminatory metabolites with high diagnostic accuracy. Some of these metabolites 
share similarity to the ones identified in the west African study and confirms that they 
are effects of hepatocarcinogenesis and not specific to aetiology of HCC. The 
divergent finding of the behaviour of glycine and phenylacetylglutamine suggests 
sequential changes in metabolism of tumours relative to their growth sizes. These 




10. BIOMARKER DISCOVERY OF HCC IN WEST AFRICAN PATIENTS USING 
MASS SPECTROMETRY 
10.0 ABSTRACT 
Background: Preliminary data of subjects recruited in the PROLIFICA project 
in two West African countries show that urinary metabolic profiles may discriminate 
HCC from controls using proton NMR spectroscopy. Ultra-Performance Liquid 
chromatography mass spectrometry (UPLC-MS) presents a high throughput assay 
that has higher ability to verify and or discover additional metabolites; and which has 
been used to identify metabolic profiles of HCC elsewhere. This present study 
hypothesised that urinary UPLC-MS will confirm HCC metabolites in this West 
African cohort and identify additional metabolites that will enhance discrimination of 
HCC from controls. 
Method: Urine samples for the experiment were from subjects that formed the 
population of the proton NMR spectroscopy work reported in chapter 8. Metabolite 
profiling was performed by ultra-performance liquid chromatography quadrupole-
time-of-flight mass spectrometry (UPLC Q-TOF MS) (Waters, Manchester, UK) that 
was equipped with an electrospray ion (ESI) source operating in either positive or 
negative mode. Following processing of acquired chromatograms using XCMS within 
R environment, further multivariate statistical methods used were principal 
components and partial least squares discriminant analyses (in SIMCA). Additionally, 
tandem mass spectrometry was employed to enhance identification of some of the 
compounds that discriminated HCC from controls. Identification of candidate 
metabolites were done by comparing the fragments obtained with standard online 
databases [HMDB (www.hmdb.ca) and metlin (www.metlin.scripps.edu)]. Univariate 
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statistical methods were applied using MedCal statistical software version 12.7.5 
(MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2013) in order 
to define the extent of alteration of identified metabolites.  
Results:  Urine samples from 35, 13, 35 and 32 subjects with HCC, cirrhosis, 
liver disease (non-cirrhosis) and healthy controls were analysed. Multivariate models 
demonstrated good separation, confirmed by 999 permutations tests, between binary 
combinations of HCC compared to the three control groups in both positive and 
negative ion modes. A panel of metabolites discriminated HCC from cirrhosis with 
sensitivity and specificity of 91% and 100% in the positive mode; and 94% and 100% 
in the negative mode. Good correlation between the relative concentrations of some 
of the adducts, versus BCLC stage of HCC was observed. Tandem MS enabled 
identification of 23 compounds that were discriminatory for HCC. 3’-sialyllactose, 
kynurenic acid, taurine, glycochenodeoxycholic acid, 9-decenoylcarnitine, among 
others were newly identified. The diagnostic performances of some of the 
metabolites were better than that of serum AFP. Furthermore, acetylcarnitine and 
kynurenic acid showed significant positive correlations with disease category as well 
as with stage of HCC.  
Conclusion: Urinary UPLC-MS identified several urinary metabolites, which confirm 
some that were identified by proton NMR spectroscopy. Most importantly, HCC was 
able to be discriminated from cirrhosis, the most important group of patients for 





Around the world, the prognosis of HCC is appalling at present, mostly as a result of 
late diagnosis. The mortality rate of HCC is about the same as its incidence in most 
developing countries (Shariff et al., 2009). AFP, the screening tool for HCC that is 
still being utilised in most developing countries is known to have a low diagnostic 
capability (Ishida, Matsuo, & Inoue, 2010). USS of the liver, widely recommended to 
be the base tool for screening by most guidelines, especially in developed countries 
is expensive, requires stable infrastructure and technical skills that are impractical for 
resource-limited countries (Ladep & Taylor-Robinson, 2007). Of note, the burden of 
HCC is highest in these developing countries. 
The search for biomarkers of HCC that will diagnostically perform better than current 
screening tools has become a priority with aim to curb the rising mortality from this 
tumour. Several investigational serum markers have not been validated to be 
significantly better than AFP in terms of diagnosing small tumours (Abu El, 2012). As 
urine presents a readily available biofluid for diagnosis that contains metabolites that 
are fingerprints of tissue processes as well as being more stable than blood, it has 
become an important direction of research endeavor in this regard. For any 
metabolite or combination of metabolites to be useful diagnostically, it must 
outperform AFP in terms of sensitivity and specificity, its concentration should mirror 
the burden of HCC, attenuate with response to treatment and lastly, accentuate with 
recurrence. 
Metabonomics hold promise to discover high-performing biomarkers that could 
revolutionise HCC diagnosis (Wang et al., 2013a). Investigations of urinary 
biomarkers of HCC have identified substances that await validation with regards to 
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the conditions required for an ideal biomarker(s) (Wang et al., 2013b;Yin et al., 
2009). Differences in the metabolic profiles of malignant liver tissues compared to 
adjacent non-malignant tissues have been described (Huang et al., 2013). 
Preliminary data have indicated that urine could be important as a source of non-
invasive means of diagnosis of HCC (Shariff et al., 2010). However, data on the 
metabolic profile of HCC in patients from Africa, a region that will readily utilize this 
point-of-care test, are still limited. As the biological behavior of HCC in Africans may 
be different to patients elsewhere, the study of urinary biomarkers of HCC in this 
population is paramount. Moreover, as the application of this technology would be 
greatly embraced in this region of the world, it is essential that patients from West 
Africa be studied. 
Preliminary data of subjects recruited in the PROLIFICA project in two West African 
countries found that urinary metabolic profiles could discriminate HCC from controls 
using NMR spectroscopy with higher diagnostic accuracy than serum AFP (chapter 
8). Liquid chromatography-mass spectrometry (LC-MS) presents a high throughput 
assay that has higher ability to discover additional metabolites and verify ones that 
were discovered by NMR, and which has been used to identify metabolic profiles of 
HCC elsewhere (Wang et al., 2013b;Wu et al., 2009). 
Hypothesis 
Urinary LC-MS will confirm HCC metabolites in the PROLIFICA cohort and identify 






 To identify urinary metabolites of HCC and assess their ability to discriminate 
HCC from healthy, non-cirrhotic liver disease and cirrhosis 
 To determine correlation of relative concentration of urinary metabolites with 
stage of HCC 
10.2 METHODS 
10.2.1 Study population 
All of the samples for the present study were from subjects recruited in Nigeria and 
Gambia, who participated in the Prevention of Liver Fibrosis and Carcinoma in Africa 
(PROLIFICA) project. Essentially they were from the population that was involved in 
the NMR experiment (chapter 8). All subjects provided informed written consent prior 
to collection of samples used in the study. The study was approved by the Ethics 
committee of Jos University Teaching Hospital, Nigeria; Medical Research Council, 
Gambia and Imperial College London. 
10.2.2 Study design 
This is a case-control study in which HCC subjects and three classes of control were 
recruited, as follows: 
i. mainly hepatitis B-related cirrhosis,  
ii. mainly non-cirrhotic chronic liver disease, and  
iii. healthy volunteers from the same African populations. 
Binary comparisons of clinical, laboratory and metabolite parameters of the cases 
and controls were embarked upon throughout the analyses. 
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10.2.3 Preparation of urine samples 
Urine was collected in universal containers, pipetted into Eppendorf bottles and 
stored at -80oC prior to air-transportation on dry ice to Imperial College London for 
analysis. At the laboratory, the samples were centrifuged at 13,000 rpm for 10 
minutes at 4oC in order to remove debris. The supernatant was aliquoted into labeled 
wells before mass analysis. 
A 2 μL aliquot of the urine was injected into  150 mm x 2.1 mm, 1.8 μm HSS T3 
column (Waters, Elstree, UK) at temperature of 40oC using an ultra-performance 
liquid chromatography system (Waters, Manchester, UK). All samples were kept at 
4oC during the analysis and mass spectrometry data collected with the use of a 
Waters Q-TOF Xevo Tandem Quadrupole (TQ) Mass Spectrometer (Waters, 
Manchester, UK) that was equipped with an electrospray ion source operating in 
either positive or negative ion mode. Data were collected from 40 to 1200 m/z with a 
scan time of 0.3 s and interscan delay of 0.02 s over a 13 min analysis time. As the 
analytes elude at different times, dependent on their polarity and hence solubility in 
the aqueous (water) or organic (acetonitrile) solvents, formic acid was added to 
provide a source of protons in reverse phase LC-MS and to reduce the pH of the 
mobile phase, suppressing the ionisation of weak organic acids and thereby 
improving retention. 
All analyses were acquired using the LockSpray to ensure accuracy and 
reproducibility. 200 pg/mL leucine-encephalin (m/z 556.2771) in H2O:CAN (50:50) 
was used as the lock mass with a flow rate of 30 mL-1. Data were collected in the 
positive and negative ion centroid mode with LockSpray frequency set at 200 sec 
and 10 data scans on average. The mass spectrometer was operated with a 
capillary voltage of 3.2 kV and 2.4 kV for positive and negative ion modes 
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respectively, cone voltage of 35 V, nebuliser gas flow of 900 L/hr, and desolvation 
temperature of 120oC. The instrument was set to acquire data over the mass range 
of m/z 50-1000 with acquisition time of 5 scans per second and an interscan delay of 
100 ms, according to the validated method of Want and colleagues (Want et al., 
2010).  
10.2.4 Data processing 
The acquired raw mass spectrometry (MS) data were exported in NetCDF format by 
MassLynx software (version 4.1; Waters, Manchester, U.K.). CDF files were 
extracted using XCMS software (within R statistical software) (sourced from 
http://metlin.scripps.edu/xcms/installation.php; La Jolla, Carlifornia, USA) (Smith et 
al., 2006). The parameters used were retention time range 0-9.5 min, mass range 
50-1000 Da, mass tolerance 0.02 Da. The result of these processes led to retention 
time deviation correction and generation of data matrix that contain information of 
arbitrarily assigned peak indices (retention time; m/z pairs), sample names 
(observations), and ion intensity information (variables). 
The two sets of data resulting from positive and negative ion modes were analysed 
separately by multivariate and univariate statistical methods. Identification of 
metabolites was achieved using further analysis of the MS/MS (tandem mass 
spectrometry) data acquired during the experiment. 
10.2.5 Statistical analyses 
10.2.5.1 Multivariate analysis (SIMCA) 
Each data set was imported into SIMCA-P 13.0 software (Umetrics, Umeå, Sweden). 
For the present study, 7 round cross-validations was applied with 1/7th of the 
samples being excluded from the model in each round to guard against over-fitting 
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was embarked upon. To study how well the model clustered the groups, an 
unsupervised multivariate statistical technique in the form of principal components 
analysis was carried out. This was followed by orthogonal partial least squares 
discriminant analysis, a supervised multivariate technique, in order to visualize the 
metabolic alterations between HCC and each of the three control groups. The 
performance of these models was validated by permutation testing. S-plots were 
applied to obtain mass/charges for subsequent metabolite identification which was 
performed separately; using web-based resources including: Human Metabolome 
Database (http://www.hmdb.ca/) and Metlin database 
(http://metlin.scripps.edu/index.php).  
10.2.5.2 Univariate analyses 
Using Graphpad Prism (version 6, CA, USA) and MedCalc for windows statistical 
software (version 12.5, Ostend, Belgium), univariate statistical analyses in the form 
of Mann Whitney U tests were performed to measure the significance of 
representative metabolites in separating HCC patients from healthy volunteers and 
non-cirrhotic liver disease and cirrhosis patients. The corresponding up and down 
regulated intensities of how these differential masses varied between HCC and 
controls were displayed using heat maps (Microsoft Excel®). 
Analysis of variance was used to calculate trends in the relative intensity of 
metabolites and 3 phenotypic states (cirrhosis, BCLC stage A-C and BCLC stage D). 
In order to further identify differences between cirrhosis and categorized stages, the 
differences between the relative intensity each of the three phenotypic groups were 
estimated using the Holm-Sidak multiple comparison test. 
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10.2.5.3 Diagnostic performance of urinary metabolites 
Logistic regression analysis by backward method was used to identify the best 
performing masses and their predictive values fitted for calculation of area under the 
receiver operating characteristic curves (AUC). Calculation of sensitivity and 
specificity of binary combination of diagnostic panels was undertaken. Lastly, 
Kendall’s tau was calculated in order to estimate correlation of relative intensity of 
some metabolites to stage of HCC. Statistically significant observations were placed 
at p values less than 0.05. 
10.2.6 Tandem mass spectrometry 
The methods so far described are limited to identification of masses which do not 
necessarily represent authentic metabolites. Identification of specific metabolites 
required accessing information of the tandem mass spectrometry (fragmentation 
experiment) data available in its raw form in the MassLynx software. The most 
significant chromatographic peaks were explored and their respective m/z vs. RT 
compared to online databases (http://metlin.scripps.edu/index.php). Identified 
discriminatory metabolites were subjected to multivariate and univariate statistical 
tests, comparing their diagnostic performances using area under the receiver 
operating characteristic curves and trends between controls and increasing HCC 
tumour burden (BCLC stage). 
10.3 RESULTS 
10.3.1 Clinical parameters 
The clinical characteristics of HCC patients and other subjects are shown in Table 
17. In the study cohort, fewer patients with cirrhosis than the rest of the other groups 
were recruited. There were more males and who were also older than the rest of 
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groups. Serum albumin, alanine aminotransferase and prothrombin time were 
abnormally different in HCC and cirrhosis groups, compared to subjects with chronic 





Table 17. Clinical and laboratory characteristics of patients with HCC and controls 
whose urine samples were analysed for detection of discriminatory metabolites 
Parameter HCC Cirrhosis Disease 
control 
Healthy p value 
Number 35 13 35 32 0.0084 
M/F 31/4 10/3 19/16 16/15 0.0033 
Age, median 
(years) 
50 45 40 40 0.015 
ALT 77 41 35 24 <0.001 
Albumin 16 21 41 43 <0.001 
Bilirubin 15.3 85.0 10.2 12.0 <0.001 
Prothrombin 
time 
20.0 29.0 16.0 22.0 0.1 
AFP 256 78 39 3.4 0.1 
Creatinine 86 76 86 72 0.07 
HBV, n 15 10 33 0  
 
 
10.3.2 Data processing 
Obtained spectra were processed using XCMS in R statistical software. Following 
normalisation, the resultant processed data can be seen in Figure 40. 
 
Figure 40. Boxplots showing results of normalisation of negative mode data  
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10.3.3 Multivariate analysis 
Principal components analysis (PCA) and orthogonal partial least squares 
discriminant analysis (OPLS-DA) were performed on the normalised datasets for 
both positive and negative ion modes. Definite trends of clustering were found for the 
PCA and there were excellent separations of HCC from controls on the scores plots 
of OPLS-DA for both modes. Notable also was the fact that all the QC samples 
clustered very well in both modes (grey circles). Figure 41 illustrates the scores plots 
of the models of study subjects by classes. In both modes, all the HCC urine 
samples (green circles) were correctly separated from the urine of subjects with 











Figure 41. Multivariate analyses in SIMCA P 13.0 of Positive mode data (top) and 
Negative mode data (botom) demonstrating clustering of study groups in principal 
components analysis (PCA). The supervised model; orthogonal partial least squares 
discriminant analysis (OPLS-DA) of hepatocelular carcinoma (HCC) versus healthy 
controls (NC), non-cirhotic liver disease controls (DC) and cirhosis patients (Cir) for 
both modes are corespondingly shown. Colour code: green circles (HCC); blue 






10.3.4 Fitness of model test 
The permutation tests (999 times) for HCC vs. Cir of the OPLS-DA models of both 
positive and negative ion modes, coresponding to their respective PCA models 
including the corelation coeficients between the original Y and the permutated Y 
versus the cumulative R2 and Q2, with regression line is shown in Figure 43. The 
intercepts (which corelate to extent of over fiting) are smal (Pos ion mode: R2=0.76 
and Q2= -0.054; Neg ion mode: R2 = 0.77 and Q2 = -0.03) and thus suggest that the 
models are satisfactory (Figure 42). 
  
 
Figure 42. Summary of 1000 permutations of positive and negative ion mode data for 
HCC versus Cirhosis partial least squares discriminant analysis (PLS-DA) 
  




10.3.5 Tandem mass spectrometry analyses 
In order to confirm the parent metabolites that were important in the discrimination of 
HCC from controls, raw chromatographic data were interrogated and those parent 
compounds that were further fragmented during tandem mass spectrometry were 
identified by comparison to fragmentation patterns of online database 





Obtained metabolic chromatographic paterns of urine of subjects and controls 
folowing fragmentation experiments are shown in figure 38 below. 
 
 
Figure 43. Chromatograms obtained folowing tandem mass spectrometry of urine in 




10.3.7 MS/MS patterns of some metabolites 
Summaries of masses obtained at specific retention times were obtained in both 
positive and negative ion modes and results compared to mass fragmentation 
patterns obtained from online databases within accuracy of 30 ppm. Via this 
mechanism, the parent compounds were identifiable (Figure 44 and Figure 45).  
 
 
Figure 44. Tandem mass spectrometry fragmentation patterns of masses 145.060 




Figure 45. Tandem mass spectrometry fragmentation patterns for masses 132.078 
and 190.050; identified as creatine and kynurenic acid respectively 
10.3.8 Summary of metabolites 
Several compounds including amino acids, nucleic acid, an oligosaccharide, bile 
components, hormones and gut flora metabolites were identified as perturbed 





Table 18. Summary of identified metabolites that were significantly expressed in 
positive and negative ion modes  
 
Positive ion mode Negative ion mode 
Mass Retention 
time 
Metabolite Mass Retention 
time 
Metabolite 
204.124 0.96 Acetylcarnitine† 212.002 3.17 Indoxylsulphate 
190.050 2.80 Kynurenic acid 263.023 1.52 3-methoxy-4-hydroxyphenyl 
ethylene glycolsulfate 
166.073 1.80 1-methylguanine 539.350 5.57 Tetrahydroxyhypoaldosterone-3-
glucuronide 
124.085 0.45 N-methylhistamine 195.053 2.38 1,3-dimethyluric acid 
314.235 5.99 9-
decenoylcarnitine 
632.202 0.69 3’-Sialyllactose 
132.078 0.62 Creatine† 124.007 0.54 Taurine 
130.050 3.26 Glutamate† 145.060 3.26 Glutamine 
150.055 1.97 Methionine† 178.051 3.26 Hippurate† 
301.217 5.64 9-cis retinoic acid *528.264 7.54 Glycochenodeoxycholic acid 
229.155 1.34 Pro Leu *283.080 3.84 P-cresol glucuronide 
139.052 0.95 Urocanic acid 




10.3.9 Relative intensity of metabolites (HCC vs. disease controls) 
Whereas glutamine, tetrahydroaldosterone-3-glucuronide and indoxylsulfate were 
significantly lower in the urine of patients with HCC, there were several metabolites 
that were up-regulated in HCC (Figure 46). 9-decenoylcarnitine, 
glycochenodeoxycholic acid, 3’-Sialyllactose, methionine, taurine, acetylcarnitine and 





Figure 46. Bar charts showing urinary metabolites that were significantly up-
regulated (above) and down-regulated (below) in urine of HCC patients (green bars) 
relative to controls (blue bars-cirrhosis and pink bars-liver disease). Error bars 




10.3.10.6 Trends of intensity by disease category   
The relative intensity of acetylcarnitine and kynurenic acid showed a significant 
positive trend to the disease category as well as stage of HCC (Figure 47 and Figure 




Figure 47. Clustered bar charts showing patterns of increase in the relative intensity 










Figure 48. Graphs of Spearman’s rank correlation coefficients for intensity of 




10.3.10 Diagnostic models of urinary metabolites 
Urinary glycochenodeoxycholic acid, 3’-Sialyllactose, taurine, methionine, 9-
decenoylcarnitine and acetylcarnitine, as single metabolites each possessed higher 
sensitivity and specificity than serum AFP in the discrimination of HCC from liver 
disease controls (Table 19). Two panels; comprising 3 urinary metabolites derived 
from logistic regression (as significant in the models) found a further higher ability of 
urinary metabolites to diagnose HCC compared to serum AFP (Table 19). Panel II 
confirms the best diagnostic schedule of metabolites to be a combination of 3’-
Sialyllactose, 9-decenoylcarnitine and methionine. 
 
Table 19. Diagnostic performance of serum AFP and urinary metabolites (single and 
multiple combinations) identified by tandem mass spectrometry 
Diagnostic plan Candidate metabolites AUC Sensitivity (%) 
Specificity 
(%) + LR  - LR  
AFP (serum) 
 
 HCC vs. Cir 0.64 50.0 66.7 1.5 0.8 




acid 0.90 85.7 91.4 10.0 0.2 
 3'-Sialyllactose 0.86 80.0 76.9 3.5 0.3 
 Taurine 0.76 65.7 84.6 4.3 0.4 
 Methionine 0.75 65.7 76.9 2.9 0.5 
 9-decenoylcarnitine 0.75 60.0 92.3 7.8 0.4 
 Acetylcarnitine 0.73 62.9 85.7 4.4 0.4 
Combination of 


















To be able to curb the menace of HCC, the discovery of more sensitive tools for 
surveillance and screening of this tumour is a priority. Using liquid chromatography 
mass spectrometry and complex multivariate/ univariate statistical analyses, several 
urinary metabolites possessing high discriminatory power for HCC were discovered 
in the present work. Most importantly, HCC was able to be discriminated from 
cirrhosis, the most challenging group of patients for which diagnosis would be 
invaluable. Metabolites, some of which complemented those that were identified by 
NMR spectroscopy were discovered via this high throughput technique. Besides 
those, additional diagnostically relevant compounds were found to be up-regulated in 
HCC population of subjects involved in this study. 
The finding of differential relative concentration of some of the metabolites between 
HCC and controls corroborates published data of patients from Chinese, Egyptian 
and Nigerian populations. These findings corroborate Warburg’s hypothesis and 
suggest that single or a panel of urinary metabolites could be developed to enhance 
early diagnosis of HCC. The finding of a high (91%) sensitivity and (100%) specificity 
of a panel, comprising 3’-Sialyllactose, 9-decenoylcarnitine and methionine confirms 
the penultimate hypothesis.  
The burden of HCC tumour mass, described by the clinical stage of disease was 
proportional to the relative intensity of acetylcarnitine in this present work, confirming 
preliminary finding (chapter 8). Another metabolite that was detected in this work to 
correlate with tumour size was kynurenic acid, a derivative of tryptophan; which has 
yet to be reported in patients with HCC. However, a study of 19 experimental rats 
has suggested that the metabolism of tryptophan may be altered in aflatoxin B1-
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induced hepatoma animals (Lemonnier et al., 1975). The finding of kynurenic acid in 
this present study population may support the altered tryptophan metabolism of HCC 
in this aflatoxin-prone population (Gouas et al., 2012). Of interest is the finding of 
down-regulation of indoxylsuphate, another tryptophan metabolite, in urine of HCC 
patients in this study population. Further studies are warranted in order to define the 
role of tryptophan metabolism in the pathogenesis of HCC.  
3’-Sialyllactose was observed to be significantly up-regulated in HCC patients 
relative to disease controls in this study population. This sialylated oligosaccharide, 
secreted in human breast milk has not featured significantly as an important urinary 
metabolite of HCC. Zhang and colleagues recently discovered its up-regulation in the 
urine of patients with pre-operative epithelial ovarian cancer relative to healthy 
controls (Zhang et al., 2013). In patients with malignant melanoma, serum sialic acid 
concentration was discovered to positively correlate with tumour stage (Silver et al., 
1979). Also, a single murine study, 3 decades ago discovered that sialic acid 
correlated with metastatic ability of tumours (Yogeeswaran and Salk, 1981). 3’-
sialyllactose may be thus be important in the modulation of cell-cell interaction of 
tumours leading to decreased containment of malignant tumours, such as HCC. The 
up-regulation of 3’-sialyllactose in HCC of this study population may thus partly 
explain the relatively higher fatality rate and short diagnosis-to-death period 
observed in West African patients. 
Glycochenodeoxycholic acid, one of the major human bile salts was relatively higher 
in the urine of HCC patients compared to controls in this study population. Alteration 
of bile acids had been demonstrated in serum (Ressom et al., 2012;Wang et al., 
2013b) and urine (Chen et al., 2011) of HCC patients relative to controls and found 
to be perturbed. The present finding thus corroborates those of earlier researchers 
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and suggests important roles for bile acids in the modulation of carcinogenetic 
process of HCC. The role of glychochenodeoxycholic acid (GCDA) in HCC is poorly 
understood and may be important in the modulation of hepatocarcinogenesis. Liao 
and colleagues have suggested that GCDA may be important as a carcinogen and 
or a survival agonist in the development of HCC (Liao et al., 2011).  
This work further confirms the possibility of the development of a urinary diagnostic 
of HCC, most probably via the use of panels, containing a number of metabolites; in 
this case, a combination of three metabolites. Exploration of complementing serum 
AFP by these urinary metabolites did not provide any significant increase in the 
diagnostic accuracy, suggesting that the panel correctly classified those that were 
diagnosable by AFP. Noteworthy in these findings is the enhanced illumination on 
the possible mechanistic development of HCC these data have provided. The down-
regulation and up-regulation of certain metabolites confirm differential metabolism of 
HCC and could be downstream effects of genetic and epigenetic changes. This 
could herald discovery of pathways that may enhance drug development for HCC.  
The strength of the present work lies in the fact that it is the first urinary metabolite 
profiling of HCC by mass spectrometry of HCC patients in a sub-Saharan African 
population, a region least studied in this regard. Second, the identification of HCC 
cases was embarked upon via validated international guidelines (EASL) and controls 
were well characterized by radiological and histological means. Third analysed urine 
samples underwent very strict laboratory conditions of storage, transportation and 
preparation. The samples were well preserved and transported on ice and only 
thawed prior to preparation for mass spectrometry. Moreover, rigorous statistical 
applications ruled out over-fitting of the models and thus provided validity to the 
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results obtained. This was confirmed by clustering of the quality control (QC) 
samples in both modes and low intercept of Q2 following 999 permutations. 
The findings are however limited by the fact that most of these metabolites were 
identified based on adducts that satisfy the classification and biological plausibility; 
although robust metabolite libraries were utilised (www.hmdb.ca and 
www.metlin.scripps.edu). To achieve a high degree of confirmation of metabolite 
identity, tandem mass spectrometry was utilized and some of the metabolites were 
identified (23 compounds). The highest level of confidence in the metabolite identity 
would be based on spiking experiments of reference laboratory standards. Future 
work is planned to verify that the metabolites are correctly identified. Furthermore, 
validation of these findings in a new set of patients that have been recruited on the 




11. VALIDATION OF HCC BIOMARKERS IN WEST AFRICAN PATIENTS 
USING PROTON MAGNETIC RESONANCE SPECTROSCOPY  
11.0 ABSTRACT 
Background: In order to achieve early diagnosis and hence curb the current trend of 
HCC, there has continued to be a search for biomarkers. Candidate urinary 
biomarkers are being identified but await verification and or validation in at-risk 
populations. The present study being reported aimed to validate urinary biomarkers 
of HCC in a separate West African cohort to the original study population.  
Methods: Urine samples were collected from a separate group of patients and 
controls at two sites in West Africa on the case-control platform of PROLIFICA. 
600MHz NMR was used to acquire one-dimensional spectral data from the urine 
samples, using a standard 1D NMR pulse sequence with presaturation of the water 
peak. Areas under the operating characteristic curves (AUC) of the relative 
concentration of metabolites identified, measured in 463 subjects: 141 with HCC, 56 
with cirrhosis (Cir), 178 with non-cirrhotic liver disease (DC) and 88 healthy 
volunteers (NC), were compared to serum AFP. Following post-acquisition 
processing of obtained spectra in MATLAB, multivariate statistical techniques in the 
form of PCA and OPLS-DA were applied using SIMCA. Further statistical handling 
(univariate and rank correlation) was carried out using MedCalc Statistical Software 
version 12.7.7 (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 
2013) with statistical significance defined as p<0.05.  
Results: There was found distinct urinary metabolic profiles of patients with HCC, 
compared to Cir, DC and NC with sensitivity/specificity of 83.6%/63.5%, 
83.6%/96.0% and 87.1%/75.0% respectively. Several metabolites were significantly 
 247 
 
increased (p<0.0001) in urine of HCC patients compared to non-HCC liver disease 
controls (DC and Cir), including: N-acetylglutamate, betaine, methionine, 
acetylcarnitine, carnitine, 2-oxoglutarate, indole-3-acetate, creatine and several 
others. Urinary metabolite profiles performed significantly better than AFP in 
discriminating HCC from other non-malignant liver conditions (AUC: HCC vs. DC; 
metabolite profile [0.9] vs. AFP [0.8], p=0.0003; HCC vs. Cir; metabolites [0.8] vs. 
AFP [0.7], p=0.034). There was observed a positive correlation of N-acetylglutamate, 
acetylcarnitine, methionine, betaine aldehyde, ribitol and creatine with BCLC stage of 
HCC. 
Conclusions: Urinary NMR of this separate validation cohort of the West African 
population has confirmed metabolites that implicate altered energy-related pathways 
in the pathogenesis and progression of HCC. Additionally, the urinary metabolic 
profiles performed better than serum AFP in the discrimination of HCC from non-





A couple of studies have suggested that metabonomics of urine can potentially be 
used to characterise underlying biochemical mechanisms and hopefully enhance 
early diagnosis of HCC (Chen et al., 2011b;Shariff et al., 2010;Shariff et al., 2011). 
Preliminary work reported in chapter 8, involving about 300 patients have confirmed 
that HCC patients could be discriminated from chronic liver disease patients with 
higher sensitivity and specificity than serum AFP, using metabolite panels identified 
by NMR spectroscopy. The identified metabolites involved in the process are mostly 
those indicative of altered energy metabolism, particularly of beta-oxidation, urea 
cycle, TCA cycle and gut floral activities. Parallel experiment (chapter 10) on a 
subset of urine samples from the cohort reported in chapter 8, using ultra high 
Performance liquid chromatography mass spectrometry confirm the possibility of 
achieving diagnosis of HCC using urinary biomarkers more accurately than serum 
AFP. 
The ideal biomarker that would overcome the hurdles against clinical utility in HCC 
should be elevated in concentration in the presence of higher burden of disease and 
attenuate with tumour ablation or response to treatment. It was possible to 
demonstrate the former phenomenon only in this West African population, as most 
patients recruited in this project presented late and with tumours that were not 
amenable to curative therapy. It is noted that there has been a dearth of data 
regarding true validation of urinary metabolites of HCC. Most published data utilised 
leave-one-out validation as well as internal validation; which are both limited by the 
fact that they only statistically manipulate the same cohort on which their training set 
data are based. The best model for such a validation would be in a different sample 
that share similar clinical characteristics. Additionally, more rapid advances have 
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been made in the prediction, detection and understanding of disease using 
metabonomics, presenting more opportunities to characterise metabolites with high 
precision. The on-going recruitment of HCC patients on the case control study of 
PROLIFICA also enabled a robust platform to study an entirely new set of patients 
with similar clinical and laboratory characteristics. 
Hypothesis  
Urinary metabolite profiles can discriminate HCC from controls better than serum 
AFP and thus validate preliminary experiments. 
Aims 
 To validate discovery of urinary metabolites of HCC in a separate validation 
cohort of West African patients, from the original study population  
 To determine the accuracy of urinary metabolites and compare with serum 
AFP in the diagnosis of HCC 
 To interrogate the correlation of relative concentration of urinary metabolites 





11.2.1 Study design/subject selection 
The design and conduct of this validation experiment were as outlined earlier 
(chapter 8). Samples were from subjects recruited in Nigeria and Gambia, who were 
formally consented to participate in the Prevention of Liver Fibrosis and Carcinoma 
in Africa (PROLIFICA) project. PROLIFICA is a European Union Framework 7-
funded project (PROLIFICA: www.prolifica.eu). The case-control platform involved 
identifying cases and controls, including: mainly hepatitis B-related cirrhosis, non-
cirrhotic chronic hepatitis B-related liver disease, and non-cancer subjects that were 
negative to HBV and HCV screening. All the patients in the present cohort were 
newly recruited during August 2012 to July 2013 and did not participate in the initial 
NMR experiment (chapter 8). 
Urine samples were collected for metabonomic studies according to earlier outlined 
protocol. The metabonomic analyses were undertaken using urinary proton (1H) 
nuclear magnetic resonance spectroscopy (NMR) at Imperial College London. 
Samples collected from patients, diagnosed with HCC according to the European 
Association for the Study of the Liver (EASL) guidelines were stored at -80oC until 
air-transported on dry ice to Imperial College London. Ethics committees of JUTH, 
Nigeria and MRC, Gambia; as well as Imperial College London granted approval for 
the study. 
All controls were confirmed not to have tumours on ultrasound scan and negative to 
HBsAg, anti-HCV and HIV screening. Staging of HCC was performed according to 
the Barcelona Clinic Liver Cancer (BCLC) classification. 
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11.2.2 Sample collection and preparation 
Approximately 5mL of non-fasted urine samples were collected into universal 
containers after obtaining informed written consent and administration of dietary 
questionnaires. Prior to spectral acquisition, samples were thawed at room 
temperature. Sample preparation and acquisition methods were performed 
according to published methods (Beckonert et al., 2007). 400 µL urine sample was 
mixed with 200 µL of phosphate buffer solution (0.2 M Na2HPO4/0.04 M NaH2PO4, 
pH = 7.4 plus 0.1% sodium azide, 1 mM 3-trimethylsilyl-1-[2,2,3,3,-2H4] propionate 
(TSP)) to stabilize the urinary pH. The samples were allowed to stand for 10 min 
prior to centrifugation at 13000 rpm for 10 min in order to remove insoluble material. 
500 µL of the supernatants from each urine sample was aliquoted into 5 mm NMR 
tubes (Wilmad LabGlassTM, New Jersey, USA) for proton nuclear magnetic 
resonance (NMR) studies. 
11.2.3 1H NMR spectral acquisition and processing 
1H NMR spectra were acquired with a 600 MHz spectrometer (Bruker Avance, 
Massachussets, USA) operating at 600.13 MHz for 1H at 300 K. It was equipped with 
a 5 mm broad-band inverse configuration probe. Samples were randomly analysed 
in automation with a B-ACS 60 sample changer system. Urine samples were 
analysed using water suppressed 1D NMR spectrum using the NOESYPRESAT 
pulse sequence (256 transients). Irradiation of the solvent (water) resonance was 
applied during presaturation delay (2.0 s) for all spectra and for the water 
suppressed 1D NMR spectra also during the mixing time (0.1 s). The pulse 
sequence parameters including the 90° pulse (~ 10 µs), pulse frequency (~ 4.8 
ppm), receiver gain (~ 200), and pulse powers were optimised for each sample set 
run.  The spectral width was 20 ppm for all spectra. The NMR data were processed 
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with an exponential line broadening of 1.0 Hz prior to Fourier transformation, which 
were collected with approximately 32 k real data points. Data [-1.0 to 10.0 ppm] were 
imported into MATLAB 7.0 software (MathWorks, Natick, MA), where they were 
automatically phased, baseline corrected and referenced to the TSP peak (0.00 
ppm), using scripts written in-house. To reduce analytical variation between samples 
the residual water signal (4.70 – 5.00 ppm) was truncated from the data 
set.   Normalization to total area was performed and metabolites identified according 
to the earlier protocol. 
11.2.4 Multivariate statistical analyses 
The acquired spectra were divided into small regions of 0.02±0.01ppm, representing 
specific metabolites. These regions were aligned (controls mild shifts in the spectra) 
and normalised (controls differential dilution of samples) using MATLAB. A matrix of 
samples against variables (ppm bins) was thus generated and transferred to SIMCA 
13.0 (statistical software) for unsupervised principal components analysis (PCA) and 
supervised orthogonal partial least squares discriminant analysis (OPLS-DA). Using 
these techniques, some outliers identified to be due to experimental errors or huge 
metabolic peaks that would adversely affect analysis were removed from the models. 
The models were subjected to “leave-one-out” validation, a technique in which each 
sample in turn was automatically excluded from the analysis, a model created from 
the remainder of the samples and the class membership of the excluded sample 
predicted. This technique was applied to every 7th sample until each sample was 
excluded once. To confirm the performance of the model, 999 permutations of 
comparison models were embarked upon. 
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11.2.5 Univariate statistical analysis 
The metabolites that contributed most to the OPLS-DA separation were identified 
through their high performance on the variable importance in projection (VIP) and 
use of S-line plots in SIMCA 13.0. Identified metabolites were confirmed using an in-
house statistical total correlation spectroscopy (STOCSY) tool. Intensities of the 
metabolites were expressed as concentration relative to creatinine. This procedure 
of correcting for creatinine intensity was aimed at controlling for muscle mass and 
differential kidney function of the subjects. Using MedCalc software, Mann-Whitney 
U test of significance was applied to study the differences in the median values of 
identified metabolites between HCC (cases) and the three classes of controls. 
The ability of each model to discriminate HCC from cirrhosis, non-cirrhotic liver 
disease and healthy control subjects were examined for sensitivity and specificity 
using area under the receiver operating characteristic (AUC) curves. The AUC 
curves were built to compare the diagnostic performance of these metabolite panels 
with serum alpha fetoprotein; each for HCC versus cirrhosis, HCC versus non-
cirrhotic liver disease and HCC versus healthy volunteers. 
Finally, Spearman’s correlation coefficients of the most influential metabolites by 
clinical stage of HCC were determined. 
11.3 RESULTS 
11.3.1 Clinical parameters 
A total of 463 urine samples, 141 of which were from patients confirmed to have 
HCC, 56 with cirrhosis, 178 with non-cirrhosis liver disease (mostly HBV infected) 
and 88 from normal healthy volunteers were analysed. As shown in Table 20, most 




Table 20. Clinical and laboratory information of HCC patients and controls (cirrhosis, 
chronic liver disease and healthy volunteers) 














Age; years 45(21-95) 36(15-69) 38(17-75) 46(18-81) 
Sex; M/F, 
n(%) 
104/31(77%/23%) 43/13(77%/23%) 92/85(52%/48%) 45/43(51%/49%) 
BCLC stage    
A-C 60(72.3) / / / 





58.0(2.0-789) 5.8(0.5-558) 4.7(2.2-571) 
Albumin, g/L 28.0(4.2-17.4) 25.0(11-41) 41.0(9-50) 40.0(12-71) 
ALT, IU/L 46.5(4-823) 59.0(16-1074) 21.0(4-1339) 22.0(8-386) 
Creatinine, 
μm/L 
90(21-423) 74(36-297) 72(30-173) 85(15-896) 
Bilirubin, 
μm/L 
10.2(5.1-295.8) 15.3(8.2-680) 10.2(5-316) 10.2(1-102) 
Aetiology of liver disease   
HBV 63(53%) 54(98%) 171(98%) 0(0%) 
HBV/HCV 3(3%) 0(0%) 0(0%) 0(0%) 
HCV 14(12%) 1(2%) 2(1%) 0(0%) 
Negative/ 
Unknown 






Figure 49. PCA scores plot based on urine metabolic profiles of subjects from 






11.3.2 Multivariate analysis results 
PCA scores plot by country of origin of subjects did not show any significant 
clustering (Figure 49). Scores plot of PCA demonstrated clustering of cases (HCC) 
and the three groups of controls (Figure 50). The supervised OPLS-DA models each 
for HCC compared to healthy volunteers, HCC compared to non-cirhotic liver 
disease and HCC compared to cirhosis, showed good separation of cases from 
controls. The prediction of the performance of each of the models was assessed to 
be satisfactory using 999 permutations. 
 
 
Figure 50.  Scores plot of PCA model based on urine samples from HCC patients 
(green circles), cirrhosis patients (blue squares), liver disease (red triangles) and 
healthy volunteers (yelow inverted triangles). Below the PCA plot are scores plot of 
OPLS-DA prediction and coresponding statistical validation of PLS-DA models by 
permutation analyses (999) of (A) HCC vs. Healthy, (B) HCC vs. DC; and (C) HCC 
vs. Cir. HCC: hepatocelular carcinoma; DC: non-cirhotic liver disease; Cir: cirhosis 
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11.3.3 Diagnostic performance of urinary metabolites 
Based on the models generated by the metabonomics of urinary metabolites, there 
was found to be a superior diagnostic accuracy of these models relative to serum 
AFP (Table 21). In particular, there was observed significantly better diagnostic 
performances of urinary models than serum AFP for HCC vs. Cir and HCC vs. DC. 
Table 21. Comparison of diagnostic accuracy of models based on urinary metabolic 
profiles and serum AFP 




HCC vs. NCα Model 0.90(0.85-0.96) 0.03 
0.08 0.05 0.12 
 AFP 0.82(0.73-0.92) 0.05 
HCC vs. DCβ Model 0.96(0.94-0.99) 0.01 
0.08 0.03 0.003 
 AFP 0.88(0.84-0.93) 0.02 
HCC vs. Cirδ Model 0.81(0.73-0.89) 0.04 
0.12 0.06 0.034 
 AFP 0.68(0.59-0.78) 0.05 
α132 patients (112 HCC and 20 NC); β208 patients (112 HCC and 96 DC); δ150 
patients (112 HCC and 38 Cir); comparisons were limited to those subjects that had 
urinary metabolic profiling performed and in whom serum alpha fetoprotein were 
determined. 
 
11.3.4 Univariate analysis results 
Major discriminatory metabolites that were identified from the processed normalized 
and aligned spectra were subjected to further univariate analyses. The metabolites 
were identified by a comprehensive method of checking online libraries such as the 
human metabolome database (www.hmdb.ca) and Chenomx nmr suite 7.7 
(www.chenomx.com). Additionally, reference standards were run under the same 
conditions as the experimental samples and their respective spectra confirmed to be 





Figure 51. NMR spectra of reference standards (red) compared against urinary NMR 
spectra of (blue) patients  
 
 
Alterations (median fold changes) in the relative concentration of urinary metabolites 
were observed when HCC was compared with disease and healthy controls (Table 
22). The metabolites identified were mostly those already identified in the initial 
cohort (chapter 8) besides additional ones including: amino acids, carbohydrates, 




Table 22. Summary of altered urinary metabolites between HCC vs. Healthy, HCC vs. liver disease and HCC vs. cirrhosis patients 
Metabolite Chemical shift(ppm) 
HCC vs. Healthy HCC vs. Liver Disease HCC vs. Cirrhosis 
VIP FC p value VIP FC p value VIP FC p value 
Lactate 1.33 1.43 1.17 0.0028       
Alpha-hydroxyisobutyrate 1.36  1.07 0.6  -3.78 0.000005    
Acetate 1.92    1.42 1.19 0.0006 5.08 1.10 0.037 
N-acetylglutamate 2.04 1.59 1.57 <0.000001 1.06 1.91 <0.000001 1.13 1.43 0.0008 
Methionine 2.14 4.46 1.55 <0.000001 2.18 1.85 <0.000001 3.30 1.39 0.009 
Pyruvate 2.35 5.28 -1.29 0.0018 3.83 -1.38 0.0017    
Succinate 2.41 1.55 1.16 0.043       
2-oxoglutarate 2.44 1.33 1.49 <0.000001 1.00 1.60 <0.000001    
Citrate 2.66 1.82 1.08 0.22 3.59 1.02 0.64 4.96 -1.20 0.37 
Dimethylamine 2.72 2.06 1.35 0.000002       
Methylguanidine 2.83 1.38 1.35 <0.000001       
Homocarnosine 2.93       2.18 -1.09 0.68 
N-Alpha-acetyllysine 3.01       1.15 1.22 0.093 
Creatine 3.04       11.33 1.15 0.035 
Acetylcarnitine 3.20 11.15 2.05 <0.000001 6.61 2.36 <0.000001 10.99 1.97 0.0007 
Carnitine 3.22 15.46 2.07 <0.000001 8.74 2.80 <0.000001 8.01 1.63 0.015 
Betaine aldehyde 3.24 1.43 1.50 <0.000001 1.00 1.75 <0.000001 0.70 1.34 0.017 
TMAO 3.27 19.81 -1.18 0.0076 10.80 -1.05 0.12 9.48 1.02 0.58 
Methylguanidine 3.36       1.18 1.05 0.41 
Choline 3.50 1.21 1.70 <0.000001 1.15 2.18 <0.000001    
Glycine 3.56 5.98 -1.03 0.46 9.30 -1.28 0.0003 10.40 -1.09 0.21 
Indole 3-acetate 3.65 5.12 1.80 <0.000001 3.79 2.02 <0.000001    
Phenylacetylglutamine 3.67 1.81 1.11 0.14       
1-Methyl-L-histidine 3.69 1.38 1.45 0.000006       
Dimethylglycine 3.72 1.14 1.49 <0.000001 1.61 1.86 <0.000001    




Ribitol 3.83       3.83 1.54 0.0001 
Pseudouridine 3.85    1.19 1.96 <0.000001    
Betaine 3.89     2.08 <0.000001    
Glycolate 3.94 3.91 1.36 0.0019       
Creatine 3.95 6.25 1.29 0.0016 3.18 1.35 <0.000001 5.44 1.19 0.14 
Hippurate 3.97 8.68 -1.67 <0.000001 9.31 -1.61 <0.000001    
O-hydroxyhippurate 3.99 3.08 1.37 <0.000001 3.61 1.61 <0.000001    
1-Methylnicotinamide 4.48 1.30 1.99 <0.000001 1.00 2.88 <0.000001    
N-formyl-L-Aspartate 4.51       1.29 -1.05 0.91 
Glyoxylic acid 5.09       1.31 1.24 0.072 
L-Fucose 5.21 0.61 1.32 0.0018 0.60 1.67 <0.000001    
N-Acetyl-5-
hydroxytryptamine 7.09       1.37 -1.62 0.019 
5-Hydroxytryptophan 7.14        1.34 0.11 
5-Hydroxyindole-3-acetate 7.21 1.67 -1.82 <0.000001 1.19 -1.36 0.0016    
Betaphenylpyruvate 7.28 1.54 -1.81 <0.000001 1.06 -1.54 4E-06    
5-Methoxytryptamine 7.32       1.38 1.18 0.028 
Phenylacetylglutamine 7.36    1.69 -1.33 0.021    
5-Hydroxytryptamine 7.42 1.67 -1.91 0.00004 1.00 -1.63 0.003    
Phenylacetylglutamine 7.44       1.81 1.52 0.0037 
Hippurate 7.55 6.97 -3.37 <0.000001 5.86 -3.62 <0.000001  1.08 0.69 
Hippurate 7.64 3.60 -2.64 <0.000001 2.64 -1.71 <0.000001    
Alpha-hydroxyhippurate 7.84 6.36 -3.32 <0.000001 5.69 -3.78 <0.000001    





11.3.5 Concentration of metabolites relative to stage of HCC 
Owing to the fact that most HCC patients would have background cirrhosis, the 
urinary metabolites that discriminated HCC from cirrhosis were further evaluated. 
Methionine, betaine aldehyde, carnitine, N-acetylglutamate, ribitol and creatine 
showed good correlation of increasing concentration relative to stage of HCC (Table 
23). To study further the specific metabolites that may be contributing to the 
pathological processes of HCC disease, bar charts were used to illustrate the 
relative concentrations of identified metabolites between tumour stages relative to 
cirrrhosis. Of note, acetylcarnitine, N-acetylglutamate, ribitol and creatine, which are 
mainly metabolites involved in altered metabolism revealed increasing trends (Figure 
52). 
 
Table 23. Summary of correlation of urinary metabolite concentration by HCC stage 
Metabolite  Coefficient (rho) 95%CI p value 
Acetylcarnitine  0.38 0.18-0.55 0.0005 
Carnitine  0.39 0.19-0.56 0.0003 
Methionine  0.42 0.23-0.59 0.0001 
N-acetylglutamate  0.28 0.07-0.47 0.011 
Betaine aldehyde  0.43 0.23-0.59 0.0001 
Ribitol  0.37 0.16-0.54 0.0007 












Figure 52. Bar charts showing progressive increase in relative concentration of 
urinary metabolites among patients at different stages of HCC relative to cirrhosis; 
AceCar: acetylcarnitine; Bet: betaine aldehyde; Car: carnitine; Crea: creatine; Rib: 






Lack of verification and/or true validation of candidate biomarkers have been the 
bottle-neck of translation from bench to clinical utility of severally reported markers in 
scientific literature. As of 2007, about 1,261 proteins had been cited in the literature 
as being altered in human cancers, yet only about 3% are being used in some 
clinical capacity (Polanski and Anderson, 2007). There has been a lot of interest in 
defining urinary biomarkers of cancer in recent times. A review of urinary bladder 
cancer studies identified some studies that have been conducted; and it noted that 
these markers have lower specificity than invasive cystoscopy for screening of 
bladder cancer (Xylinas et al., 2013). Data are also available for urinary markers of 
ovarian (Macuks et al., 2012) and gastric cancer (Dong et al., 2013), but findings are 
yet to be validated.  
Increasing attempts at defining relevant biomarkers of HCC in urine have yielded 
interesting results, yet these have been hampered by small sample sizes (Shariff et 
al., 2010) and lack of external validation of preliminary findings (Chen et al., 
2011b;Shariff et al., 2011). The data presented in this report studied a large number 
of samples in which there were 141 HCC subjects, and confirmed urinary 
metabolites that were discovered in a separate cohort of patients from West Africa, 
possessing similar clinical and laboratory characteristics as in the preliminary cohort. 
Moreover, the profiles of the urinary metabolite models diagnostically outperformed 
serum AFP, similar to the findings of the initial experiment. It is to be noted that 
whereas most diagnostic performances of biomarkers identified in previous studies 
were described between cancer patients and healthy controls, this work compared 




(cirrhosis and non-cirrhosis liver disease), besides comparison with healthy 
volunteers. 
Almost all the urinary metabolites that were described in the preliminary work were 
confirmed to have similar alterations in the present work. Additional metabolites 
found in this validation cohort include 5-hydroxytryptamine, betaphenylpyruvate, 
pseudouridine, guanosine, homocarnosine and ribitol. Together with the ones found 
in the previous work, these metabolites indicate fingerprints of significantly altered 
pathways including glycolysis, tricarboxylic acid cycle, pentose phosphate pathway, 
DNA methylation, choline, gut flora and beta-oxidation. A schema of how these 
alterations may have evolved is charted as shown in Figure 53. 
The present work also confirms alterations of urinary metabolites with stage of HCC; 
suggesting their role for prognostication of this tumour. Until at time of writing up 
these data, there has been little attempt to illustrate the possible complex pathway 
alterations that may be important in HCC. The human metabolome database and the 
Kyoto Encyclopaedia of Genes and Genomes (KEGG) database were used to map 
modifications in the metabolic pathways. Fatty acid metabolism (acetylcarnitine and 
carnitine), energy provision for the tumour (acetate, butyrate and creatine), choline 
metabolism (dimethylglycine and TMAO), glutaminolysis (glutamate, alanine), 
tricarboxylic acid cycle (2-oxoglutarate and succinate), DNA methylation (formate, 
methionine, betaine, glycine) and gut metabolism (tryptophan, tryptamine and indole-






Figure 53. Presumed altered metabolic pathways in HCC identified from 
discriminating urinary metabolites. Items within blue borders highlight pathways; 
whereas direction of arrow indicate up or down-regulation 
 
There appears to be a heightened free fatty acid metabolism in patients with HCC. In 
both preliminary and validation experiments, acetylcarnitine and carnitine, co-factors 
in the initial phase of beta-oxidation were up-regulated in urine of patients with HCC. 
In the carnitine shuttle, transformed fatty acid, Acyl CoA is transferred to the hydroxyl 
group of carnitine by carnitine acyltransferase located on the outer membrane of the 
mitochondrion. Acylcarnitine is then shuttled inside by carnitine-acylcarnitine 
translocase. Carnitine acyltransferase II, located on the inner membrane of the 
mitochondrion, converts acylcarnitine to acyl CoA and carnitine. The liberated 




shown by relatively higher acetate, butyrate and phenylacetylglutamine in the urine 
of HCC patients than in controls. The excess production of these metabolites in HCC 
patients confirms that ketone bodies are possible requirements of HCC and may fuel 
the growth and progression of HCC. This phenomenon had been validated by 
researchers in a recent study (Martinez-Outschoorn et al., 2012) in which ketone 
bodies were identified as drivers of tumour growth and metastasis. 
Glycine was consistently down-regulated in urine of HCC patients. This finding 
corroborates data from Shariff and colleagues in a study of HCC patients from an 
Egyptian population (Shariff et al., 2011), as well as preliminary data (chapter 8). The 
involvement of glycine in aberrant DNA methylation, a hallmark of carcinogenesis 
may explain this finding. Indeed, methionine, betaine aldehyde and formate; all three 
metabolites significant in DNA methylation were up-regulated. However, up-
regulation of 1-methylnicotinamide in this HCC cohort suggests overexpression of 
nicotinamide-N-methyltransferase (NNMT) and thus impairment of DNA methylation. 
This phenomenon has been confirmed by a metabolomic study (Ulanovskaya et al., 
2013) and may give rise to hypomethylated histones and other cancer-related 
proteins. Hypomethylation has been well-described as a cause of chromosomal 
instability in particularly, non-HCV associated HCC tissues (Nishida et al., 2013) and 
in those patient groups exposed to aflatoxin B1 (Zhang et al., 2012). Methylation 
studies of tissues will be helpful to uncover the occurrence of this phenomenon, 
especially as HBV formed the most prevalent associated aetiological agent of HCC 
in this aflatoxin-prone study population.  
Dimethylglycine (DMG), choline and TMAO, metabolites involved in choline 




and choline were up-regulated, there was a down-regulation of TMAO. These 
alterations corroborate the findings of published data in which choline metabolism 
was identified to play a significant role in malignant transformation of tissues (Glunde 
et al., 2011). The role of choline metabolism has been confirmed in tissues from 
patients, not only with liver cancer (Bell and Bhakoo, 1998), but also brain, breast, 
lung, ovarian and prostatic cancers (Glunde, Bhujwalla, & Ronen, 2011). Excess 
choline metabolites in urine of HCC patients thus indicate downstream changes in 
which genetic or epigenetic changes in HCC tissues would have led to what is 
observed in the present study, and could serve as a possible target of therapy. 
Current data support the hypothesis that altered metabolism of cancer results from 
active reprogramming by growth factor regulators such as oncogenes and tumour 
suppressors (Ward & Thompson, 2012), and which drives the process of cancer 
development. There is thus a significant paradigm shift from the former hypothesis 
that altered metabolism in cancer are a consequence of carcinogenesis (Costello 
and Franklin, 2012). 
While creatine and methylguanidine were up-regulated in HCC, creatinine was 
significantly lower in HCC patients and maintained a significant negative correlation 
in both preliminary and validation sets of patients. Creatinine is converted to creatine 
reversibly by the enzyme, creatine kinase; and non-enzymatically to 
methylguanidine. Whereas creatine, chiefly produced in the liver from arginine, 
methionine and glycine, is known for its role in the energy shuttle, methylguanidine 
has been shown to inhibit inducible nitric oxide synthase (iNOS) and tumour necrosis 
factor alpha (TNF-α) release (Autore et al., 1999) both in vitro and in vivo. Not much 




However, the immune deregulations associated with methylguanidine on TNF-α 
synthesis and release, may be important in promoting carcinogenesis via reduced 
immune surveillance. 
N-acetylglutamate is up-regulated in HCC as well as correlates significantly with 
tumour stage. Glutamate is a non-essential amino acid and would have been 
produced through the action of glutaminase enzyme on glutamine. The elevated 
level of this amino acid in HCC patients may thus suggest enhanced glutaminolysis 
in HCC subjects relative to controls in this study. Glutamate has been identified as 
an important metabolite that contributes to triggering of cell growth and inhibition of 
autophagy (Duran et al., 2012) and thus equip tumour cells to evade apoptosis. 
Additionally, cancer cells solely rely on glutamine as a carbon source for the TCA 
cycle (DeBerardinis et al., 2007). The finding of up-regulation of 2-oxoglutarate and 
succinate in the present work confirms this phenomenon. Also, the finding of down-
regulation of glutamine (chapter 10) in HCC suggests increased utilisation by the 
HCC tissues. This finding has implications for anti-metabolite drug developments for 
HCC, and which is being pursued for other cancers currently (Zhao et al., 2013). 
The metabolites that discriminated HCC from controls in this work have thus 
confirmed the preliminary data and highlight several pathways that are altered in 
tumour metabolism. The fact that most of these metabolite alterations have 
previously been identified in tumours other than HCC suggest that the metabolites 
alterations identified may not possess specificity to HCC. Be that as it may, within 
the at-risk population of liver disease, most especially, HBV population of Africa, a 
combination of the metabolites could be helpful in screening patients for HCC. 




limitations. First, most of the HCC patients recruited in the study population had 
intermediate or advanced stage of disease. It would be more beneficial to diagnose 
HCC at stages during which cure is achievable. However, as the health-care seeking 
behaviour of the current study population is such that most patients present when 
illnesses are advanced, on-going work by the PROLIFICA programme has been able 
to sensitise the populace and may lead to recruitment of early stage patients. Indeed 
the metabolic profiling result of the UK HCC population (chapter 9) is a proof of the 
principle that detection of early stage disease using urinary metabolites is 
practicable. 
Second, the influence of diet, drugs and exercise on urinary metabolite excretion 
could significantly affect the interpretation of the current data. In order to control for 
this, detailed dietary, exercise and drug questionnaires were administered to 
consenting patients and volunteers before samples were obtained. Recall of 
information such as historical facts may otherwise be distorted in patients that were 
recruited. Some of the patients had hepatic encephalopathy, a condition that may be 
associated with amnesia. This was obviated by confirming historical facts from 
carers of the patients. 
Also, advanced HCC is often complicated by cancer cachexia with associated 
sarcopenia. Urinary creatinine concentration has been recognised as a biomarker of 
sarcopenia (Pahor et al., 2009). Although urinary creatinine excretion is directly 
proportional to total body muscle mass, its determination is a Herculean task, often 
requiring strict dietary restrictions. This was controlled for by normalising the 




Further verification and discovery of additional urinary metabolites by mass 
spectrometry and identification of a combination of metabolites vital to diagnosis of 
small HCCs would be the most rationale direction of future research. Most of the 
metabolites discovered in the experiment have been identified in several other 
tumours remote to the liver. Comparison of metabolite differences between HCC and 
secondary tumours to the liver, as well as primary cancers other than HCC deserves 
additional work. All the urinary metabonomic studies reported in this dissertation 
involved a global approach. Targeted metabonomic studies will seek to identify, 
quantify and determine the diagnostic performance of single or a combination of key 
metabolites. Several hypotheses of altered pathways that have yet to be established 
will form another direction of future study. For example, the involvement of gut flora 
metabolism in the evolution of HCC deserves further studies. The concept of gene-
environment interaction in the aetiology of diseases has recently been suggested by 
Heinzmann and colleagues (Heinzmann et al., 2012). Several tryptophan 
metabolites, including: indole-3-acetate, indoxyl sulphate, kynurenic acid and 5-
hydroxytryptamine were identified in the present work. Studies linking up the 
mechanistic development of HCC, involving genetic approaches would pave way to 





12. SUMMARY AND CONCLUSIONS 
12.0 Background 
PLC is the 5th most commonly diagnosed cancer and 3rd cause of cancer-related 
deaths globally. Although less common than in the developing countries, an 
exponential increase in the mortality from PLC in England and Wales was reported 
towards the end of the last century. Lifestyle and temporal changes have warranted 
close monitoring of the trends in the mortality, incidence, modes of diagnosis and 
ethnic distribution of this fatal cancer. This was, therefore, one of the objectives of 
my thesis. 
The absence of good quality cancer database in high incident countries such as 
Africa limited the appraisal of the current epidemiology of PLC in this region of the 
world. However, the availability of resources involved in HIV research allowed me to 
perform some detailed examination of liver-related morbidities in a Nigerian HIV 
cohort. Thus, it was possible to determine the rates and impact of PLC risk factors 
(HBV and HCV) in the HIV population of that cohort. 
The high case fatality associated with HCC engendered biomarker discovery studies 
using samples from two West African countries (Nigeria and Gambia), which I 
undertook as a spin-off of the PROLIFICA study. The poor diagnostic accuracy of 
serum AFP and the need to further simplify identification of HCC in resource-limited 
regions, as well as proliferation of new techniques (metabonomics) created 




12.1 Research questions 
There are insufficient data on the most important factors responsible for rising rates 
of PLC and subtypes. Until my study, the question of whether changes in diagnosis, 
ICD classification and immigration are impacting on the increasing rates of PLC, 
particularly in England and Wales had not been investigated.  
The incidence of HCC has been reported to have risen from 0.2 to 2.8 cases per 
1000 person-years between 2000 and 2009 in HIV-infected patients in Spain 
(Merchante et al., 2013). Hitherto, studies of liver-related morbidities in HIV 
populations in African communities have been limited by small sample sizes and 
relatively shorter duration of follow up compared to data from Western countries. My 
study in Africa aimed to obviate the shortcomings in the published literature. 
Previous pilot studies utilising urinary metabonomics have identified several 
metabolites that are perturbed in HCC patients, yet these remain to be validated in 
large cohorts; and particularly African patient groups, something which I have now 
addressed in this thesis. I have assessed how these metabolites perform 
diagnostically and have provided pointers as to how these compare in relation to 
tumour size. I have postulated how these techniques could provide in-roads into 
point-of-care diagnostic and drug development efforts for HCC, as well as 





12.2 Innovations and breakthroughs 
12.2.1 Epidemiological study (PLC) 
I have reported for the first time, how errors in ICD coding of tumours and changes in 
the mode of diagnosis of PLC could be contributing to the changing trends in the 
incidence of PLC subtypes in England and Wales. Estimation of survival, using MIR 
calculations provided information on the outlook of PLC in the immediate term. 
Studying the ethnic distribution of PLC, data were obtained from national registries, 
which include all incident cases and are thus much more representative, compared 
to previous data. Although a significant proportion of the registered cases were found 
not to have information on basis of diagnosis and ethnic background, the findings 
highlight information that would be relevant for follow up studies. 
12.2.2 Epidemiology study (Liver-related morbidity in HIV) 
In the present study, I characterised the HIV-infected patients, based on hepatitis 
status, comparing them with a HIV mono-infected cohort and have shown that HBV, 
in particular, was associated with attenuated CD4 cell increase following long-term 
ART. Additionally, HBsAg serological status was identified as a significant factor in 
the mortality of HIV-infected patients that were on ART, an effect that was annulled 
in those co-infected patients (HBV/HIV), who were on an ART regimen, in which 
Tenofovir was a component. 
12.2.3 HCC biomarker discovery 
It is to be noted that whereas most diagnostic performances of biomarkers identified 
in previous studies were described between cancer patients and healthy controls, 
this work additionally compared the diagnostic accuracy of identified markers 




renal function and sarcopenia could alter the nature of excreted metabolites in the 
urine, normalisation to creatinine peaks was embarked upon prior to univariate 
analyses. 
Almost all the urinary metabolites that were described in the preliminary work were 
confirmed to have similar alterations in the validation set in which 141 HCC subjects 
were studied. The complex interactions of pathways that were discovered to be 
altered in the present study were mapped using the Kyoto Encyclopaedia of Genes 
and Genomes (KEGG) database. Fatty acid metabolism, ketone bodies, choline 
metabolism, glutaminolysis, tricarboxylic acid cycle, DNA methylation and gut 
metabolism pathway alterations were identified. UPLC-MS and tandem mass 
spectrometry coupled with multivariate analyses identified single and panels of 
metabolites that diagnostically outperformed serum AFP in the discrimination of HCC 
in the studied population.  
12.3 Applications 
12.3.1 Changes in epidemiology of PLC and subtypes 
The findings of increasing incidence and mortality rates of PLC, and particularly, the 
IHBD subtype, despite ICD coding errors, provide a number of important pointers for 
future healthcare provision. The predilection of Afro-Caribbean ethnicity, with the 
projected overall worsening outcomes of PLC, carries several implications. First, 
efforts need to be intensified regarding control of risk factors that may be contributing 
to the rising incidence of PLC, as well as the development of surveillance tools 
aimed at early diagnosis, particularly targeted in migrant communities, in order to 
provide curative treatments. Second, cancer registries need to be unambiguous in 




to ethnicity. Whenever there is an epidemiological debate, such as in the case of 
whether hilar CC should be referenced to C22.1 or C22.4, there should be 
immediate multi-disciplinary team intervention to address this. The fact that ethnic 
information registration in the England and Wales cancer registry was available in 
only a 3rd of the cases but increasing suggest that in the future, it must be possible to 
describe the distribution of PLC by ethnicity, more accurately. The latter will provide 
useful information that shall inform clinicians to provide targeted surveillance of at-
risk population groups.   
12.3.2 Impact of HBV in HIV-infected patients in an African cohort 
With such a high and rising rate of hepatitis infection in HIV-infected patient cohort in 
a representative African population, there is obvious need to intensify efforts at 
ensuring that the recommended hepatitis screening pre-ART is adhered to by 
implementing partners. Tenofovir, a nucleotide analogue, with therapeutic effect on 
both HIV and HBV, has become available in the past few years and is recommended 
for use by expert panels, such as AASLD and EASL. The present study fortifies the 
significance of those recommendations, particularly in resource-limited settings. It 
would be sensible to recommend that HIV/HBV co-infected patients embarking on 
treatment are commenced on a Tenofovir-containing regimen, unless otherwise 
contraindicated. Nevertheless, HIV patients who are co-infected with hepatitis 
require close monitoring and follow up, and this may flag-up additional cases that 





12.3.3 HCC urinary biomarker development 
As an extension of my work, future diagnostic biomarker and drug developments are 
possible applications of my urinary metabonomics research. For example, a 
diagnostic screening and surveillance panel could improve case ascertainment of 
HCC in patients with cirrhosis. This is particularly so in African patients where AFP is 
still being relied upon for diagnosis. The present data highlighted the superior 
performance of urinary metabolite batteries (using both NMR and UPLC-MS) over 
serum AFP. A urinary diagnostic panel would be readily available and applicable to 
large populations and thus amenable to community surveys. Future work on larger 
cohorts around the world is needed to validate my findings in Africa and the UK. 
Also, the findings from this work have further highlighted pathogenic alterations in 
HCC. Whether these pathways represent a milieu required for, or are consequent 
upon carcinogenesis are subjects deserving further studies. They, however, 
complement genetic and epigenetic data and could be valuable in drug development 
for HCC. 
12.4 Future directions 
12.4.1 Changes in epidemiology of PLC  
Differential patterns of the increase in the incidence and mortality rates of HCC and 
IHBD, in which females were more affected than males with regard to IHBD in 
England and Wales deserve further study. It is uncertain whether oral contraceptive 
pills have any role to play aetiopathologically. Indeed, existing data suggest 
otherwise (Lam et al., 2005), although better designed studies will yield more 
meaningful results. Second, the use of ethnic information to implicate immigration in 




Studies involving stratification of immigration patterns, such as first and second 
generation immigrant status will provide more meaningful results than ethnicity 
status, as environmental factors are also important in disease processes. The risk 
factors in the pathogenesis of IHBD, particularly, in England and Wales will 
constitute a worthwhile study area in the future; as effective control measures will 
rest on such findings. The impact of guidelines, adherence to surveillance schedules 
and tumour stage at diagnosis on the survival of patients with PLC will need further 
studies. A search for better performing screening and diagnostic tools should be a 
priority study subject, as the poor survival forecasted by the current trends suggests 
that available tools have suboptimal diagnostic accuracy. 
12.4.2 Liver-related morbidities in HIV in African patients 
Prior to availability of free ARVs, most HIV-infected patients in sub Saharan African 
countries died of AIDS. Most AIDS–related deaths have been on the decline (Weber 
et al., 2006), but the incidence of HCC among HIV-infected patients has been 
reported to be increasing. However, reports of the relatively higher incidence of HCC 
in HIV patients, compared to non-HIV patients have been absent from this 
population, although, they are reported to be so in developed countries of the world. 
Well-designed cross-sectional studies in which HIV/HBV patients form the cases, 
while HBV patient groups constitute the controls will help to answer the issues of 
increasing incidence of HCC in the ART era. Characterisation of HCC cases was 
noted to be poor in the present data and any prospective study should yield higher 
quality data if suspected cases of HCC are investigated according to international 




12.4.3 HCC biomarker discovery 
The ultimate goal of the current endeavour is to develop a point-of-care test that 
would be accessible, affordable and simple, such as a urinary dip-stick for use in the 
field. To be able to translate my research findings into such a reality,, there needs to 
be external validation of altered metabolites, in particular, in small HCCs. Also, 
corroboration of the pattern of alteration in blood, as well as liver tissues, would 
provide unequivocal evidence of the implicated metabolites. Patients recruited on to 
the PROLIFICA studies are being followed up in this regard. Those with cirrhosis and 
those who may develop HCC will have their initial urine samples compared to the 
samples that will be collected at the time that HCC diagnosis would be confirmed.  
Most of the metabolites discovered in my work have been described in tumours other 
than HCC and these may therefore represent carcinogenesis, rather than specificity 
to HCC. Studies comparing metabolic profiles of non-HCC tumours (such as tumours 
of the ovary, prostate, breast, colon and metastasis to the liver) with HCC would be 
valuable in this regard. The pathways such as glutaminolysis, gut flora metabolism, 
beta-oxidation, DNA methylation and others, which were inferred to be altered from 
the present findings, will need further elucidation, as they may hold key to further 
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Appendix A: Number of deaths from primary liver cancer (PLC) by subcategories 
(HCC, IHBD and Liver NOS) in England and Wales, 1968-2008 
Year PLC   HCC   IHBD   LIVER NOS  
 M F TOTAL M F TOTAL M F TOTAL M F TOTAL 
1968 571 396 967 292 180 472 21 17 38 258 199 457 
1969 603 458 1061 282 180 462 20 30 50 301 248 549 
1970 587 451 1038 276 147 423 35 22 57 276 282 558 
1971 551 443 994 271 158 429 23 16 39 257 269 526 
1972 599 424 1023 310 163 473 22 23 45 267 238 505 
1973 637 478 1115 313 184 497 27 25 52 297 269 566 
1974 611 449 1060 311 196 507 21 34 55 279 219 498 
1975 589 418 1007 312 181 493 40 30 70 237 207 444 
1976 629 433 1062 319 156 475 36 19 55 274 258 532 
1977 625 453 1078 309 180 489 53 38 91 263 235 498 
1978 606 398 1004 332 151 483 48 47 95 226 200 426 
1979 583 336 919 434 208 642 54 66 120 95 62 157 
1980 522 376 898 380 227 607 78 74 152 64 75 139 
1981 628 419 1047 430 220 650 78 89 167 120 110 230 
1982 597 463 1060 341 230 571 91 101 192 165 132 297 
1983 594 396 990 409 231 640 127 123 250 58 42 100 
1984 713 466 1179 479 231 710 148 148 296 86 87 173 
1985 680 499 1179 425 220 645 145 171 316 110 108 218 
1986 750 514 1264 456 218 674 183 206 389 111 90 201 
1987 726 526 1252 437 229 666 185 206 391 104 91 195 
1988 837 583 1420 467 207 674 227 242 469 143 134 277 
1989 802 576 1378 465 220 685 239 248 487 107 108 215 
1990 818 570 1388 458 207 665 231 252 483 129 111 240 
1991 879 645 1524 501 242 743 269 301 570 109 102 211 
1992 919 684 1603 528 223 751 285 372 657 106 89 195 
1993 970 735 1705 348 142 490 329 355 684 293 238 531 
1994 983 781 1764 374 132 506 335 405 740 274 244 518 
1995 999 761 1760 366 142 508 347 402 749 286 217 503 
1996 1052 770 1822 416 164 580 349 387 736 287 219 506 
1997 1133 848 1981 459 156 615 414 473 887 260 219 479 
1998 1118 803 1921 462 158 620 402 463 865 254 182 436 
1999 1134 818 1952 491 205 696 415 451 866 228 162 390 




2001 1160 868 2028 465 164 629 456 542 998 239 162 401 
2002 1223 917 2140 555 193 748 444 549 993 224 175 399 
2003 1342 853 2195 622 165 787 489 543 1032 231 145 376 
2004 1356 941 2297 671 197 868 509 609 1118 176 135 311 
2005 1461 994 2455 716 186 902 556 680 1236 189 128 317 
2006 1619 1041 2660 785 208 993 623 710 1333 210 122 332 
2007 1615 1100 2715 802 240 1042 610 758 1368 200 101 301 


















Appendix B: Number of cases of primary liver cancer (PLC) by subcategories (HCC, 
IHBD and Liver NOS) in England and Wales, 1979-2008 
Year PLC   HCC   IHBD   LIVER NOS  
 M F TOTAL M F TOTAL M F TOTAL M F TOTAL 
1979 608 350 958 519 281 800 32 38 70 57 33 90 
1980 580 415 995 471 296 767 42 42 84 67 77 144 
1981 639 407 1046 509 304 813 57 61 118 73 42 115 
1982 607 408 1015 476 315 791 62 53 115 69 40 109 
1983 627 414 1041 524 310 834 70 68 138 33 36 69 
1984 621 433 1054 524 319 843 57 76 133 40 38 78 
1985 692 467 1159 592 367 959 60 59 119 40 41 81 
1986 669 421 1090 571 333 904 50 60 110 48 28 76 
1987 740 512 1252 634 378 1012 68 95 163 38 39 77 
1988 778 501 1279 627 366 993 89 92 181 62 43 105 
1989 739 485 1224 594 341 935 78 93 171 67 51 118 
1990 778 471 1249 611 323 934 115 111 226 52 37 89 
1991 818 553 1371 674 365 1039 100 127 227 44 61 105 
1992 920 574 1494 731 371 1102 142 165 307 47 38 85 
1993 913 591 1504 711 376 1087 150 179 329 52 36 88 
1994 949 640 1589 719 395 1114 168 189 357 62 56 118 
1995 1003 685 1688 536 280 816 290 294 584 177 111 288 
1996 1127 806 1933 605 321 926 305 357 662 217 128 345 
1997 1182 864 2046 668 323 991 355 413 768 159 128 287 
1998 1250 864 2114 722 342 1064 362 413 775 166 109 275 
1999 1281 824 2105 719 315 1034 367 385 752 195 124 319 
2000 1408 925 2333 803 306 1109 420 504 924 185 115 300 
2001 1347 965 2312 774 371 1145 437 473 910 136 121 257 
2002 1469 968 2437 877 355 1232 441 506 947 151 107 258 
2003 1465 883 2348 848 315 1163 464 474 938 153 94 247 
2004 1502 996 2498 869 334 1203 489 573 1062 144 89 233 
2005 1757 1101 2858 1030 368 1398 559 592 1151 131 107 238 
2006 1854 1107 2961 1069 309 1378 608 676 1284 157 94 251 
2007 1916 1176 3092 1140 366 1506 557 691 1248 170 93 263 





Appendix C: Cases of Hepatocellular carcinoma (HCC) in whom ethnicity was registered in England and Wales, 1993-2008 
(percentages in parentheses) 
Year Hepatocellular carcinoma 
 All HCC Whites Afro- Caribbeans Black Africans South Asians Chinese Others 
1993 362(34.2) 355(98.1) 1(0.3) 0(0.0) 6(1.7) 0(0.0) 0(0.0) 
1994 355(32.5) 346(97.5) 1(0.3) 1(0.3) 4(1.1) 0(0.0) 3(0.8) 
1995 243(30.9) 229(94.2) 2(0.8) 2(0.8) 3(1.2) 4(1.6) 3(1.2) 
1996 409(44.6) 390(95.4) 1(0.2) 2(0.5) 6(1.5) 2(0.5) 8(2.0) 
1997 430(46.7) 410(95.3) 1(0.2) 4(0.9) 8(1.9) 5(1.2) 2(0.5) 
1998 493(50.3) 462(93.7) 3(0.6) 7(1.5) 9(1.8) 5(1.0) 7(1.4) 
1999 445(46.0) 412(92.6) 4(0.9) 2(0.4) 12(2.7) 5(1.1) 10(2.2) 
2000 440(41.5) 396(90.0) 12(2.7) 8(1.8) 12(2.7) 3(0.7) 9(2.0) 
2001 218(19.7) 167(76.6) 20(9.2) 5(2.3) 10(4.6) 6(2.8) 10(4.6) 
2002 265(22.0) 220(83.0) 15(5.7) 7(2.6) 11(4.2) 7(2.6) 5(1.9) 
2003 249(21.4) 196(78.7) 14(5.6) 7(2.8) 18(7.2) 3(1.2) 11(4.4) 
2004 342(28.2) 275(80.4) 17(5.0) 16(4.7) 13(3.8) 6(1.8) 15(4.4) 
2005 466(33.3) 388(83.3) 31(6.7) 14(3.0) 17(3.6) 6(1.3) 10(2.1) 
2006 543(39.4) 421(77.5) 62(11.4) 10(1.8) 28(5.2) 10(1.8) 12(2.2) 
2007 637(42.3) 492(77.2) 64(10.0) 13(2.0) 31(4.9) 15(2.4) 22(3.5) 








Appendix D: Cases of Intrahepatic Bile Duct carcinoma (IHBD) in whom ethnicity information was available in England and Wales, 
1993-2008 (percentages in parentheses) 
Year Intrahepatic bile duct tumours 
All IHBD Whites Afro-Caribbeans Black Africans South Asians Chinese Others 
1993 156(47.7) 155(99.4) 0(0.0) 0(0.0) 1(0.6) 0(0.0) 0(0.0) 
1994 166(45.9) 166(100.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 
1995 289(48.2) 287(99.3) 0(0.0) 0(0.0) 2(0.7) 0(0.0) 0(0.0) 
1996 378(56.6) 375(99.2) 2(0.5) 0(0.0) 0(0.0) 1(0.3) 0(0.0) 
1997 447(58.1) 441(98.7) 0(0.0) 0(0.0) 3(0.7) 2(0.4) 1(0.2) 
1998 463(59.7) 458(98.9) 2(0.4) 0(0.0) 3(0.6) 0(0.0) 0(0.0) 
1999 412(54.6) 401(97.3) 6(1.5) 0(0.0) 2(0.5) 2(0.5) 1(0.2) 
2000 444(48.1) 428(96.4) 12(2.7) 0(0.0) 3(0.7) 1(0.2) 0(0.0) 
2001 174(18.9) 152(87.4) 13(7.5) 3(1.7) 1(0.6) 1(0.6) 4(2.3) 
2002 211(21.8) 188(89.1) 8(3.8) 1(0.5) 7(3.3) 2(0.9) 5(2.4) 
2003 205(20.7) 189(92.2) 6(2.9) 3(1.5) 5(2.4) 0(0.0) 2(1.0) 
2004 323(29.2) 296(91.6) 13(4.0) 2(0.6) 7(2.2) 0(0.0) 5(1.5) 
2005 370(32.1) 331(89.5) 23(6.2) 1(0.3) 8(2.2) 2(0.5) 5(1.4) 
2006 487(37.9) 426(87.7) 29(6.0) 3(0.6) 16(3.3) 0(0.0) 13(2.7) 
2007 526(42.1) 463(88.0) 43(8.2) 1(0.2) 9(1.7) 3(0.6) 7(1.3) 








Appendix E: Cases of Liver tumours, not otherwise specified (NOS) in whom ethnicity information was available in England and 
Wales, 1993-2008 (percentages in parentheses) 
Year Liver NOS 
 All NOS Whites Afro- Caribbeans Black Africans South Asians Chinese Others 
1993 45(52.3) 44(97.8) 1(2.2) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 
1994 49(43.4) 49(100.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 
1995 64(28.4) 63(98.4) 0(0.0) 0(0.0) 1(1.6) 0(0.0) 0(0.0) 
1996 85(32.1) 83(97.6) 0(0.0) 1(1.2) 0(0.0) 1(1.2) 0(0.0) 
1997 87(31.6) 87(100.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 
1998 86(33.1) 84(97.7) 0(0.0) 0(0.0) 1(1.2) 0(0.0) 1(1.2) 
1999 128(41.0) 126(98.4) 0(0.0) 0(0.0) 0(0.0) 1(0.8) 1(0.8) 
2000 81(28.2) 77(95.1) 0(0.0) 0(0.0) 2(2.5) 1(1.2) 1(1.2) 
2001 43(18.0) 38(88.4) 2(4.7) 0(0.0) 0(0.0) 0(0.0) 3(7.0) 
2002 45(17.8) 45(100.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 
2003 50(20.6) 48(96.0) 0(0.0) 0(0.0) 2(4.0) 0(0.0) 0(0.0) 
2004 68(29.8) 68(100.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 
2005 56(23.5) 52(92.9) 1(1.8) 2(3.6) 0(0.0) 0(0.0) 1(1.8) 
2006 114(45.4) 108(94.7) 4(3.5) 0(0.0) 2(1.8) 0(0.0) 0(0.0) 
2007 96(36.5) 88(91.7) 3(3.1) 0(0.0) 1(1.0) 2(2.1) 2(2.1) 




Appendix F. Visual protocol for collection, preparation, packaging and transportation 
of samples from Africa used in the analyses 
